<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006775.pub3" GROUP_ID="EYES" ID="346206060617164661" MERGED_FROM="" MODIFIED="2017-06-19 09:19:18 +0100" MODIFIED_BY="Anupa Shah" REVIEW_NO="ANER01" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2017-06-19 09:19:14 +0100" MODIFIED_BY="Anupa Shah">
<TITLE>Punctal occlusion for dry eye syndrome</TITLE>
<CONTACT MODIFIED="2017-06-19 09:19:14 +0100" MODIFIED_BY="Anupa Shah"><PERSON ID="E2B3E75482E26AA2001B9B039FA17DE5" ROLE="AUTHOR"><FIRST_NAME>Ann-Margret</FIRST_NAME><LAST_NAME>Ervin</LAST_NAME><SUFFIX>PhD, MPH</SUFFIX><POSITION>Assistant Scientist</POSITION><EMAIL_1>aervin@jhsph.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>Johns Hopkins Bloomberg School of Public Health</ORGANISATION><ADDRESS_1>615 N. Wolfe Street, E6146</ADDRESS_1><CITY>Baltimore</CITY><ZIP>21205</ZIP><REGION>Maryland</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 410 502 4633</PHONE_1><FAX_1>+1 410 502 4623</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-06-19 09:19:14 +0100" MODIFIED_BY="Anupa Shah"><PERSON ID="E2B3E75482E26AA2001B9B039FA17DE5" ROLE="AUTHOR"><FIRST_NAME>Ann-Margret</FIRST_NAME><LAST_NAME>Ervin</LAST_NAME><SUFFIX>PhD, MPH</SUFFIX><POSITION>Assistant Scientist</POSITION><EMAIL_1>aervin@jhsph.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>Johns Hopkins Bloomberg School of Public Health</ORGANISATION><ADDRESS_1>615 N. Wolfe Street, E6146</ADDRESS_1><CITY>Baltimore</CITY><ZIP>21205</ZIP><REGION>Maryland</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 410 502 4633</PHONE_1><FAX_1>+1 410 502 4623</FAX_1></ADDRESS></PERSON><PERSON ID="z1406031714380437652308813574945" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Andrew</FIRST_NAME><LAST_NAME>Law</LAST_NAME><POSITION>Methodologist</POSITION><EMAIL_1>alaw6@jhu.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>Johns Hopkins Bloomberg School of Public Health</ORGANISATION><ADDRESS_1>615 N. Wolfe Street</ADDRESS_1><CITY>Baltimore</CITY><ZIP>21205</ZIP><REGION>Maryland</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>4105042306</PHONE_1></ADDRESS></PERSON><PERSON ID="02320879594239233011110527200431" ROLE="AUTHOR"><FIRST_NAME>Andrew</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>Pucker</LAST_NAME><SUFFIX>OD, PhD</SUFFIX><POSITION>Assistant Professor</POSITION><EMAIL_1>apucker@uab.edu</EMAIL_1><ADDRESS><DEPARTMENT>Optometry &amp; Vision Science</DEPARTMENT><ORGANISATION>University of Alabama at Birmingham</ORGANISATION><ADDRESS_1>1716 University Blvd</ADDRESS_1><CITY>Birmingham</CITY><ZIP>35294</ZIP><REGION>Alabama</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>205.975.9938</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-06-19 08:30:11 +0100" MODIFIED_BY="Anupa Shha">
<UP_TO_DATE>
<DATE DAY="8" MONTH="12" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="8" MONTH="12" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="8" MONTH="12" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="9" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-06-19 08:30:33 +0100" MODIFIED_BY="Anupa Shha">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-06-19 08:30:33 +0100" MODIFIED_BY="Anupa Shha">
<DATE DAY="16" MONTH="6" YEAR="2017"/>
<DESCRIPTION>
<P>Issue 6, 2017: electronic searches updated on 8 December 2016.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2017-06-16 15:16:08 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="6" YEAR="2017"/>
<DESCRIPTION>
<P>Issue 6, 2017: 11 new trials added to the review; one ongoing trial identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-04-28 13:35:12 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-28 13:35:12 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2017-06-19 08:34:49 +0100" MODIFIED_BY="Anupa Shha">
<INTERNAL_SOURCES MODIFIED="2010-07-13 16:39:58 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-07-13 16:39:58 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Human Genome Research Institute Intramural funds, National Institutes of Health</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>This research was supported in part by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2017-06-19 08:34:49 +0100" MODIFIED_BY="Anupa Shha">
<SOURCE MODIFIED="2016-12-16 21:11:55 +0000" MODIFIED_BY="[Empty name]">
<NAME>Grant 1 U01 EY020522, National Eye Institute, National Institutes of Health</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2017-06-19 08:34:49 +0100" MODIFIED_BY="Anupa Shha">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<UL>
<LI>Richard Wormald, Co-ordinating Editor for Cochrane Eyes and Vision (CEV) acknowledges financial support for his CEV research sessions from the Department of Health through the award made by the NIHR to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology.</LI>
<LI>This review was supported by the NIHR, via Cochrane Infrastructure funding to the CEV UK editorial base.</LI>
</UL>
<P>The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-06-19 09:02:50 +0100" MODIFIED_BY="Anupa Shha">
<SUMMARY MODIFIED="2017-06-19 08:41:38 +0100" MODIFIED_BY="Anupa Shha">
<TITLE MODIFIED="2010-01-22 19:13:18 +0000" MODIFIED_BY="[Empty name]">Punctal plugs for dry eye syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2017-06-19 08:41:38 +0100" MODIFIED_BY="Anupa Shha">
<P>
<B>What is the aim of this review?</B>
<BR/>The aim of this Cochrane Review was to determine whether punctal plugs, which are inserted into the tear ducts to block tear drainage, can treat dry eye syndrome. Cochrane review authors searched for all relevant studies and identified 18 clinical trials.</P>
<P>
<B>Key messages</B>
<BR/>It is unclear whether punctal plugs are effective for treating dry eye syndrome. Punctal plugs may be associated with watery eyes, though the evidence for this finding is weak.</P>
<P>
<B>What did we study in this review?</B>
<BR/>Dry eye is a common, chronic condition that affects millions of people around the world. Dry eye sufferers frequently experience burning, foreign body sensation (something in the eye), and blurry vision, which lead them to seek medical care. The typical first-line treatment for dry eye is over-the-counter artificial tears (eye drops). If these fail to relieve symptoms, persons with dry eyes may receive other treatment. Punctal plugs are one type of advanced dry eye treatment; they work by blocking the tear ducts (puncta) of the upper and lower eyelids. Punctal plugs come in several materials, shapes, and sizes.</P>
<P>
<B>What are the main results of the review?</B>
<BR/>This review included 18 trials with 711 participants (1249 eyes), most of whom were women. The trials took place from March 1998 to May 2014 and included participants from Austria, Canada, China, Greece, Japan, Mexico, Netherlands, Turkey, the UK, and the USA. The 18 trials differed greatly in design; they compared different types of punctal plugs and reported results in different ways.</P>
<P>The evidence from this review suggests that punctal plugs do not conclusively improve dry eye symptoms. No type of punctal plug used in the trials we examined was significantly better than another for relieving symptoms of dry eye. It is still unclear if punctal plugs are better than oral treatment (oral pilocarpine) or eye drops such as cyclosporine or artificial tears.</P>
<P>The evidence from this review suggests that punctal plugs may be associated with watery eyes and sometimes with more serious conditions such as infection or swelling in the tear sac (part of the eye where tears drain).</P>
<P>The conclusions of this updated review are similar to the original review published in 2010, though 11 new trials were included.</P>
<P>
<B>How up-to-date is this review?</B>
<BR/>Cochrane review authors searched for trials that were published up to 8 December 2016.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-06-19 08:35:53 +0100" MODIFIED_BY="Anupa Shha">
<ABS_BACKGROUND MODIFIED="2017-04-25 18:26:19 +0100" MODIFIED_BY="[Empty name]">
<P>Dry eye syndrome is a disorder of the tear film that is associated with symptoms of ocular discomfort. Punctal occlusion is a mechanical treatment that blocks the tear drainage system in order to aid in the preservation of natural tears on the ocular surface.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-02-09 07:53:51 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of punctal plugs versus no punctal plugs, different types of punctal plugs, and other interventions for managing dry eye.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-05-02 15:06:49 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 11), MEDLINE Ovid (1946 to 8 December 2016), Embase.com (1947 to 8 December 2016), PubMed (1948 to 8 December 2016), LILACS (Latin American and Caribbean Health Sciences Literature Database) (1982 to 8 December 2016), the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>; last searched 18 November 2012 - this resource is now archived), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>; searched 8 December 2016), and the WHO International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>; searched 8 December 2016). We did not use any date or language restrictions in the electronic searches for trials. We also searched the Science Citation Index-Expanded database and reference lists of included studies. The evidence was last updated on 8 December 2016</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-04-29 15:21:05 +0100" MODIFIED_BY="Anupa Shah">
<P>We included randomized and quasi-randomized controlled trials of collagen or silicone punctal plugs in symptomatic participants diagnosed with aqueous tear deficiency or dry eye syndrome.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-02-02 18:49:38 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed trial quality and extracted data. We contacted study investigators for additional information when needed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-06-19 08:35:53 +0100" MODIFIED_BY="Anupa Shha">
<P>We included 18 trials (711 participants, 1249 eyes) from Austria, Canada, China, Greece, Japan, Mexico, Netherlands, Turkey, the UK, and the USA in this review. We also identified one ongoing trial. Overall we judged these trials to be at unclear risk of bias because they were poorly reported. We assessed the evidence for eight comparisons.</P>
<P>Five trials compared punctal plugs with no punctal plugs (control). Three of these trials employed a sham treatment and two trials observed the control group. Two trials did not report outcome data relevant to this review. There was very low-certainty evidence on symptomatic improvement. The three trials that reported this outcome used different scales to measure symptoms. In all three trials, there was little or no improvement in symptom scores with punctal plugs compared with no punctal plugs. Low-certainty evidence from one trial suggested less ocular surface staining in the punctal plug group compared with the no punctal plug group however this difference was small and possibly clinically unimportant (mean difference (MD) in fluorescein staining score -1.50 points, 95% CI -1.88 to -1.12; eyes = 61). Similarly there was a small difference in tear film stability with people in the punctal plug group having more stability (MD 1.93 seconds more, 95% CI 0.67 to 3.20; eyes = 28, low-certainty evidence). The number of artificial tear applications was lower in the punctal plug group compared with the no punctal plugs group in one trial (MD -2.70 applications, 95% CI -3.11 to -2.29; eyes = 61, low-certainty evidence). One trial with low-certainty evidence reported little or no difference between the groups in Schirmer scores, but did not report any quantitative data on aqueous tear production. Very low-certainty evidence on adverse events suggested that events occurred reasonably frequently in the punctal plug group and included epiphora, itching, tenderness and swelling of lids with mucous discharge, and plug displacement.</P>
<P>One trial compared punctal plugs with cyclosporine (20 eyes) and one trial compared punctal plugs with oral pilocarpine (55 eyes). The evidence was judged to be very low-certainty due to a combination of risk of bias and imprecision.</P>
<P>Five trials compared punctal plugs with artificial tears. In one of the trials punctal plugs was combined with artificial tears and compared with artificial tears alone. There was very low-certainty evidence on symptomatic improvement. Low-certainty evidence of little or no improvement in ocular surface staining comparing punctal plugs with artificial tears (MD right eye 0.10 points higher, 0.56 lower to 0.76 higher, MD left eye 0.60 points higher, 0.10 to 1.10 higher) and low-certainty evidence of little or no difference in aqueous tear production (MD 0.00 mm/5 min, 0.33 lower to 0.33 higher)</P>
<P>Three trials compared punctal plugs in the upper versus the lower puncta, and none of them reported the review outcomes at long-term follow-up. One trial with very low-certainty evidence reported no observed complications, but it was unclear which complications were collected.</P>
<P>One trial compared acrylic punctal plugs with silicone punctal plugs and the trial reported outcomes at approximately 11 weeks of follow-up (36 eyes). The evidence was judged to be very low-certainty due to a combination of risk of bias and imprecision.</P>
<P>One trial compared intracanalicular punctal plugs with silicone punctal plugs at three months follow-up (57 eyes). The evidence was judged to be very low-certainty due to a combination of risk of bias and imprecision.</P>
<P>Finally, two trials with very low-certainty evidence compared collagen punctal plugs versus silicone punctal plugs (98 eyes). The evidence was judged to be very low-certainty due to a combination of risk of bias and imprecision.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-06-17 13:43:35 +0100" MODIFIED_BY="[Empty name]">
<P>Although the investigators of the individual trials concluded that punctal plugs are an effective means for treating dry eye signs and symptoms, the evidence in this systematic review suggests that improvements in symptoms and commonly tested dry eye signs are inconclusive. Despite the inclusion of 11 additional trials, the findings of this updated review are consistent with the previous review published in 2010. The type of punctal plug investigated, the type and severity of dry eye being treated, and heterogeneity in trial methodology confounds our ability to make decisive statements regarding the effectiveness of punctal plug use. Although punctal plugs are believed to be relatively safe, their use is commonly associated with epiphora and, less commonly, with inflammatory conditions such as dacryocystitis.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-06-19 08:37:21 +0100" MODIFIED_BY="Anupa Shha">
<BACKGROUND MODIFIED="2017-04-25 18:24:21 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2017-02-17 16:17:37 +0000" MODIFIED_BY="[Empty name]">
<P>Dry eye syndrome, or keratoconjunctivitis sicca, is defined as "a disorder of the tear film due to tear deficiency or excessive tear evaporation which causes damage to the interpalpebral ocular surface and is associated with symptoms of ocular discomfort" (<LINK REF="REF-Lemp-1995" TYPE="REFERENCE">Lemp 1995</LINK>; <LINK REF="REF-Lemp-1998" TYPE="REFERENCE">Lemp 1998</LINK>; <LINK REF="REF-Pflugfelder-2000" TYPE="REFERENCE">Pflugfelder 2000</LINK>). Dry eye affects 10% to 20% of adults, with 1 million to 4 million affected adults aged 65 to 84 in the USA (<LINK REF="REF-AAO-2003" TYPE="REFERENCE">AAO 2003</LINK>; <LINK REF="REF-Schein-1997b" TYPE="REFERENCE">Schein 1997b</LINK>). Investigators have also estimated dry eye prevalence in Sweden (15%), India (18.4%), Australia (8.6% to 16.3%), and Indonesia (27.5%) (<LINK REF="REF-Lee-2002" TYPE="REFERENCE">Lee 2002</LINK>; <LINK REF="REF-Lemp-1998" TYPE="REFERENCE">Lemp 1998</LINK>; <LINK REF="REF-McCarty-1998" TYPE="REFERENCE">McCarty 1998</LINK>; <LINK REF="REF-Sahai-2005" TYPE="REFERENCE">Sahai 2005</LINK>). The condition has been associated with age, sex, Sjögren's syndrome, arthritis, diabetes, corneal transplants, multivitamin use, laser in situ keratomileusis (LASIK), and photorefractive keratectomy (PRK) (<LINK REF="REF-Dalzell-2003" TYPE="REFERENCE">Dalzell 2003</LINK>; <LINK REF="REF-De-Paiva-2006" TYPE="REFERENCE">De Paiva 2006</LINK>; <LINK REF="REF-Dew-2007" TYPE="REFERENCE">Dew 2007</LINK>; <LINK REF="REF-Moss-2000" TYPE="REFERENCE">Moss 2000</LINK>). Symptoms may include redness, burning, itchiness, foreign body sensation, and in severe cases corneal ulceration and bacterial infection (<LINK REF="REF-Lemp-1998" TYPE="REFERENCE">Lemp 1998</LINK>; <LINK REF="REF-Sheppard-2003" TYPE="REFERENCE">Sheppard 2003</LINK>; <LINK REF="REF-Wilson-2003" TYPE="REFERENCE">Wilson 2003</LINK>). Assessments of ocular surface damage and measures of tear stability and hyperosmolarity also aid the diagnosis of dry eye syndrome (<LINK REF="REF-Lemp-1995" TYPE="REFERENCE">Lemp 1995</LINK>). Due to a lack of correlation among self-reported symptoms and clinical measures, it is difficult to diagnose dry eye precisely (<LINK REF="REF-Lemp-1995" TYPE="REFERENCE">Lemp 1995</LINK>; <LINK REF="REF-Nichols-2004" TYPE="REFERENCE">Nichols 2004</LINK>; <LINK REF="REF-Schein-1997a" TYPE="REFERENCE">Schein 1997a</LINK>).</P>
<P>Artificial tears, the typical initial treatment for patients with dry eye, hydrate the eye and provide short-term symptomatic relief for affected individuals (<LINK REF="REF-Pucker-2016" TYPE="REFERENCE">Pucker 2016</LINK>). Preservative-free artificial tears are preferable for long-term use because preserved formulations may be toxic to the cornea and conjunctival epithelium (<LINK REF="REF-Lemp-1994" TYPE="REFERENCE">Lemp 1994</LINK>; <LINK REF="REF-Pflugfelder-2000" TYPE="REFERENCE">Pflugfelder 2000</LINK>; <LINK REF="REF-Pucker-2016" TYPE="REFERENCE">Pucker 2016</LINK>). Interventions such as bandage contact lenses (physical coverage of the ocular surface), estrogens (hormone replacement), topical corticosteroids (general immunosuppressant), cyclosporine (immunosuppressant agent that decreases T-cell production), pilocarpine (cholinergic parasympatheticomimetic agonist), and punctal plugs (lacrimal drainage occlusion device) also have been shown to be effective treatments in selected settings (<LINK REF="REF-DEWS-2007a" TYPE="REFERENCE">DEWS 2007a</LINK>; <LINK REF="REF-Freeman-1975" TYPE="REFERENCE">Freeman 1975</LINK>; <LINK REF="REF-Jehangir-2016" TYPE="REFERENCE">Jehangir 2016</LINK> <LINK REF="REF-Lemp-1994" TYPE="REFERENCE">Lemp 1994</LINK>; <LINK REF="REF-Pflugfelder-2000" TYPE="REFERENCE">Pflugfelder 2000</LINK>; <LINK REF="REF-Sall-2000" TYPE="REFERENCE">Sall 2000</LINK>; <LINK REF="REF-Sheppard-2003" TYPE="REFERENCE">Sheppard 2003</LINK>; <LINK REF="REF-Wilson-2003" TYPE="REFERENCE">Wilson 2003</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2017-04-25 18:23:36 +0100" MODIFIED_BY="[Empty name]">
<P>Punctal occlusion is a non-pharmacological intervention for dry eye when artificial tears do not ameliorate symptoms (<LINK REF="REF-Balaram-2001" TYPE="REFERENCE">Balaram 2001</LINK>; <LINK REF="REF-Freeman-1975" TYPE="REFERENCE">Freeman 1975</LINK>; <LINK REF="REF-Willis-1987" TYPE="REFERENCE">Willis 1987</LINK>). Semi-permanent silicone or temporary collagen punctal plugs are inserted into the upper, lower, or both puncta of the affected eye(s) (<LINK REF="REF-Lemp-1994" TYPE="REFERENCE">Lemp 1994</LINK>). Collagen plugs dissolve within four to seven days, while silicone plugs either dislodge spontaneously or are removed by a physician. Clinicians typically prescribe the silicone punctal plugs after an affected patient has found symptomatic relief with the collagen punctal plugs (<LINK REF="STD-Altan_x002d_Yaycioglu-2005" TYPE="STUDY">Altan-Yaycioglu 2005</LINK>). Thermal cautery or argon laser achieves permanent occlusion of the puncta (<LINK REF="REF-AAO-2003" TYPE="REFERENCE">AAO 2003</LINK>; <LINK REF="REF-Dohlman-1978" TYPE="REFERENCE">Dohlman 1978</LINK>; <LINK REF="REF-Lemp-1994" TYPE="REFERENCE">Lemp 1994</LINK>). Similar to punctal occlusion, intracanalicular plugs also block tear drainage, though they act by blocking the canaliculus instead of the punctum (<LINK REF="REF-Jehangir-2016" TYPE="REFERENCE">Jehangir 2016</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2017-04-25 18:23:53 +0100" MODIFIED_BY="[Empty name]">
<P>Punctal plugs are believed to block tear drainage by occluding the puncta. Blockage is subsequently thought to aid in the preservation of natural tears and to improve the quality and quantity of the tear film. (<LINK REF="REF-Barnard-1996" TYPE="REFERENCE">Barnard 1996</LINK>; <LINK REF="REF-Dohlman-1978" TYPE="REFERENCE">Dohlman 1978</LINK>; <LINK REF="REF-Tai-2002" TYPE="REFERENCE">Tai 2002</LINK>). The most common side effects of occlusion are epiphora (overflow of tears), inhibited tear clearance, and desensitization of the corneal surface (<LINK REF="REF-Lemp-1994" TYPE="REFERENCE">Lemp 1994</LINK>; <LINK REF="REF-Sheppard-2003" TYPE="REFERENCE">Sheppard 2003</LINK>; <LINK REF="REF-Tai-2002" TYPE="REFERENCE">Tai 2002</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-04-25 18:24:21 +0100" MODIFIED_BY="[Empty name]">
<P>An updated systematic review examining the efficacy of punctal occlusion, specifically punctal plugs, for managing dry eye is necessary. There was appreciable variability in the interventions and study designs of the trials included in the previous systematic review thus precluding quantitative syntheses. The effectiveness of punctal plugs for treating dry eye has not yet been established. This review summarizes the best available evidence for the use of punctal occlusion in the treatment of dry eye.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-02-09 08:25:19 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of punctal plugs versus no punctal plugs, different types of punctal plugs, and other interventions for managing dry eye. This is an update to a Cochrane Review initially published in 2010 (<LINK REF="REF-Ervin-2010" TYPE="REFERENCE">Ervin 2010</LINK>).</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-06-19 08:36:18 +0100" MODIFIED_BY="Anupa Shha">
<SELECTION_CRITERIA MODIFIED="2017-04-25 18:25:23 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2017-02-17 16:28:35 +0000" MODIFIED_BY="[Empty name]">
<P>We selected only randomized and quasi-randomized controlled clinical trials for inclusion in this review. We considered studies to be quasi-randomized if the investigators did not use randomization to allocate participants to treatment groups but used techniques intended to allocate patients in an unbiased fashion. Some examples include allocation based on the day of the week, year of birth, or hospital admission number.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-02-09 08:43:52 +0000" MODIFIED_BY="[Empty name]">
<P>We included symptomatic participants who were diagnosed with aqueous tear deficiency or keratoconjunctivitis sicca (dry eye syndrome). There were no restrictions with respect to age, sex, comorbidities, or use of adjunctive therapy.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-04-25 18:25:23 +0100" MODIFIED_BY="[Empty name]">
<P>We considered clinical trials comparing occlusion of the lower or upper punctum or upper and lower puncta with collagen versus silicone punctal plugs and studies comparing these plugs to other treatments such as artificial tears, pilocarpine, cyclosporine, or diathermy (use of electrodes to heat and contract punctal tissues). We also considered clinical trials using collagen or silicone plugs in conjunction with adjunctive therapies such as artificial tears, as well as trials comparing occlusion versus no treatment, placebo, or sham treatments.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-04-25 18:25:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-04-25 18:25:15 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome was subjective report of symptomatic improvement in dry eye symptoms such as burning and grittiness and other symptoms as defined by included studies at the long-term follow-up visit (2-12 months).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-02-14 16:07:08 +0000" MODIFIED_BY="[Empty name]">
<P>We included secondary outcomes assessed post-treatment or at other reported time points in this review.</P>
<UL>
<LI>
<I>Ocular surface staining</I>, as defined by the mean change in total Rose Bengal score from baseline to follow-up. We reported change in fluorescein and lissamine green scores where appropriate.</LI>
<LI>
<I>Aqueous tear production</I>, as measured by the mean change in Schirmer I test scores (mm). We included Schirmer I tests performed with anesthesia and Schirmer II tests without anesthesia.</LI>
<LI>
<I>Tear film stability</I>, as measured by the mean change in tear film break-up time (seconds).</LI>
<LI>Change in the frequency of <I>artificial tear use</I>, as defined by included studies.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Follow-up</HEADING>
<P>We assessed the secondary outcomes at two weeks, four weeks, and at long-term follow-up. We considered follow-up at 12 to 16 days to be two weeks follow-up. We also considered follow-up between 26 to 30 days to be four weeks follow-up. We defined long-term follow-up as between two months and one year.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse outcomes</HEADING>
<P>We reported adverse outcomes such as epiphora, corneal ulcers, and plug extrusion (total or partial displacement of the punctal plug) where appropriate. We summarized other adverse outcomes reported in included studies.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-06-19 08:30:57 +0100" MODIFIED_BY="Anupa Shha">
<P>
<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2017-06-19 08:30:57 +0100" MODIFIED_BY="Anupa Shha">
<P>The Cochrane Eyes and Vision Information Specialist conducted systematic searches in the following databases for randomized controlled trials and controlled clinical trials. There were no language or publication year restrictions. The date of the search was 8 December 2016.</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 11) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched 8 December 2016) (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1701311302053029560081437769166&amp;format=REVMAN#APP-01">Appendix 1</A>);</LI>
<LI>MEDLINE Ovid (1946 to 8 December 2016) (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1701311302053029560081437769166&amp;format=REVMAN#APP-02">Appendix 2</A>);</LI>
<LI>Embase.com (1947 to 8 December 2016) (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1701311302053029560081437769166&amp;format=REVMAN#APP-03">Appendix 3</A>);</LI>
<LI>PubMed (1948 to 8 December 2016) (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1701311302053029560081437769166&amp;format=REVMAN#APP-04">Appendix 4</A>);</LI>
<LI>LILACS (Latin American and Caribbean Health Science Information database (1982 to 8 December 2016) (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1701311302053029560081437769166&amp;format=REVMAN#APP-05">Appendix 5</A>);</LI>
<LI>
<I>meta</I>Register of Controlled Trials (<I>m</I>RCT) (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>; last searched 18 November 2012- this resource is now archived) (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1701311302053029560081437769166&amp;format=REVMAN#APP-06">Appendix 6</A>);</LI>
<LI>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>; searched 8 December 2016) (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1701311302053029560081437769166&amp;format=REVMAN#APP-07">Appendix 7</A>);</LI>
<LI>World Health Organization International Clinical Trials Registry Platform (<A HREF="http://www.who.int/ictrp">www.who.int/ictrp</A>; searched 8 December 2016) (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1701311302053029560081437769166&amp;format=REVMAN#APP-08">Appendix 8</A>).</LI>
</UL>
<P>In 2016, we revised the searches of electronic databases from the 2010 publication of the original version of this review.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-02-13 18:39:26 +0000" MODIFIED_BY="[Empty name]">
<P>We searched reference lists of included studies to identify any additional inclusions. We also used the Science Citation Index-Expanded database to identify studies that may have cited trials included in this review on 8 December 2016. We did not handsearch conference proceedings or journals.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-06-19 08:36:18 +0100" MODIFIED_BY="Anupa Shha">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2017-02-09 10:03:49 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently reviewed titles and abstracts resulting from the literature searches according to the inclusion criteria stated above. We classified the abstracts as 'definitely exclude', 'unsure,' or 'definitely include'. We retrieved the full-text reports corresponding to abstracts classified as 'definitely include' or 'unsure' by either review author and re-assessed the study for inclusion. We contacted the authors of studies classified as 'unsure' for further information, as required, after examining the full report. We resolved disagreements through discussion. We excluded studies labeled as 'exclude' by both review authors from the review and documented the reasons for exclusion. We assessed studies labeled 'definitely include' for methodological quality.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-02-21 15:08:04 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted data using a form developed by Cochrane Eyes and Vision, resolving discrepancies by discussion. One review author entered data into Review Manager 5 (RevMan 5) and a second author verified all values entered (<LINK REF="REF-Review-Manager-5-2014" TYPE="REFERENCE">Review Manager 5 2014</LINK>). When quantitative data were not available, we abstracted data from graphs using <LINK REF="REF-GetData-Graph-Digitalizer" TYPE="REFERENCE">GetData Graph Digitalizer</LINK>.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-04-26 17:21:11 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed the included studies for sources of systematic bias according to the guidelines in Chapter 8 of the C<I>ochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). We evaluated the studies for the following criteria: sequence generation and allocation concealment before assignment (selection bias), masking of outcome assessors (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias), and other sources of bias. We reported the judgment for each criterion as 'yes (low risk of bias)', 'no (high risk of bias)' or 'unclear (information is insufficient to assess)'.</P>
<P>We reported the adequacy of sequence generation and allocation concealment before assignment. Methods of sequence generation considered to be at low risk of bias include references to random number tables or computer generated random numbers and coin tosses. We considered any method of allocation concealment that provided reasonable confidence that the allocation sequence was concealed from participating physicians and patients to confer low risk of bias, for example centralized randomization or use of sequentially numbered opaque envelopes.</P>
<P>We noted masking of outcome assessors by individual study outcomes. Masking of investigators and participants would not have been possible with the interventions being compared in some studies, but we noted it where mentioned.</P>
<P>For incomplete outcome data, we examined rates of follow-up, reasons for loss to follow-up and analysis by the principle of intention-to-treat (ITT). We assessed whether follow-up rates for treatment and control arms were similar and whether data were missing for outcomes of interest. We considered studies to be at low risk of bias when there were no missing data and no participants for whom outcome data were not reported, and where all participants, including those who received some or none of the allocated treatment, were included in the analyses of outcomes. We noted the method of data imputation, when appropriate, for included studies.</P>
<P>We considered studies to be at low risk of bias for selective outcome reporting whenever all pre-specified outcomes of interest in the protocol or register record were consistent with the outcomes specified in the published report.</P>
<P>We examined included studies for other sources of bias and considered studies at low risk of bias when there was no evidence of research misconduct or potential for bias based on study methodology, or when the study was not stopped early due to evidence of harm or benefit. When available, we used trial registration records, source(s) of funding, or conflicts of interest to identify other potential sources of bias.</P>
<P>We resolved disagreements through discussion. We contacted the authors of the studies for additional information on issues that were unclear from the study report. In case of failure to communicate with the primary investigators, or if no response was received within six weeks, we assessed the methodological quality on the basis of the available information.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-04-25 18:47:02 +0100" MODIFIED_BY="[Empty name]">
<P>We calculated a summary risk ratio for dichotomous outcomes including the primary outcome of symptomatic improvement and reports of adverse events. We verified normality of distributions of continuous outcome data and calculated mean differences for secondary outcomes as follows: mean change in Rose Bengal, fluorescein, and lissamine green staining scores, mean change in tear production as measured by the Schirmer I/Schirmer II test, and mean change in tear film break-up time. </P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2017-05-04 18:53:24 +0100" MODIFIED_BY="[Empty name]">
<P>We reported the unit of analysis for the included studies in the Results section (<LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK>). We did not include cross-over trials, but if we identify eligible cross-over trials for inclusion in a subsequent update, we will attempt to extract data from the study reports or request data from the investigators to account appropriately for the study design. If we are unable to retrieve these data, we will incorporate statistical techniques to approximate a paired analysis as outlined in Chapter 16.4 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2017-02-09 10:23:35 +0000" MODIFIED_BY="[Empty name]">
<P>We contacted primary authors of included studies to obtain missing or unclearly reported information such as details regarding study methods, standard deviations not reported with mean values, and data required for an ITT analysis. Whenever there was no response from the primary authors within six weeks, we imputed data where possible using available information such as P values or confidence intervals. We describe the assumptions we made during imputation where appropriate.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-02-09 10:23:53 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed statistical, methodological, and clinical heterogeneity. When including additional studies to this update, we computed the I<SUP>2</SUP> statistic (%) to determine statistical heterogeneity, that is, the proportion of variation due to heterogeneity among effect estimates from individual studies in a meta-analysis. We considered an I<SUP>2 </SUP>value larger than 75% to suggest considerable statistical heterogeneity. We also examined the result of the Chi<SUP>2</SUP> test and the degree of overlap in confidence intervals of included studies because poor overlap of estimates and confidence intervals suggests the presence of heterogeneity. We assessed clinical and methodological heterogeneity by examining variations among included studies with respect to participant characteristics, inclusion/exclusion criteria, and assessments of primary and secondary outcomes.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2017-03-29 18:56:36 +0100" MODIFIED_BY="[Empty name]">
<P>Because fewer than 10 studies were included in any meta-analysis, we did not assess reporting biases with funnel plots. If we identify more studies in future updates and a meta-analysis includes data from 10 or more studies, we will assess reporting bias using funnel plots.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-04-25 21:01:06 +0100" MODIFIED_BY="[Empty name]">
<P>When considering meta-analysis, we took statistical, methodological, and clinical heterogeneity into consideration. We considered an I<SUP>2</SUP> statistic greater than 75% to suggest considerable statistical heterogeneity, as defined above in '<LINK TAG="HETEROGENEITY_ASSESSMENT" TYPE="SECTION">Assessment of heterogeneity</LINK>'. When the number of trials was fewer than three, we used a fixed-effect model, which in these cases provides a more robust estimate of the treatment effect. When meta-analysis had three or more included trials, we used a random-effects model to estimate the overall intervention effects when appropriate. When analyzing binary (dichotomous) outcomes, we estimated the risk ratio (RR). For continuous outcomes, we estimated the mean difference (MD).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2017-02-09 10:27:15 +0000" MODIFIED_BY="[Empty name]">
<P>Sufficient data were not available to conduct subgroup analyses. We will use the following guidelines for future updates of this review: if there is considerable statistical heterogeneity and evidence of potential clinical or methodological heterogeneity, and if data are available, we will conduct a subgroup analysis of tear deficient classifications of dry eye as defined by the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes (<LINK REF="REF-Lemp-1995" TYPE="REFERENCE">Lemp 1995</LINK>).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-06-19 08:36:18 +0100" MODIFIED_BY="Anupa Shha">
<P>We did not perform sensitivity analyses due to insufficient data. We will consider sensitivity analyses during future updates of this review to determine the impact of excluding studies with lower methodological quality or industry funding as well as studies that were unpublished at the time of our review. We also will conduct sensitivity analyses to determine the impact of including quasi-randomized trials.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings table</HEADING>
<P>We used the GRADE approach to evaluate the certainty of evidence for each outcome (<LINK REF="REF-GRADEpro-2014" TYPE="REFERENCE">GRADEpro 2014</LINK>). Two review authors independently assessed each outcome as being of very low-, low-, moderate-, or high-certainty according to five criteria: risk of bias in individual trials, indirectness, heterogeneity, imprecision of estimate (wide confidence intervals), and publication bias. We resolved discrepancies by discussion. We present the main outcomes for each comparison in a 'Summary of findings' table. Since dry eye syndrome is a chronic condition, long-term follow-up is the most clinically relevant and patient important time point. Therefore, we included the following seven outcomes at long-term follow-up: symptomatic improvement, ocular surface staining with fluorescein, ocular surface staining with Rose Bengal, aqueous tear production, tear film stability, artificial tear use, and adverse events.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-06-19 08:37:21 +0100" MODIFIED_BY="Anupa Shha">
<STUDY_DESCRIPTION MODIFIED="2017-05-05 20:46:18 +0100" MODIFIED_BY="[Empty name]">
<P>We describe the full-text studies we assessed for inclusion in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' and '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' tables.</P>
<SEARCH_RESULTS MODIFIED="2017-02-13 18:12:35 +0000" MODIFIED_BY="[Empty name]">
<P>In the original 2010 manuscript, the electronic search identified a total of 115 titles and abstracts (<LINK REF="REF-Ervin-2010" TYPE="REFERENCE">Ervin 2010</LINK>). We retrieved 19 articles for full-text assessment, and we finally included 6 and excluded 13 for the review. We identified and included one additional study from the list of references in the protocol for this systematic review and from a search of the Science Citation Index-Expanded database.</P>
<P>On 8 December 2016, the electronic searches yielded an additional 211 records (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We assessed 20 full-text reports from 20 studies. Eleven met our eligibility criteria for inclusion, while one was ongoing. We excluded the remaining eight studies for the reasons noted in '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'. Therefore, the updated version of this systematic review includes a total of 18 included studies and 1 ongoing study.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-05-05 20:46:18 +0100" MODIFIED_BY="[Empty name]">
<P>The 18 studies included in this review enrolled 711 participants (1249 eyes); we describe the studies in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table. The intervention comparisons are summarized in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> did not report the number of participants but did report the number of eyes studied.</P>
<P>The unit of randomization for the included studies was the participant for 11 studies (<LINK REF="STD-Altan_x002d_Yaycioglu-2005" TYPE="STUDY">Altan-Yaycioglu 2005</LINK>;<LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK>;<LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK>; <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK>;<LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>; <LINK REF="STD-Qiu-2012" TYPE="STUDY">Qiu 2012</LINK>; <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK>;<LINK REF="STD-Rabensteiner-2013" TYPE="STUDY">Rabensteiner 2013</LINK>; <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK>;<LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK>; <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>), the eye for 5 studies (<LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK>; <LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK>; <LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK>;<LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>;<LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>), and was unclear for 2 studies (<LINK REF="STD-Feng-2011" TYPE="STUDY">Feng 2011</LINK>; <LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK>;).</P>
<P>The unit of analysis was the participant for 3 studies as the average of the participant's right and left eyes was ana lysed (<LINK REF="STD-Rabensteiner-2013" TYPE="STUDY">Rabensteiner 2013</LINK>; <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK>;<LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK>). The unit of analysis was the eye for 7 studies (<LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK>;<LINK REF="STD-Feng-2011" TYPE="STUDY">Feng 2011</LINK>; <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK>; <LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK>; <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>; <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK>; <LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>) although the study investigators did not discuss whether the analyses accounted for the correlation between eyes of a participant. The unit of analysis was unclear for the remaining 8 studies (<LINK REF="STD-Altan_x002d_Yaycioglu-2005" TYPE="STUDY">Altan-Yaycioglu 2005</LINK>;<LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK>; <LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK>; <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK>;<LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>; <LINK REF="STD-Qiu-2012" TYPE="STUDY">Qiu 2012</LINK>; <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>; <LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK>).</P>
<P>In this review we included the following comparisons (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<OL>
<LI>Punctal plugs versus observation.</LI>
<LI>Punctal plugs versus cyclosporine.</LI>
<LI>Punctal plugs versus oral pilocarpine.</LI>
<LI>Punctal plugs versus artificial tears.</LI>
<LI>Punctal plugs in the lower puncta versus the upper puncta.</LI>
<LI>Acrylic punctal plugs versus silicone punctal plugs.</LI>
<LI>Intracanalicular plugs versus Silicone punctal plugs.</LI>
<LI>Collagen punctal plugs versus silicone punctal plugs.</LI>
</OL>
<P>Concomitant use of artificial tears was permitted irrespective of the treatment assignment in the <LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK>; <LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK>;<LINK REF="STD-Rabensteiner-2013" TYPE="STUDY">Rabensteiner 2013</LINK>; <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK>;<LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK>; <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> studies. There was no mention of concomitant artificial tear use in the <LINK REF="STD-Altan_x002d_Yaycioglu-2005" TYPE="STUDY">Altan-Yaycioglu 2005</LINK>; <LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK>; <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK>; <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK>; <LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK>; <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>; <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>; <LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK> studies. The objective in the <LINK REF="STD-Feng-2011" TYPE="STUDY">Feng 2011</LINK>, <LINK REF="STD-Qiu-2012" TYPE="STUDY">Qiu 2012</LINK>, <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK>, and <LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK> studies was to compare artificial tears to punctal plugs so only participants assigned to the artificial tear group received this treatment.</P>
<P>For eight of 18 included trials, the unit of analysis was unclear, as trial investigators did not report if they had only included one eye in the analysis or took the averaged of both eyes (<LINK REF="STD-Altan_x002d_Yaycioglu-2005" TYPE="STUDY">Altan-Yaycioglu 2005</LINK>; <LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK>; <LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK>; <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK>; <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>; <LINK REF="STD-Qiu-2012" TYPE="STUDY">Qiu 2012</LINK>; <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>; <LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK>). Only one paired-eye RCT used paired t-test (<LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>), while the other four paired-eye RCTs, but did not mention an analysis accounting for correlation between the left and right eye (<LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK>; <LINK REF="STD-Feng-2011" TYPE="STUDY">Feng 2011</LINK>; <LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK>; <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>). The remaining four of 18 trials reported averaging both eyes (<LINK REF="STD-Rabensteiner-2013" TYPE="STUDY">Rabensteiner 2013</LINK>; <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK>), analyzed the right eye (<LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK>; <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK>), or reporting the mean outcome of left and right eyes (<LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-02-13 09:04:31 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded 21 studies, listing them in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table along with the reasons for exclusion.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-04-26 17:21:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> presents a summary of the risk of bias judgements for the individual included studies.</P>
<ALLOCATION MODIFIED="2017-04-25 20:00:51 +0100" MODIFIED_BY="[Empty name]">
<P>We judged the methods of sequence generation to confer low risk of bias for nine studies (<LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK>; <LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK>; <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>; <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>; <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK>; <LINK REF="STD-Rabensteiner-2013" TYPE="STUDY">Rabensteiner 2013</LINK>; <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK>; <LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK>; <LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK>). All these studies used some form of a computer-generated randomization scheme. We assessed <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> as being at high risk of bias because participants were assigned based on their patient ID number; participants with an odd patient ID number were assigned to the punctal plug group, while those with even patient ID numbers were assigned to the non-punctal plug group. The eight remaining studies did not discuss sequence generation (<LINK REF="STD-Altan_x002d_Yaycioglu-2005" TYPE="STUDY">Altan-Yaycioglu 2005</LINK>; <LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK>; <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK>; <LINK REF="STD-Feng-2011" TYPE="STUDY">Feng 2011</LINK>; <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK>; <LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK>; <LINK REF="STD-Qiu-2012" TYPE="STUDY">Qiu 2012</LINK>; <LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>).</P>
<P>We considered three studies at low risk of bias for allocation concealment: the investigators used opaque envelopes in <LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK> and <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK>, while in <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> an external statistical committee prepared random assignments and placed them in sealed envelopes. We rated <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> at high risk of bias because participants were assigned to treatment groups based upon their patient ID numbers, as described above. The remaining 14 trials did not describe allocation concealment.</P>
<SUBSECTION>
<HEADING LEVEL="3">Masking (performance bias and detection bias)</HEADING>
<P>
<LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> did not mask participants and personnel, so we considered this study to be at high risk of performance bias. We judged 7 of the 18 included studies to be at low risk of both performance bias and detection bias, as they reported masking both the participants and study personnel (<LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK>; <LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK>; <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK>; <LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK>; <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>; <LINK REF="STD-Rabensteiner-2013" TYPE="STUDY">Rabensteiner 2013</LINK>; <LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>) although it is not possible to mask the personnel administering punctal plugs. For the remaining studies, the study investigators did not report masking of participants and personnel although given the nature of the interventions compared it was not possible to mask participants and personnel administering the punctal plugs. We judged the remaining studies as having an unclear risk of bias. </P>
<P>
<A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0005">Mansour 2007</A> , <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK>, and <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> reported that the outcome assessors were not masked, so we rated these studies as being at high risk of detection bias. <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0005">Mansour 2007</A> reported that the same investigator performed all measurements and presumably was unmasked to treatment assignment. <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> reported that the "medication was dispensed open-label." In <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>, the study authors informed us through email that the outcome assessors were not masked. We judged 8 of the 18 included studies to be at low risk of detection bias because they reported masking of the outcome assessors (<LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK>; <LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK>; <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK>; <LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK>; <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>; <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK>; <LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>; <LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK>). We judged the remaining studies to be at unclear risk of detection bias; this group included <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0001">Altan-Yaycioglu 2005</A>, where the nuclear medicine specialist who evaluated the lacrimal scintigraphy images was masked to treatment assignment; however, lacrimal scintigraphy was not a measurement included in this review. It is unclear whether other outcome assessors were masked in <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0001">Altan-Yaycioglu 2005</A>.</P>
</SUBSECTION>
</ALLOCATION>
<EXCLUSIONS MODIFIED="2017-04-26 17:21:16 +0100" MODIFIED_BY="[Empty name]">
<P>We judged <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>, <LINK REF="STD-Rabensteiner-2013" TYPE="STUDY">Rabensteiner 2013</LINK>, <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK>, and <LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK> to be at high risk of bias for failure to report complete outcome data. <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>, <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> and <LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK> excluded 20% or more participants from their analyses of outcomes. <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> reported potential attrition bias by replacing participants who withdrew from their study (participants were not included in their analyses). In <LINK REF="STD-Rabensteiner-2013" TYPE="STUDY">Rabensteiner 2013</LINK>, the proportion of participants lost to follow-up differed across groups.</P>
<P>We judged eight studies to be at low risk of bias for incomplete outcome data (<LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK>; <LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK>; <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK>; <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK>; <LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK>; <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>; <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK>; <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>). These studies reported no loss to follow-up or missing data, which we confirmed by comparing the number randomized versus the number ana lysed in the results reported.</P>
<P>We assessed all the remaining studies to be at unclear risk of attrition bias (<LINK REF="STD-Altan_x002d_Yaycioglu-2005" TYPE="STUDY">Altan-Yaycioglu 2005</LINK>; <LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK>; <LINK REF="STD-Feng-2011" TYPE="STUDY">Feng 2011</LINK>; <LINK REF="STD-Qiu-2012" TYPE="STUDY">Qiu 2012</LINK>; <LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK>; <LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK>). <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0001">Altan-Yaycioglu 2005</A> did not report sample sizes in the Results, so it was unclear whether all participants completed follow-up examinations. We noted that investigators assessed most outcomes immediately after insertion of the punctal plugs with the exception of ocular surface staining, which was typically assessed three days after occlusion. <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0002">Burgess 2008</A> and <LINK REF="STD-Feng-2011" TYPE="STUDY">Feng 2011</LINK> did not include sample sizes for all outcomes, so it was unclear whether all randomized participants completed their follow-up examinations. In <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0007">Tsifetaki 2003</A>, one participant was lost to follow-up and one participant discontinued due to local ocular infection, but we could not determine whether these participants were excluded from the analyses. <LINK REF="STD-Qiu-2012" TYPE="STUDY">Qiu 2012</LINK> reported that less than 10% of participants were lost to follow-up, and <LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK> did not report losses to follow-up.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-02-09 11:11:05 +0000" MODIFIED_BY="[Empty name]">
<P>We accessed study protocols and registry records and compared outcomes reported with the outcomes described in the protocol or trial registry record. We judged one study to be at low risk of bias, as we were able to confirm that all of the outcomes defined in the trial registry were reported in the full text (<LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK>). The reports from the remaining included studies did not include a trial registration number, and we did not have access to a study protocol, so we were unable to compare the reported outcomes in the full-text studies with the outcomes before the study began.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-02-09 11:12:59 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias for other potential sources of bias based on declared industry funding and conflict of interest. We rated two studies as being at high risk of bias because the investigators received industry funding or declared a conflict of interest (<LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK>; <LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>). <LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK>, <LINK REF="STD-Qiu-2012" TYPE="STUDY">Qiu 2012</LINK>, and <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK> declared no conflicts of interest and received no funding support or funding from their university, so we assigned them a low risk rating. The remaining studies did not include a source of funding or conflict of interest, and we judged them to be at unclear risk of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-06-19 08:37:21 +0100" MODIFIED_BY="Anupa Shha">
<SUBSECTION>
<HEADING LEVEL="3">1. Punctal plugs versus no punctal plugs</HEADING>
<P>Five trials compared punctal plugs with no punctal plugs (<LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK>; <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>; <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>; <LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>; <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>).</P>
<P>When we refer to the punctal plug group, the group could include participants assigned to intracanalicular punctal plugs alone (<LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK>), silicone punctal plugs alone (<LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>; <LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>; <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>), and collagen plus silicone punctal plugs (<LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>). Similarly, the no punctal plugs group participants received sham treatment (<LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK>; <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>; <LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>) or observation (<LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>; <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>).</P>
<P>Two of the five trials did not report the review outcomes at two weeks, one month, or long-term (<LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK>; <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>). <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK> ascertained outcomes between 6 and 20 weeks after occlusion but did not report a more precise time point than that. <LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK> reported only five days of follow-up, so we did not report any study outcomes in this review.</P>
<SUBSECTION>
<HEADING LEVEL="4">Symptomatic improvement</HEADING>
<P>Of the five trials, three included reports of symptomatic improvement at two weeks, one month, or long-term (<LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>; <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>; <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>). We judged the certainty of the evidence to be very low for all follow-up time points after downgrading for high risk of detection and attrition bias (1 level) and methodological heterogeneity (2 levels).</P>
<P>The three trials reported symptomatic improvement slightly differently. <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> and <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> reported dry eye symptom scores that ranged from 0 to 3 points (0 = absence of the symptom, 1 = mild, 2 = moderate, and 3 = severe). However, <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> also reported "a total symptoms score, which is a measure of the overall severity of the patient's conjunctival and dry eye condition, and the score was calculated by multiplying (for each individual symptom/condition) the numerical values corresponding to frequency and severity, and then adding the products for all symptoms" (p 11). For <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>, we assume that the score could range from 0 to 105 points based on the description in the text (minimum: 0 points for severity x 0 points for frequency x 7 symptoms; maximum: 5 points for severity x 3 points for frequency x 7 symptoms). Finally, <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK> use Ocular and Oral Symptoms score (According to the European Criteria for the Classification of Sjögren's Syndrome, and noted discomfort scores that were a summary score from 0 to 10, with higher values denoting more discomfort.</P>
<P>Since the three trials had high methodological heterogeneity, we report the results as a narrative synthesis. Each of the three trials used different scoring methods; <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK> used the Ocular and Oral Symptoms score, <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> reported a total symptoms score, and <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> reported dry eye symptom scores. <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK> reported little or no difference in the Ocular and Oral Symptoms score, which ranged from 0 to 10 points (MD -0.46 points, 95% CI -1.24 to 0.32; eyes = 26). <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> reported a slight decrease in symptom score, assumed to range from 0 to 105 points, but this finding is not clinically important (MD -2.07 points, 95% CI -2.70 to -1.44; eyes = 61). However, <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> also noted a significant improvement in individual symptom scores at four weeks in the punctal plug group compared with the no punctal plugs group (dryness, itching, burning, foreign body sensation, fluctuating vision, light sensitivity). <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> reported little or no difference in dry eye symptom score, ranging from 0 to 3 points (MD 0.06 points, 95% CI -0.69 to 0.80; eyes = 28)</P>
<P>Two trials included long-term results indicated slightly favorable symptomatic improvement in the punctal plug group versus the no punctal plugs group, but the confidence interval includes values that are not clinically important (<LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>; <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>). As mentioned above, different scales were used by <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> and <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>. <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> reported a slight decrease in symptom score, although not clinically meaningful. However, <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> noted there were also significant differences in the frequency of individual symptom scores (dryness, watery eyes, itching, burning, foreign body sensation, fluctuating vision, light sensitivity) with participants in the collagen/silicone group reporting lower frequency of these symptoms. <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> reported little or no difference in dry eye symptom score, ranging from 0 to 3 points (MD -0.75 points, 95% CI -1.53 to 0.02; eyes = 28)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ocular surface staining</HEADING>
<P>Three trials reported ocular surface staining as an outcome at two weeks, one month, or long-term follow-up (<LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>; <LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>; <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>). <LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK> reported Rose Bengal scores that ranged from 0 to 4, where 0 represented no staining and 4 represented heavy staining. <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> and <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> reported the sodium fluorescein staining scores that ranged from 0 to 4, where 0 represented no staining and 4 represented heavy staining. We judged the certainty of the evidence to be low after downgrading for imprecision as the confidence interval was either wide or clinically not important (1 level) and there was a high risk of attrition bias (1 level).</P>
<P>One of the three trials included two-week results that reported no difference between the groups (<LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>). <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> reported a slightly lower difference in sodium fluorescein staining scores in the punctal plugs group compared with the no punctal plugs group on the scale of 0 to 4, where a lower score is more advantageous (MD &#8722;0.80 points, 95% CI &#8722;1.10 to &#8722;0.50; eyes = 122; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). However, we judged that the difference was not clinically significant.</P>
<P>One of the three trials included one-month results, which showed little or no difference between punctal plugs and no punctal plugs ( <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>). <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> found little or no difference between the groups in fluorescein staining scores of 0 to 4 points (MD 0.59 points, 95% CI &#8722;0.19 to 1.37; eyes = 28; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>One of the three trials included long-term results comparing punctal plugs over no punctal plugs, and punctal plugs were not consistently favored (<LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>). <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> reported that punctal plugs were somewhat better than no punctal plugs for sodium fluorescein staining score (MD -1.50 points, 95% CI -1.88 to -1.12; eyes = 61 <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aqueous tear production</HEADING>
<P>One study reported aqueous tear production (<LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>) assessed using the Schirmer test with anesthesia. We judged the certainty of the evidence to be low after downgrading for imprecision as the confidence interval was either wide or clinically not important (1 level), and there was a high risk of attrition bias (1 level).</P>
<P>
<LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> reported Schirmer score results without specifying the follow-up time point and did not provide data that could be included in a meta-analysis. <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> reported that "Schirmer values tended to increase in the plug group after plug insertion; however, the changes did not reach significance" (p 211).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tear film stability</HEADING>
<P>Two studies reported the tear film stability outcome (<LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>; <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>). We judged the certainty of the evidence to be low after downgrading for inconsistency in results as TBUT did not consistently favor punctal plugs over no punctal plugs at one and three months follow-up (1 level) and there was a high risk of attrition bias (1 level).</P>
<P>
<LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK> reported mean tear film break-up times but did not report the respective standard deviations or the exact P value. The investigators stated: "the average prelens tear film break-up time for all patients at the 2 baseline visits was 16.1s[econds] for the eye assigned to receive the plugs, and 16. 7s[econds] for the control eye. The difference between these values is not statistically significant (paired t-test, p &gt; 0.05)" (p 333).</P>
<P>
<LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> reported tear film stability at one and three months. At the one and three month follow-up visits, <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> found little or no difference in tear film break-up time between the groups (MD &#8722;0.41 seconds, 95% CI &#8722;1.25 to 0.43; eyes = 28 and MD 1.93 seconds, 95% CI 0.67 to 3.20; eyes = 28, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK> and <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> respectively).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Artificial tear use</HEADING>
<P>One trial compared the frequency of artificial tear use (<LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>). We judged the certainty of the evidence to be very low after downgrading for high risk of performance, detection, and attrition bias (2 levels).</P>
<P>At two weeks follow-up, <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> reported slightly less artificial tear use in the punctal plug group compared with the no punctal plugs group (MD -1.40, 95% CI -1.86 to -0.94; eyes = 61; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). At the one-month follow-up visit, there was slightly less artificial tear use in the punctal plug group compared with the no punctal plugs group (MD -1.80, 95% CI -2.09 to -1.51; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). At the long-term follow-up visit <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> reported slightly less artificial tear use in the punctal plug group compared with the no punctal plugs group (MD -2.70, 95% CI -3.11 to -2.29; eyes = 61); <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse outcomes</HEADING>
<P>Three of the five studies reported on adverse outcomes (<LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>; <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>; <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>). We judged the evidence to be very low-certainty after downgrading for limitations in the design and implementation of available studies suggesting high likelihood of attrition bias (2 levels) and sparse and inconsistent data, particularly with respect to epiphora (1 level).</P>
<P>
<LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK> reported several adverse events, all in the punctal plug group (28 participants); 23 participants (82%) had epiphora, 3 (11%) reported itching in the area of plug placement, and 1 (3.5%) had tenderness and swelling of the eyelids with mucous discharge. <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK> reported spontaneous plug loss in 6 of 20 eyes (30%) with silicone punctal plugs. <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> reported epiphora in one participant who had received collagen and silicone punctal plugs. The remaining studies did not report adverse events (<LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK>; <LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Punctal plugs versus cyclosporine</HEADING>
<P>One study compared punctal plugs to cyclosporine (<LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK>). We judged the certainty of the evidence to be very low after downgrading for imprecision of results (1 level) and high risk of detection, performance, attrition, and other bias (two levels).</P>
<SUBSECTION>
<HEADING LEVEL="4">Symptomatic improvement</HEADING>
<P>The study investigators did not report this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ocular surface staining</HEADING>
<P>At one month, <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> reported little or no between-group difference in Rose Bengal staining scores on a scale of 0 to 4 points (MD 0.10 points, 95% CI &#8722;0.32 to 0.52; eyes = 20). The Rose Bengal staining score "was graded on the following scale: 0 = no staining, 1 = staining of the nasal conjunctiva only, 2 = staining of both the nasal and temporal conjunctiva, 3 = peripheral corneal staining, 4 = central corneal staining." p 806 The study investigators of <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> stated: "there was greater improvement in conjunctival staining with cyclosporine or the combination than with plugs alone." It was unclear whether Rose Bengal or fluorescein staining was used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aqueous tear production</HEADING>
<P>At one month, <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> also reported little or no difference between the punctal plug and cyclosporine groups for aqueous tear production (Schirmer test without topical anesthesia: MD 6.00 mm/3 min, 95% CI 4.96 to 7.04; eyes = 20; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). Likewise at long-term follow-up, there was little or no difference between the punctal plug and cyclosporine groups for aqueous tear production (MD 0.80 mm/3 min, 95% CI -0.74 to 2.34; eyes = 20; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tear film stability</HEADING>
<P>
<LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> did not report this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Artificial tear use</HEADING>
<P>At one month, <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> reported less daily artificial tear use in the punctal plug group compared with the cyclosporine group (MD &#8722;1.70 applications/day, 95% CI &#8722;3.04 to &#8722;0.36; eyes = 20; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>). But at long-term follow-up, there was little or no difference between the punctal plug and cyclosporine groups for daily artificial tear use (MD 1.10 applications/day, 95% CI -0.04 to 2.24; eyes = 20)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse outcomes</HEADING>
<P>
<LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> reported that 1 of 11 participants (9%) experienced plug displacement in the punctal plug group, while 1 of 11 participants (9%) in the cyclosporine group experienced a burning sensation.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Punctal plugs versus oral pilocarpine</HEADING>
<P>One trial compared punctal plugs to oral pilocarpine (<LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Symptomatic improvement</HEADING>
<P>
<LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK> reported significantly greater improvements in subjective ocular symptoms in participants who received oral pilocarpine (90% improvement) versus collagen punctal plugs (60% improvement) at three months (RR 0.69, 95% CI 0.49 to 0.95; eyes = 55; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). The study investigators defined improvement in subjective ocular symptoms as an improvement of &gt;55 mm for responses to the eye questionnaire on a 100 mm VAS. We judged the certainty of the evidence to be very low after downgrading for high risk of performance and detection bias, as the participant and outcome assessors were not masked to the treatment groups, and the self-reported symptomatic improvement could have been biased (2 levels) and imprecision as the confidence interval is either wide or clinically not important (1 level).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ocular surface staining</HEADING>
<P>
<LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK> noted small differences in Rose Bengal ocular surface staining scores, with participants who received oral pilocarpine showing more improvement at three months than participants randomized to collagen punctal plugs. The Rose Bengal ocular surface staining scores was graded using the van Bijsterveld schema, which is on a scale of 0 to 9 points (right eyes: MD 0.10 points, 95% CI &#8722;0.56 to 0.76; eyes = 55; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>.1; left eyes: MD 0.60 points, 95% CI 0.10 to 1.10; eyes = 55; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>.1). Mean differences ± standard deviations at follow-up were: &#8722;1.0 point ± 1.3 (right eye) and &#8722;1.1 points ± 1.0 (left eye) for oral pilocarpine; and &#8722;0.9 points ± 1.2 (right eye) and &#8722;0.5 points ± 0.9 (left eye) for collagen punctal plugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aqueous tear production</HEADING>
<P>
<LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK> noted no difference in the Schirmer test (without topical anesthesia) scores when comparing oral pilocarpine versus collagen punctal plugs (right eyes: MD &#8722;0.10 mm/5 min, 95% CI &#8722;0.53 to 0.33; eyes = 55; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>.1; left eyes: MD &#8722;0.50 mm/5 min, 95% CI &#8722;1.06 to 0.06; eyes = 55; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>.2). Mean differences ± standard deviations at follow-up were: 0.3 ± 1.1 mm (right eyes) and 1.2 ± 1.3 mm (left eyes) for oral pilocarpine; and 0.2 ± 0.4 mm (right eyes) and 0.7 ± 0.8 mm (left eyes) for collagen punctal plugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tear film stability</HEADING>
<P>The study investigators did not report this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Artificial tear use</HEADING>
<P>The study investigators did not report this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse outcomes</HEADING>
<P>
<LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK> reported that "four patients had mild headache, of whom three also presented with nausea, vomiting, and sweating" (p 1205), and "one patient in the inferior puncta occlusion group had blepharitis and was withdrawn from the study" (p 1204).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Punctal plugs versus artificial tears</HEADING>
<P>Five trials compared punctal plugs with artifical tears (<LINK REF="STD-Feng-2011" TYPE="STUDY">Feng 2011</LINK>; <LINK REF="STD-Qiu-2012" TYPE="STUDY">Qiu 2012</LINK>; <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK>; <LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK>; <LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK>). <LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK> compared punctal plugs plus artificial tears versus artificial tears alone, while the rest of the trials compared punctal plugs versus artificial tears. Also <LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK> randomized both eyes of each participants to the same treatment group, hence they reported the mean and SD for the left and right eyes individually. All participants included in <LINK REF="STD-Feng-2011" TYPE="STUDY">Feng 2011</LINK> had undergone LASIK surgery.</P>
<SUBSECTION>
<HEADING LEVEL="4">Symptomatic improvement</HEADING>
<P>Four of the five trials reported symptomatic improvement (<LINK REF="STD-Qiu-2012" TYPE="STUDY">Qiu 2012</LINK>; <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK>; <LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK>; <LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK>). We judged the certainty of the evidence to be very low after downgrading for there was a high risk of performance and detection bias, as the lack of masking in participants and outcome assessors could have influenced self-reported symptomatic improvement (2 levels), and there was unexplained statistical heterogeneity or inconsistent results (1 level), and imprecision of results as the confidence interval was either wide or clinically not important (1 level).</P>
<P>At two weeks, <LINK REF="STD-Qiu-2012" TYPE="STUDY">Qiu 2012</LINK> reported eight symptom outcomes: dryness, foreign body sensation, visual fatigue, burning, red eye, stinging, secretion on eyelash, and difficulty opening eyes in the morning due to dryness. Each symptom was scored from "1 to 10; 1 being the absence of the type of discomfort and 10 being the most severe level that one could bear." There was little or no difference in symptomatic improvement score (MD &#8722;0.30 points, 95% CI &#8722;3.87 to 3.27; eyes = 28; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
<P>At three months, <LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK> reported more improvements in ocular symptoms in the group receiving punctal plugs plus artificial tears than in the group receiving artifical tears alone (RR 2.29, 95% CI 1.20 to 4.38; eyes = 54; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). As mentioned above, improvements in subjective ocular symptoms was defined as an improvement of &gt;55 mm for responses to the eye questionnaire on a 100 mm VAS.</P>
<P>At three months, <LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK> and <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK> reported mean symptomatic improvement scores. <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK> reported scores on the 12-item Ocular Surface Disease Index (OSDI). Each item on the questionnaire is graded from 0 to 4 points, where 0 = never, 1 = some of the time, 2 = half of the time, 3 = most of the time, and 4 = all the time. <LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK> reported a symptoms score, defined as the sum of scores for dryness, foreign body sensation, and visual fatigue. The dryness score was graded from 0 to 6 points, where 0 = none, 2 = occasional, 4 = my eyes are often dry and uncomfortable, 6 = my eyes are always unbearably dry. Foreign body sensation was scored from 0 to 3 points, where 0 = none; 1 = occasional; 2 = often, I often want to blink; and 3 = often, I have to blink frequently, and want to rub my eyes with my hands. The visual fatigue score ranged from 0 to 6 points, where 0 = none, 2 = quick to fatigue, 4 = the duration that I can read or see has shortened, 6 = my eyelids feel like falling off, so I cannot read or see. Punctal plugs showed slightly better symptomatic improvement than artificial tears group at three months (SMD &#8722;0.88, 95% CI &#8722;1.24 to &#8722;0.51; eyes = 130; I<SUP>2</SUP> = 86%; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ocular surface staining</HEADING>
<P>We judged the certainty of the evidence to be low after downgrading for imprecision in results as the confidence interval is wide and clinically not important (2 levels). At two-week follow-up, <LINK REF="STD-Feng-2011" TYPE="STUDY">Feng 2011</LINK> reported little or no difference in Rose Bengal scores between groups (MD 0.81 points, 95% CI &#8722;0.09 to 1.71; eyes = 54; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>)</P>
<P>Both <LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK> and <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK> reported ocular surface staining at three months follow-up but assessed it differently. Because <LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK> randomized both eyes of each participant to the same treatment group, they reported the mean and SD for the left and right eye respectively. Further more, both treatment groups received artificial tears, and noted small differences in Rose Bengal ocular surface staining scores on a scale of 0 to 3 (right eyes: MD 0.10 points, 95% CI &#8722;0.56 to 0.76; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>.1; left eyes: MD 0.60 points, 95% CI 0.10 to 1.10; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>.2). <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK> reported little or no difference in fluorescein staining scores on a scale of 0 to 3 (MD &#8722;0.21 points, 95% CI &#8722;0.49 to 0.07; eyes = 40; <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aqueous tear production</HEADING>
<P>We judged the certainty of the evidence to be low after downgrading for imprecision as the confidence interval are wide or clinically not important (1 level) and results were inconsistent (1 level). At two weeks, <LINK REF="STD-Feng-2011" TYPE="STUDY">Feng 2011</LINK> noted little or no difference in Schirmer scores (without topical anesthesia) when comparing collagen punctal plugs versus artificial tears (MD 0.83 mm/5 min, 95% CI -1.05 to 2.71; eyes = 82; <LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>).</P>
<P>At three months, <LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK> noted small differences in Schirmer scores (without topical anesthesia) when both treatment groups received artificial tears and both eyes of each participant was in the same treatment group (right eye: MD 0.00 mm/5 min, 95% CI -0.33 to 0.33; <LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>.1; left eye: MD 0.10 mm/5 min, 95% CI -0.35 to 0.55; <LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>.2). The meta-analysis of <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK> and <LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK> favored punctal plugs over artificial tears (MD 2.16 mm/5 min, 95% CI 1.41 to 2.90; eyes = 130; I<SUP>2</SUP> = 0%; <LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tear film stability</HEADING>
<P>We judged the certainty of the evidence to be moderate after downgrading for imprecision of results (1 level).</P>
<P>At two weeks, the pooled analysis of <LINK REF="STD-Feng-2011" TYPE="STUDY">Feng 2011</LINK> and <LINK REF="STD-Qiu-2012" TYPE="STUDY">Qiu 2012</LINK> showed little or no difference in tear film stability when comparing collagen punctal plugs versus artificial tears (MD 0.26 seconds, 95% CI &#8722;0.57 to 1.09; eyes = 82; I<SUP>2</SUP> = 0%; <LINK REF="CMP-004.10" TYPE="ANALYSIS">Analysis 4.10</LINK>).</P>
<P>At three months, the pooled analysis of <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK> and <LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK> showed little or no difference in tear film stability when comparing collagen punctal plugs versus artificial tears (MD 1.02 seconds, 95% CI 0.60 to 1.44; eyes = 130; I<SUP>2</SUP> = 55%; <LINK REF="CMP-004.11" TYPE="ANALYSIS">Analysis 4.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Artificial tear use</HEADING>
<P>The investigators of these studies did not report this outcome, as one of the interventions consisted of artificial tears.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse outcomes</HEADING>
<P>We judged the certainty of the evidence to be low after downgrading for imprecision because of wide confidence intervals (2 levels). <LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK> reported that "four patients had mild headache, of whom three also presented with nausea, vomiting, and sweating" (p 1205) and that "one patient in the inferior puncta occlusion group had blepharitis and was withdrawn from the study" (p 1204).</P>
<P>
<LINK REF="STD-Qiu-2012" TYPE="STUDY">Qiu 2012</LINK> reported little or no difference in punctate epithelial keratopathy between the intervention groups (RR 1.33, 95% CI 0.57 to 3.12; eyes = 28; <LINK REF="CMP-004.12" TYPE="ANALYSIS">Analysis 4.12</LINK>).</P>
<P>
<LINK REF="STD-Feng-2011" TYPE="STUDY">Feng 2011</LINK>, <LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK>, and <LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK> did not report adverse outcomes.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Punctal plugs in the upper versus lower puncta</HEADING>
<P>Three trials compared upper versus lower punctal plug placement (<LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK>; <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK>; <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK>). <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK> compared participants with lower puncta occlusion only, with participants receiving a combination of upper and lower puncta occlusion. <LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK> and <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK> investigated collagen punctal plugs while <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK> included silicone punctal plugs. <LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK> reported only 10 days of follow-up, so we present no quantitative data for this comparison.</P>
<SUBSECTION>
<HEADING LEVEL="4">Symptomatic improvement</HEADING>
<P>We judged the certainty of the evidence to be low after downgrading for imprecision of results as the confidence interval was wide (1 level) and potential bias as there was unclear risk of selection, performance, detection, attrition, and reporting bias (1 level). None of the studies reported this outcome beyond one month of follow-up. <LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK> did not report this outcome.</P>
<P>
<LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK> reported median McMonnies symptom scores for participants receiving collagen punctal plugs in the lower puncta versus the upper and lower puncta for the right and left eyes separately. While study investigators of <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK> noted using a modified McMonnies questionnaire, they did not publish the modified questionnaire, but did note that higher scores denote increased symptom reports. The median (range) values for the right eye at baseline, 5 days, and 12 days post-occlusion were 7 points (3 to 12), 3 points (0 to 8), and 3 points (0 to 10), respectively, for participants with collagen plugs in their lower puncta and 7 points (6 to 13), 3 points (0 to 11) and 3 points (0 to 7), respectively, for participants with collagen plugs in their lower and upper puncta. The authors stated that "the median symptom score reduced significantly from 7 to 3 between baseline and day 5," but "there was no significant shift in symptom score between days 5 and 12 (Wilcoxon signed-rank test)" (p 3).</P>
<P>At one month, <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK> noted little or no difference in symptomatic improvement when comparing punctal plugs in the upper versus lower puncta (RR 1.07, 95% CI 0.85 to 1.36; eyes = 43; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK> reported the number of participants who expressed satisfaction with resolution of symptoms or satisfaction with resolution of symptoms despite epiphora.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ocular surface staining</HEADING>
<P>We judged the certainty of the evidence to be low after downgrading for imprecision of results as the confidence interval was wide (1 level) and potential bias as there was unclear risk of selection, performance, detection, attrition, and reporting bias (1 level). <LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK> and <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK> measured ocular surface staining using a sodium fluorescein strip graded from 0 to 3 points, with 0 indicating no staining and 3 indicating the most intense staining.</P>
<P>At one month, <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK> reported the means ± standard deviation of the upper and lower puncta group to be 0.4 ± 0.9 points and 0.0 ± 0.0 points; therefore, we were not able to estimate the mean difference. None of the trials reported this outcome at two weeks or for long-term follow-up. <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK> did not report this outcome at any follow-up time.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aqueous tear production</HEADING>
<P>We judged the certainty of the evidence to be low after downgrading for imprecision of results as the confidence interval was wide (1 level) and potential bias as there was unclear risk of selection, performance, detection, attrition, and reporting bias (1 level). <LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK> measured aqueous tear production using a Schirmer test with anesthesia, but <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK> used a Schirmer test without anesthesia (mm/5 min).</P>
<P>At one month, <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK> reported slightly less aqueous tear production in the peripheral cornea when comparing punctal plugs in the upper puncta to punctal plugs in the lower puncta (MD &#8722;4.50 mm/5 min, 95% CI &#8722;8.63 to &#8722;0.37; eyes = 43; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>). None of the trials reported this outcome at two weeks or for long-term follow-up. <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK> did not report this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tear film stability</HEADING>
<P>We judged the certainty of the evidence to be low after downgrading for imprecision of results as the confidence interval was wide (1 level) and potential bias as there was unclear risk of selection, performance, detection, attrition, and reporting bias (1 level). Both <LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK> and <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK> reported tear film stability via assessment with sodium fluorescein.</P>
<P>At one month, <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK> noted little or no difference in tear film break-up time between punctal plugs in the upper versus lower puncta (MD &#8722;0.10 seconds, 95% CI &#8722;1.73 to 1.53; eyes = 43; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>). None of the trials reported this outcome at two weeks or at long-term follow-up. <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK> did not report this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Artificial tear use</HEADING>
<P>None of the studies reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse outcomes</HEADING>
<P>We judged the certainty of the evidence to be low after downgrading for imprecision of results as the confidence interval was wide (1 level) and potential bias as there was unclear risk of selection, performance, detection, attrition, and reporting bias (1 level). <LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK> reported that "no complication was observed in dry eye patients or control subjects during the period of this study." It is unclear which complications were ana lysed. <LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK> and <LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK> did not report this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Acrylic punctal plugs versus silicone punctal plugs</HEADING>
<P>
<LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK> was the only trial that compared acrylic punctal plugs with silicone punctal plugs; the investigators reported outcomes at approximately 11 weeks of follow-up. We judged the certainty of the evidence for all outcomes to be low after downgrading for imprecision as the confidence interval was wide (2 levels) and risk of bias as selection, attrition and reporting bias were judged to be unclear (1 level). The study investigators did not report this outcome at two weeks or four weeks.</P>
<SUBSECTION>
<HEADING LEVEL="4">Symptomatic improvement</HEADING>
<P>
<LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK> reported no difference in mean subjective symptom score when comparing silicone and acrylic punctal plugs. The study investigators used a "subjective symptom scoring was assessed for each eye by using standard, vertical, nonanchored visual analog scales 10 cm in length for symptoms of dryness, grittiness, foreign body sensation, pain, stinging, burning, and itching. After rating symptoms individually, we summed scores to give the total symptom score." We assumed the score ranged from 0 to 70 points, where a lower score was more advantageous. At baseline and approximately 11 weeks follow-up, mean scores ± standard deviations were 29.6 points ± 16.9 and 21.0 points ± 14.5, respectively, among participants with silicone plugs, and 38.9 points ± 16.7 and 21.9 points ± 18.8 among participants with acrylic plugs group (MD 0.90 points, 95% CI &#8722;6.94 to 8.74; eyes = 36; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ocular surface staining</HEADING>
<P>
<LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK> found no differences in Rose Bengal and sodium fluorescein ocular surface staining when comparing silicone versus acrylic punctal plugs (Rose Bengal baseline versus approximately 11 weeks follow-up on a scale of 0 to 3 points: MD 0.45 points, 95% CI &#8722;0.09 to 0.99; eyes = 36; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>.1; sodium fluorescein baseline versus approximately 11 weeks follow-up on a scale of 0 to 3 points: MD 0.43 points, 95% CI &#8722;1.61 to 2.47; eyes = 36; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aqueous tear production</HEADING>
<P>Similarly, <LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK> found no difference in mean Schirmer test results (without topical anesthesia) when comparing silicone versus acrylic punctal plugs (MD 1.07 mm, 95% CI &#8722;1.62 to 3.76; eyes = 36; <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>). However, <LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK> did not report the duration of the Schirmer test.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tear film stability</HEADING>
<P>
<LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK> reported no difference in tear film break-up time when comparing silicone versus acrylic punctal plugs (MD 0.36 seconds, 95% CI &#8722;1.22 to 1.94; eyes = 36; <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Artificial tear use</HEADING>
<P>In the <LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK> study, silicone and acrylic punctal plugs reduced the use of artificial tears in 10 (55.6%) and 11 (61.1%) participants, respectively, but the difference in mean reduction in artificial tear use (as measured by the symptom score) was not statistically significant (mean 1.55 applications, 95% CI &#8722;1.50 to 4.60; P = 0.27, <I>t</I> test).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse outcomes</HEADING>
<P>
<LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK> reported that 1 of 18 eyes receiving an acrylic punctal plug experienced epiphora, 1 of 18 eyes receiving a silicone punctal plug eye experienced intermittent ocular irritation, and 2 eyes in the silicone punctal plug group and 1 in the acrylic punctal plug experienced temporary foreign body sensation.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7. Intracanalicular punctal plugs versus silicone punctal plugs</HEADING>
<P>
<LINK REF="STD-Rabensteiner-2013" TYPE="STUDY">Rabensteiner 2013</LINK> was the only trial to compare intracanalicular punctal plugs with silicone punctal plugs. For all outcomes, we downgraded the evidence two levels to very low-certainty because of wide confidence intervals indicating imprecision of effect estimates (2 levels) and high risk of attrition bias (1 level).</P>
<SUBSECTION>
<HEADING LEVEL="4">Symptomatic improvement</HEADING>
<P>
<LINK REF="STD-Rabensteiner-2013" TYPE="STUDY">Rabensteiner 2013</LINK> reported subjective dry eye symptoms for each eye. Investigators measured soreness, scratching, grittiness, dryness and/or burning using a 100 mm visual analog scale (VAS; 0 mm = no symptoms, 100 mm = maximum intensity). At three months follow-up, moderate-certainty evidence showed little or no difference in symptomatic improvement score (MD &#8722;3.10 mm, 95% CI &#8722;14.97 to 8.77; eyes = 57; <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ocular surface staining</HEADING>
<P>At three months follow-up, moderate-certainty evidence showed little or no difference in ocular surface staining for Rose Bengal on the van Bijsterveld scale of 0 to 9 points (MD 0.20 points, 95% CI &#8722;0.71 to 1.11; <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>.1) and fluorescein of a scale from 0 to 4 points (MD 0.40 points, 95% CI &#8722;0.04 to 0.84; <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>.2). Fluorescein was graded using zero points indicates no staining, one point less than one-third, two points less than two thirds, and three points more than two-thirds staining of the cornea.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aqueous tear production</HEADING>
<P>At three months follow-up, moderate-certainty evidence showed little or no difference in aqueous tear production (MD &#8722;0.70 mm/5 min, 95% CI &#8722;3.46 to 2.06; <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tear film stability</HEADING>
<P>At three months follow-up, moderate-certainty evidence showed little or no difference in tear film stability (MD 0.80 seconds, 95% CI &#8722;0.00 to 1.60; <LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Artificial tear use</HEADING>
<P>At three months follow-up, moderate-certainty evidence showed little or no difference in daily artificial tear use (MD &#8722;1.30 applications, 95% CI &#8722;4.04 to 1.44; <LINK REF="CMP-007.05" TYPE="ANALYSIS">Analysis 7.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse outcomes</HEADING>
<P>No studies reported adverse events.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">8. Collagen punctal plugs versus silicone punctal plugs</HEADING>
<P>
<LINK REF="STD-Altan_x002d_Yaycioglu-2005" TYPE="STUDY">Altan-Yaycioglu 2005</LINK> and <LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK> compared collagen punctal plugs with silicone punctal plugs. <LINK REF="STD-Altan_x002d_Yaycioglu-2005" TYPE="STUDY">Altan-Yaycioglu 2005</LINK> did not report any review outcomes at two weeks, one month, or at long-term follow-up. <LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK> reported symptomatic improvement (measured using the Canadian Dry Eye Assessment), aqueous tear production (Schirmer I without anesthesia), and tear film stability at one month and at long-term follow-up (six months). The Canadian Dry Eye Assessment range from 0 to 48 points; where less than 5 points was normal, 5 to 15 points was mild, 20 to 25 points was moderate, 30 to 48 points was severe. However, the study investigators did not report standard deviations or the exact P value at the one month follow-up. At the long-term follow-up, we used the reported group means and exact P values to compute the MD and respective 95% CI.</P>
<P>We judged the certainty of the evidence for all outcomes to be very low after downgrading for imprecision of estimates as the confidence interval were wide or clinically not important (2 levels) and risk of bias as we judged selection, performance, detection, attrition, and reporting bias to be unclear (1 level).</P>
<SUBSECTION>
<HEADING LEVEL="4">Symptomatic improvement</HEADING>
<P>At long-term follow-up, <LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK> reported little or no difference between the groups for Canadian Dry Eye Assessment scores on a scale of 0 to 48 points (MD 0.81 points, 95% CI &#8722;2.94 to 4.56; eyes = 50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ocular surface staining</HEADING>
<P>At long-term follow-up, <LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK> reported both sodium fluorescein staining scores and lissamine green staining scores. There were few or no between-group differences for fluorescein staining score on a scale of 0 to 4 points (MD &#8722;0.76 points, 95% CI &#8722;18.5 to 17.0) and for lissamine green score on a scale of 0 to 3 points (MD 0.03 points, 95% CI &#8722;0.15 to 0.21; eyes = 50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aqueous tear production</HEADING>
<P>At long-term follow-up, <LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK> reported little or no difference between groups for the Schirmer test I without anesthesia (MD 0.67 mm, 95% CI &#8722;17.28 to 18.62; eyes = 50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tear film stability</HEADING>
<P>At long-term follow-up, <LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK> reported little or no between-group differences for tear break-up time (MD 0.21 seconds, 95% CI &#8722;1.81 to 2.23; eyes = 50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Artificial tear use</HEADING>
<P>At long-term follow-up, <LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK> reported little or no difference between groups in daily frequency of artificial tear applications (MD &#8722;0.06 applications/day, 95% CI &#8722;0.23 to 0.12; eyes = 50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse outcomes</HEADING>
<P>
<LINK REF="STD-Altan_x002d_Yaycioglu-2005" TYPE="STUDY">Altan-Yaycioglu 2005</LINK> stated that "none of the patients developed adverse events related to the procedure" (p 88.e3). Likewise, <LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK> reported that "there were no additional significant differences between groups and no plug complications reported" (p 238).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-04-25 21:06:43 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2017-04-25 21:06:43 +0100" MODIFIED_BY="[Empty name]">
<P>Despite the inclusion of 18 trials, only a maximum of two studies contributed outcome data at any given follow-up time point across eight comparisons due to significant study heterogeneity. Punctal plugs did not show consistent symptomatic improvement over the observation group at 2 weeks, 1 month, or at 2 to 12 months follow-up. When comparing symptomatic improvement in different types of punctal plugs at long-term follow-up, there was little or no difference between silicone and collagen or acrylic punctal plugs. Punctal plugs may be more effective than oral pilocarpine, but artificial tears may be more effective than punctal plugs for treating dry eye signs and symptoms. The location of the occlusion (lower versus upper puncta) resulted in little or no difference in symptomatic improvement. Overall, this review update includes new evidence, though we cannot draw strong conclusions from the current body of evidence.</P>
<SUBSECTION>
<HEADING LEVEL="3">Adverse outcomes</HEADING>
<P>
<A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0007">Tsifetaki 2003</A> was the only study to report on adverse outcomes with collagen plugs only; 1 participant of 28 discontinued the study due to a local infection. The most common adverse outcomes in silicone plug studies were: spontaneous plug loss (6 of 28 in <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0005">Mansour 2007</A>, 6 of 20 in <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0002">Burgess 2008</A>); epiphora (1 case each in <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0002">Burgess 2008</A> and <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0006">Nava-Castaneda 2003</A>, 4 in <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0003">Farrell 2003</A>); ocular irritation or foreign body sensation (3 cases in <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0002">Burgess 2008</A>); and local inflammatory reaction to silicone (1 case in <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0005">Mansour 2007</A>). In addition, <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0005">Mansour 2007</A> reported one case of corneal melting and perforation, and <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006775.pub2/full#CD006775-bbs2-0006">Nava-Castaneda 2003</A> reported one instance of corneal ulceration. The trial investigators believed that neither of these serious conditions was related to the punctal plugs.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-02-17 16:42:11 +0000" MODIFIED_BY="[Empty name]">
<P>We included 18 trials, but no more than two studies reported the same review outcome at any review follow-up time points across eight comparisons of interventions. Meta-analysis was not possible for the primary review outcome thus the evidence regarding punctal occlusion for dry eye-related symptoms is incomplete. </P>
<P>The certainty of the evidence ranged from moderate to very low, as we frequently downgraded the evidence for the high risk of bias or imprecision in effect estimates.</P>
</APPLICABILITY_OF_FINDINGS>
<POTENTIAL_BIASES MODIFIED="2017-02-17 16:42:24 +0000" MODIFIED_BY="[Empty name]">
<P>We used standard Cochrane methods to conduct this review and are unaware of any potential bias.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-02-17 15:23:18 +0000" MODIFIED_BY="[Empty name]">
<P>Many investigators have published reviews of punctal plug use for dry eye syndrome (<LINK REF="REF-Hamano-2005" TYPE="REFERENCE">Hamano 2005</LINK>; <LINK REF="REF-Marcet-2015" TYPE="REFERENCE">Marcet 2015</LINK>; <LINK REF="REF-Yellepeddi-2015" TYPE="REFERENCE">Yellepeddi 2015</LINK>; <LINK REF="REF-Jehangir-2016" TYPE="REFERENCE">Jehangir 2016</LINK>). Nevertheless, these reviews do not include meta-analyses of randomized controlled trials or other comparative studies. <LINK REF="REF-Hamano-2005" TYPE="REFERENCE">Hamano 2005</LINK> and <LINK REF="REF-Yellepeddi-2015" TYPE="REFERENCE">Yellepeddi 2015</LINK> was a general review of punctal plug types and the ways in which punctal plugs are used for treating dry eye. <LINK REF="REF-Marcet-2015" TYPE="REFERENCE">Marcet 2015</LINK> was a narrative review of 27 studies, which included both case series and randomized trials. <LINK REF="REF-Jehangir-2016" TYPE="REFERENCE">Jehangir 2016</LINK> provided an extensive review of the available punctal plug materials, designs, and uses, as well as the complications associated with punctal plugs treatment. Overall, the authors concluded that punctal plugs were an effective and relatively safe means for treating dry eye.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-06-17 13:34:27 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2017-04-26 17:16:33 +0100" MODIFIED_BY="[Empty name]">
<P>The effectiveness of punctal plugs for treating dry eye syndrome cannot be assessed based on the evidence in this updated systematic review. The investigators of the included studies suggest that punctal plugs are efficacious, but the strength of the evidence is limited due to high methodological and clinical heterogeneity. Effectiveness may vary by the characteristics of the punctal plug, i.e., placement, materials used, shape, and size. It is also possible that punctal plugs may not be an effective treatment for every patient based upon the classification, etiology, and severity of dry eye. Thus, additional randomized trials are necessary to assess the effectiveness of punctal plugs based on design, classification of disease, and against the appropriate gold standard treatment.</P>
<P>Overall, punctal plugs are believed to be a relatively safe treatment, yet their use is not without potential complications, including epiphora, punctal plug loss, or rarely, a more serious complication such as dacryocystitis.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-06-17 13:34:27 +0100" MODIFIED_BY="[Empty name]">
<P>The current evidence suggests that punctal plugs are a modestly effective means of treating dry eye, though we cannot draw strong conclusions about the effectiveness of punctal plugs based on the findings of this systematic review. Heterogeneity in methodology among the included studies, such as varied participant characteristics, testing protocols, follow-up periods, punctal plug designs and comparison interventions were limiting factors. The limitations highlighted in this review should be addressed in future trials to maximize study comparability and enable more comprehensive and generalizable conclusions about the utility of punctal plugs for treating dry eyes. </P>
<P>Investigators should recruit a sufficient number of participants utilizing statistical techniques to determine the appropriate sample size based on the anticipated treatment effect. Trial investigators should also avoid quasi randomization and should employ appropriate methods for allocation concealment and masking of participants and personnel assessing outcomes. When masking of personnel administering the intervention is not possible, excluding these persons from the assessment of treatment outcomes through use of masked examiners and objective outcomes minimizes information bias. Assessment of outcomes at two months or longer should be considered to provide evidence of the long term effect of punctal occlusion. Standardized patient oriented outcome measures would allow comparisons across individual studies. As well, investigators should report the unit of analysis and appropriately account for the correlation among fellow eyes in analyses.</P>
<P>Future randomized controlled trials on dry eye should examine the efficacy of punctal plugs for treating the two primary types of dry eye, aqueous deficient and evaporative dry eye, or more specifically the utility of using punctal plugs for treating conditions like Sjögren's syndrome (<LINK REF="REF-DEWS-2007a" TYPE="REFERENCE">DEWS 2007a</LINK>). Comparisons of punctal plugs and other dry eye treatments such as topical cyclosporine and serum should be conducted to guide treatment decisions for each classification of dry eye (<LINK REF="REF-DEWS-2007b" TYPE="REFERENCE">DEWS 2007b</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-06-17 13:35:53 +0100" MODIFIED_BY="[Empty name]">
<P>The authors would like to thank Iris Gordon and Lori Rosman, Informationists for Cochrane Eyes and Vision (CEV), for designing the search strategy and conducting the electronic searches. We also acknowledge the CEV editorial team's support during the preparation of this review and thank Oliver Schein and Robert Wojciechowski for their contributions to the prior review published in 2010. We would like to also acknowledge Ke Chen, Xinyi Chen, and Shi-ming Li for their help in screening full-text reports, abstracting data, and translating Mandarin publications. Finally, we would like to thank our peer reviewers Jod Mehta and Barbara Hawkins.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-06-19 09:02:50 +0100" MODIFIED_BY="Anupa Shha">
<P>AE: none known.<BR/>AL: none known.<BR/>AP: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-02-09 15:00:39 +0000" MODIFIED_BY="[Empty name]">
<P>Review co-ordination: AE, AL</P>
<P>Data collection for the review update</P>
<UL>
<LI>Designing search strategies: AE, RW, OS, CEV Trials Search Co-ordinator</LI>
<LI>Undertaking searches: CEV Trials Search Co-ordinator</LI>
<LI>Screening search results: AE, AL</LI>
<LI>Organizing retrieval of papers: AL</LI>
<LI>Screening retrieved papers against inclusion criteria: AE, AL</LI>
<LI>Appraising quality of papers: AE, AL</LI>
<LI>Extracting data from papers: AE, AL</LI>
<LI>Writing to authors of papers for additional information: AE</LI>
<LI>Providing additional data about papers: AE</LI>
<LI>Obtaining and screening data on unpublished studies: AE, AL</LI>
</UL>
<P>Data management for the review</P>
<UL>
<LI>Entering data into RevMan: AE, AL</LI>
<LI>Analyzing data: AE, AL</LI>
</UL>
<P>Interpretation of data</P>
<UL>
<LI>Providing a methodological perspective: AE, AL</LI>
<LI>Providing a clinical perspective: AP</LI>
<LI>Providing a policy perspective: AE, AP</LI>
<LI>Providing a consumer perspective: AE</LI>
</UL>
<P>Writing the review: AE, AL, AP<BR/>Providing general advice on the review: AE, AL, AP<BR/>Securing funding for the review: NA<BR/>Performing previous work that was the foundation of the current study: NA</P>
<P>Guarantor for review: AE</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-02-09 15:03:33 +0000" MODIFIED_BY="[Empty name]">
<P>Cochrane methodology regarding assessments of the risk of bias in included studies has changed, and the review authors updated the '<LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK>' section of the Methods to reflect these updated methodological. We also added methods for assessing the certainty of evidence using the GRADE approach and preparing 'Summary of findings' tables.</P>
<P>
<LINK TAG="DATA_SYNTHESIS" TYPE="SECTION">Data synthesis</LINK>: We did not solely base our decision to perform meta-analysis on the I<SUP>2</SUP> statistic; we took statistical, methodological, and clinical heterogeneity into consideration.</P>
<P>We modified the follow-up time points for our primary and secondary outcomes to two and four weeks. Two and four weeks were considered the clinically relevant time points for this review because this is when clinicians tend to schedule follow-up visits for dry eye patients. We also chose these time points because two other systematic reviews (treatment of dry eye with over the counter artifical tears and treatment of dry eye with autologous serum) on dry eye used these time points when comparing similar dry eye outcomes (<LINK REF="REF-Pan-2013" TYPE="REFERENCE">Pan 2013</LINK>; <LINK REF="REF-Pucker-2016" TYPE="REFERENCE">Pucker 2016</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-06-19 09:19:18 +0100" MODIFIED_BY="Anupa Shah">
<STUDIES MODIFIED="2017-05-08 19:19:57 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2017-02-21 14:59:47 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Altan_x002d_Yaycioglu-2005" MODIFIED="2010-07-09 13:52:58 +0100" MODIFIED_BY="[Empty name]" NAME="Altan-Yaycioglu 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-07-09 13:52:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altan-Yaycioglu R, Gencoglu EA, Akova YA, Dursun D, Cengiz F, Akman A</AU>
<TI>Silicone versus collagen plugs for treating dry eye: results of a prospective randomized trial including lacrimal scintigraphy</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2005</YR>
<VL>140</VL>
<NO>1</NO>
<PG>88-93</PG>
<IDENTIFIERS MODIFIED="2010-07-09 13:51:16 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854704"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854703"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brissette-2015" MODIFIED="2017-02-21 14:46:40 +0000" MODIFIED_BY="[Empty name]" NAME="Brissette 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-02-21 14:46:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Brissette 2015</AU>
<TI>Query regarding your publication in AJO: Punctal plug retention rates for the treatment of moderate to severe dry eye (for inclusion in a systematic review)</TI>
<SO>Email to: Dr. Baxter</SO>
<YR>19 December 2016</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773808"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-02-10 12:19:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Brissette AR, Mednick ZD, Schweitzer KD, Bona MD, Baxter SA</AU>
<TI>Punctal plug retention rates for the treatment of moderate to severe dry eye: a randomized, double-masked, controlled clinical trial</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2015</YR>
<VL>160</VL>
<NO>2</NO>
<PG>238-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773809"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773807"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burgess-2008" MODIFIED="2017-02-21 14:47:38 +0000" MODIFIED_BY="[Empty name]" NAME="Burgess 2008" YEAR="2008">
<REFERENCE MODIFIED="2017-02-21 14:47:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgess PI, Koay P, Clark P</AU>
<TI>SmartPlug versus silicone punctal plug therapy for dry eye: a prospective randomized trial</TI>
<SO>Cornea</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>4</NO>
<PG>391-4</PG>
<IDENTIFIERS MODIFIED="2010-07-09 13:54:40 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854706"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854705"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2010" MODIFIED="2017-02-21 14:47:57 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-02-21 14:47:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen F, Wang J, Chen W, Shen M, Xu S, Lu F</AU>
<TI>Upper punctal occlusion versus lower punctal occlusion in dry eye</TI>
<SO>Investigative Ophthalmology and Visual Science</SO>
<YR>2010</YR>
<VL>51</VL>
<NO>11</NO>
<PG>5571-7</PG>
<IDENTIFIERS MODIFIED="2017-02-08 01:22:19 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773811"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773810"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farrell-2003" MODIFIED="2017-02-21 14:48:20 +0000" MODIFIED_BY="[Empty name]" NAME="Farrell 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-02-21 14:48:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farrell J, Patel S, Grierson DG, Sturrock RD</AU>
<TI>A clinical procedure to predict the value of temporary occlusion therapy in keratoconjunctivitis sicca</TI>
<SO>Ophthalmic and Physiological Optics</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS MODIFIED="2010-07-09 13:54:54 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854708"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854707"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feng-2011" MODIFIED="2017-02-14 18:24:01 +0000" MODIFIED_BY="[Empty name]" NAME="Feng 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-02-14 18:00:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feng YN, Fang XJ, Su Y, Mo JB, Shi TY</AU>
<TI>Using punctum plugs at the early stage after LASIK</TI>
<TO>&#27882;&#36947;&#22622;&#22312;LASIK &#26415;&#21518;&#30340;&#26089;&#26399;&#24212;&#29992;</TO>
<SO>International Journal of Ophthalmology</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>9</NO>
<PG>1666-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773813"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773812"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaido-2012" MODIFIED="2017-02-08 01:23:43 +0000" MODIFIED_BY="[Empty name]" NAME="Kaido 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-02-08 01:23:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaido M, Ishida R, Dogru M, Tsubota K</AU>
<TI>Visual function changes after punctal occlusion with the treatment of short BUT type of dry eye</TI>
<SO>Cornea</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>9</NO>
<PG>1009-13</PG>
<IDENTIFIERS MODIFIED="2017-02-08 01:23:43 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773815"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773814"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lowther-1995" MODIFIED="2017-02-14 18:24:19 +0000" MODIFIED_BY="[Empty name]" NAME="Lowther 1995" YEAR="1991">
<REFERENCE MODIFIED="2010-07-09 13:56:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lowther GE, Semes L</AU>
<TI>Effect of absorbable intracanalicular collagen implants in hydrogel contact lens patients with symptoms of dryness</TI>
<SO>International Contact Lens Clinic</SO>
<YR>1995</YR>
<VL>22</VL>
<PG>238-43</PG>
<IDENTIFIERS MODIFIED="2008-07-01 22:14:00 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854710"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-02-14 18:24:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lowther GE, Semes L</AU>
<TI>Effect of intracanalicular collagen implants on drying symptoms and the tear film of hydrogel contact lens patients</TI>
<SO>American Academy of Optometry; 1991 Dec; Anaheim (CA)</SO>
<YR>1991</YR>
<PG>Abstract number 75</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854711"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854709"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mansour-2007" MODIFIED="2010-07-09 13:57:33 +0100" MODIFIED_BY="[Empty name]" NAME="Mansour 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-07-09 13:57:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mansour K, Leonhardt CJ, Kalk WW, Bootsma H, Bruin KJ, Blanksma LJ</AU>
<TI>Lacrimal punctum occlusion in the treatment of severe keratoconjunctivitis Sicca caused by Sjogren syndrome: a uniocular evaluation</TI>
<SO>Cornea</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>2</NO>
<PG>147-50</PG>
<IDENTIFIERS MODIFIED="2010-07-09 13:57:33 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854713"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854712"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nava_x002d_Castaneda-2003" MODIFIED="2010-07-09 13:57:56 +0100" MODIFIED_BY="[Empty name]" NAME="Nava-Castaneda 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-07-09 13:57:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nava-Castaneda A, Tovilla-Canales JL, Rodriguez L, Tovilla Y, Pomar JL, Jones CE</AU>
<TI>Effects of lacrimal occlusion with collagen and silicone plugs on patients with conjunctivitis associated with dry eye</TI>
<SO>Cornea</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>1</NO>
<PG>10-4</PG>
<IDENTIFIERS MODIFIED="2010-07-09 13:57:49 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854715"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854714"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qiu-2012" MODIFIED="2017-02-10 12:27:41 +0000" MODIFIED_BY="[Empty name]" NAME="Qiu 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-02-10 12:27:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qiu W, Liu Z, Zhang Z, Ao M, Li X, Wang W</AU>
<TI>Punctal plugs versus artificial tears for treating dry eye: a comparative observation of their effects on contrast sensitivity</TI>
<SO>Journal of Ocular Biology, Diseases, and Informatics</SO>
<YR>2012</YR>
<VL>5</VL>
<NO>1</NO>
<PG>19-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773817"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773816"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qiu-2013" MODIFIED="2017-02-21 14:51:42 +0000" MODIFIED_BY="[Empty name]" NAME="Qiu 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-02-21 14:51:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qiu W, Liu Z, Ao M, Li X, Wang W</AU>
<TI>Punctal plugs versus artificial tears for treating primary Sjögren's syndrome with keratoconjunctivitis SICCA: a comparative observation of their effects on visual function</TI>
<SO>Rheumatology International</SO>
<YR>2013</YR>
<VL>33</VL>
<NO>10</NO>
<PG>2543-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773819"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773818"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabensteiner-2013" MODIFIED="2017-01-12 20:34:49 +0000" MODIFIED_BY="Andrew Law" NAME="Rabensteiner 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-01-12 20:34:49 +0000" MODIFIED_BY="Andrew Law" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabensteiner DF, Boldin I, Klein A, Horwath-Winter J</AU>
<TI>Collared silicone punctal plugs compared to intracanalicular plugs for the treatment of dry eye</TI>
<SO>Current Eye Research</SO>
<YR>2013</YR>
<VL>38</VL>
<NO>5</NO>
<PG>521-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773821"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773820"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberts-2007" MODIFIED="2017-02-21 14:54:47 +0000" MODIFIED_BY="[Empty name]" NAME="Roberts 2007" YEAR="2007">
<REFERENCE MODIFIED="2017-02-21 14:54:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carniglia P, Roberts C</AU>
<TI>Cyclosporine with and without punctal plugs in the relief of symptoms and reduction of signs of dry eye</TI>
<SO>Optometry</SO>
<YR>2005</YR>
<VL>76</VL>
<NO>6</NO>
<PG>391</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773823"/><IDENTIFIER OTHERTYPE="ID Number" TYPE="OTHER" VALUE="CN-00772991"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-02-08 01:25:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberts CW, Carniglia PE, Brazzo BG</AU>
<TI>Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye</TI>
<SO>Cornea</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>7</NO>
<PG>805-9</PG>
<IDENTIFIERS MODIFIED="2017-02-08 01:25:06 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773824"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773822"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slusser-1998" MODIFIED="2017-02-14 18:41:06 +0000" MODIFIED_BY="[Empty name]" NAME="Slusser 1998" YEAR="1998">
<REFERENCE MODIFIED="2017-02-14 18:41:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Slusser 1998</AU>
<TI>Questions for Dr. Slusser regarding a publication in OVS for inclusion in asystematic review</TI>
<SO>Email to Dr. Todd Slusser</SO>
<YR>20th December 2016</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773826"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-02-14 18:25:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Slusser TG, Lowther GE</AU>
<TI>Effects of lacrimal drainage occlusion with non-dissolvable intracanalicular plugs on hydrogel contact lens related dry eye</TI>
<SO>American Academy of Optometry</SO>
<YR>1994</YR>
<VL>15</VL>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773827"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-02-08 01:25:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Slusser TG, Lowther GE</AU>
<TI>Effects of lacrimal drainage occlusion with nondissolvable intracanalicular plugs on hydrogel contact lens wear</TI>
<SO>Optometry and Vision Science</SO>
<YR>1998</YR>
<VL>75</VL>
<NO>5</NO>
<PG>330-8</PG>
<IDENTIFIERS MODIFIED="2017-02-08 01:25:24 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773828"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773825"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsifetaki-2003" MODIFIED="2010-07-09 13:59:11 +0100" MODIFIED_BY="[Empty name]" NAME="Tsifetaki 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-07-09 13:59:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsifetaki N, Kitsos G, Paschides CA, Alamanos Y, Eftaxias V, Voulgari PV, et al</AU>
<TI>Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren's syndrome: a randomised 12 week controlled study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>62</VL>
<NO>12</NO>
<PG>1204-7</PG>
<IDENTIFIERS MODIFIED="2010-07-09 13:58:07 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854717"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854716"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yung-2012" MODIFIED="2017-02-21 14:58:42 +0000" MODIFIED_BY="[Empty name]" NAME="Yung 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-02-21 14:58:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Yung 2012</AU>
<TI>Query regarding your publication in the Japanese Journal of Ophthalmology (for inclusion in a Cochrane systematic review)</TI>
<SO>Email to: Dr. Toda</SO>
<YR>12th December 2016</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773830"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-02-08 01:25:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yung YH, Toda I, Sakai C, Yoshida A, Tsubota K</AU>
<TI>Punctal plugs for treatment of post-LASIK dry eye</TI>
<SO>Japanese Journal of Ophthalmology</SO>
<YR>2012</YR>
<VL>56</VL>
<NO>3</NO>
<PG>208-13</PG>
<IDENTIFIERS MODIFIED="2017-02-08 01:25:41 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773831"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773829"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2016" MODIFIED="2017-02-21 14:59:47 +0000" MODIFIED_BY="[Empty name]" NAME="Zhou 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-02-21 14:59:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou ZX, Yi SP</AU>
<TI>Effect of lacrimal plug treated refractory dry eye video terminal</TI>
<SO>International Eye Science</SO>
<YR>2016</YR>
<VL>16</VL>
<NO>12</NO>
<PG>2285-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773833"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773832"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-05-08 19:19:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bukhari-2015" MODIFIED="2017-01-19 22:48:45 +0000" MODIFIED_BY="[Empty name]" NAME="Bukhari 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-01-19 22:48:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bukhari AA</AU>
<TI>Botulinum neurotoxin type A versus punctal plug insertion in the management of dry eye disease</TI>
<SO>Oman Journal of Ophthalmology</SO>
<YR>2014</YR>
<VL>7</VL>
<NO>2</NO>
<PG>61-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773835"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773834"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capita-2015" MODIFIED="2017-02-08 01:26:32 +0000" MODIFIED_BY="[Empty name]" NAME="Capita 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-02-08 01:26:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Capita L, Chalita MR, dos Santos-Neto LL</AU>
<TI>Prospective evaluation of hypromellose 2% for punctal occlusion in patients with dry eye</TI>
<SO>Cornea</SO>
<YR>2015</YR>
<VL>34</VL>
<NO>2</NO>
<PG>188-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773837"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773836"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Charnetski_x002d_Sites-2001" MODIFIED="2017-02-14 18:28:28 +0000" MODIFIED_BY="[Empty name]" NAME="Charnetski-Sites 2001" YEAR="2001">
<REFERENCE MODIFIED="2017-02-14 18:28:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Charnetski-Sites C, Bucci FA Jr</AU>
<TI>Do silicone punctal plugs impact tear lactoferrin levels following LASIK</TI>
<SO>American Academy of Optometry; 2001 Dec; Philadelphia (PA)</SO>
<YR>2001</YR>
<PG>Abstract 203</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854719"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854718"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geldis-2008" MODIFIED="2017-02-21 15:00:51 +0000" MODIFIED_BY="[Empty name]" NAME="Geldis 2008" YEAR="2008">
<REFERENCE MODIFIED="2017-02-21 15:00:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geldis JR, Nichols JJ</AU>
<TI>The impact of punctal occlusion on soft contact lens wearing comfort and the tear film</TI>
<SO>Eye and Contact Lens</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>5</NO>
<PG>261-5</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:00:09 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854721"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854720"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giovagnoli-1992" MODIFIED="2010-07-09 14:02:47 +0100" MODIFIED_BY="[Empty name]" NAME="Giovagnoli 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-07-09 14:02:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giovagnoli D, Graham SJ</AU>
<TI>Inferior punctal occlusion with removable silicone punctal plugs in the treatment of dry-eye related contact lens discomfort</TI>
<SO>Journal of the American Optometric Association</SO>
<YR>1992</YR>
<VL>63</VL>
<NO>7</NO>
<PG>481-5</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:01:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854723"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854722"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goto-2003" MODIFIED="2010-07-09 14:03:39 +0100" MODIFIED_BY="[Empty name]" NAME="Goto 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-07-09 14:03:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goto E, Yagi Y, Kaido M, Matsumoto Y, Konomi K, Tsubota K</AU>
<TI>Improved functional visual acuity after punctal occlusion in dry eye patients</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2003</YR>
<VL>135</VL>
<NO>5</NO>
<PG>704-5</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:03:14 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854725"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854724"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guzey-2001" MODIFIED="2010-07-09 14:05:23 +0100" MODIFIED_BY="[Empty name]" NAME="Guzey 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-07-09 14:05:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guzey M, Ozardali I, Kilic A, Basar E, Dogan Z, Satici A, et al</AU>
<TI>The treatment of severe trachomatous dry eye with canalicular silicone plugs</TI>
<SO>Eye</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>Pt 3</NO>
<PG>297-303</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:05:23 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854727"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854726"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamano-2002" MODIFIED="2017-02-21 15:01:36 +0000" MODIFIED_BY="[Empty name]" NAME="Hamano 2002" YEAR="2002">
<REFERENCE MODIFIED="2017-02-21 15:01:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamano T</AU>
<TI>Atelocollagen punctal occlusion for the treatment of the dry eye</TI>
<SO>Advances in Experimental Medicine and Biology</SO>
<YR>2002</YR>
<VL>506</VL>
<NO>Pt B</NO>
<PG>1283-4</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:06:18 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854729"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854728"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kojima-2014" MODIFIED="2017-01-12 20:32:15 +0000" MODIFIED_BY="Andrew Law" NAME="Kojima 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-01-12 20:32:15 +0000" MODIFIED_BY="Andrew Law" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kojima T, Matsumoto Y, Ibrahim OM, Wakamatsu TH, Dogru M, Tsubota K</AU>
<TI>Evaluation of a thermosensitive atelocollagen punctal plug treatment for dry eye disease</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2014</YR>
<VL>157</VL>
<NO>2</NO>
<PG>311-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773839"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773838"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2012" MODIFIED="2017-02-14 18:29:41 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-02-14 18:29:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li M, Wang J, Shen M, Cui L, Tao A, Chen Z, et al</AU>
<TI>Effect of punctal occlusion on tear menisci in symptomatic contact lens wearer</TI>
<SO>Cornea</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>9</NO>
<PG>1014-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773841"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773840"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malet-1997" MODIFIED="2016-07-04 23:32:41 +0100" MODIFIED_BY="Andrew Law" NAME="Malet 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-07-04 23:32:36 +0100" MODIFIED_BY="Andrew Law" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malet T, David N, Maalouf T, Angioi K, Bertr A, George JL</AU>
<TI>Scintigraphic evaluation of the degree of lacrimal duct occlusion after implantation of an intracanalicular plug</TI>
<SO>Orbit</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>4</NO>
<PG>241-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773843"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773842"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murube-del-Castillo-1995" MODIFIED="2008-06-27 16:16:59 +0100" MODIFIED_BY="[Empty name]" NAME="Murube del Castillo 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-06-27 16:16:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murube del Castillo J, Olivares C, Murube E</AU>
<TI>Treatment of dry eye by punctum patch</TI>
<SO>Orbit</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854731"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854730"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishii-2004" MODIFIED="2017-02-08 01:27:34 +0000" MODIFIED_BY="[Empty name]" NAME="Nishii 2004" YEAR="2004">
<REFERENCE MODIFIED="2017-02-08 01:27:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishii M, Yokoi N, Komuro A, Kinoshita S</AU>
<TI>Clinical investigation of extrusion of a new punctal plug (Flex Plug)</TI>
<SO>Nippon Ganka Gakkai Zasshi</SO>
<YR>2004</YR>
<VL>108</VL>
<NO>3</NO>
<PG>139-43</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:07:29 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854733"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854732"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozkan-2001" MODIFIED="2010-07-09 14:09:55 +0100" MODIFIED_BY="[Empty name]" NAME="Ozkan 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-07-09 14:09:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozkan Y, Bozkurt B, Gedik S, Irkec M, Orhan M</AU>
<TI>Corneal topographical study of the effect of lacrimal punctum occlusion on corneal surface regularity in dry eye patients</TI>
<SO>European Journal of Ophthalmology</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>2</NO>
<PG>116-9</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:09:03 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854735"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854734"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patten-1976" MODIFIED="2010-07-09 14:12:37 +0100" MODIFIED_BY="[Empty name]" NAME="Patten 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-07-09 14:12:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patten JT</AU>
<TI>Punctal occlusion with n-butyl cyanoacrylate tissue adhesive</TI>
<SO>Ophthalmic Surgery</SO>
<YR>1976</YR>
<VL>7</VL>
<NO>2</NO>
<PG>24-6</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:10:09 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854737"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854736"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sainz-2000" MODIFIED="2017-02-10 12:33:36 +0000" MODIFIED_BY="[Empty name]" NAME="Sainz 2000" YEAR="2000">
<REFERENCE MODIFIED="2017-02-10 12:33:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sainz M, Simon Castellvi C, KABBANI 0</AU>
<TI>Nonpreserved topical steroids and punctal occlusion for severe keratoconjunctivitis sicca</TI>
<TO>Esteroides tópicos sin conservantes y oclusión de los puntos lagrimales para la queraconjuntivitis sicca grave</TO>
<SO>Archivos de la Sociedad Española de Oftalmología</SO>
<YR>2000</YR>
<VL>75</VL>
<PG>751-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773845"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773844"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schultze-2004" MODIFIED="2017-05-08 19:19:57 +0100" MODIFIED_BY="[Empty name]" NAME="Schultze 2004" YEAR="2004">
<REFERENCE MODIFIED="2017-05-08 19:19:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;As above for conference papers&lt;/p&gt;" NOTES_MODIFIED="2017-05-08 19:19:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Schultze RL, Michra G</AU>
<TI>Comparison of topical cyclosporine (Restasis) and punctal occlusion in the treatment of dry eye syndrome</TI>
<SO>American Academy of Optometry; 2004 Oct; New Orleans (LA)</SO>
<YR>2004</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773847"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773846"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharpe-2001" MODIFIED="2017-02-14 18:32:34 +0000" MODIFIED_BY="[Empty name]" NAME="Sharpe 2001" YEAR="2001">
<REFERENCE MODIFIED="2017-02-14 18:32:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sharpe J, Connor C</AU>
<TI>The effect of site selection for punctal occlusion on patient symptom relief</TI>
<SO>American Academy of Optometry; 2001 Dec; Philadelphia (PA)</SO>
<YR>2001</YR>
<PG>Abstract number 299</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854739"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854738"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Virtanen-1996" MODIFIED="2010-07-09 14:13:27 +0100" MODIFIED_BY="[Empty name]" NAME="Virtanen 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-07-09 14:13:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Virtanen T, Huotari K, Harkonen M, Tervo T</AU>
<TI>Lacrimal plugs as a therapy for contact lens intolerance</TI>
<SO>Eye</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>Pt 6</NO>
<PG>727-31</PG>
<IDENTIFIERS MODIFIED="2010-07-09 14:13:11 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854741"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854740"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ward-2001" MODIFIED="2017-02-14 18:33:06 +0000" MODIFIED_BY="[Empty name]" NAME="Ward 2001" YEAR="2001">
<REFERENCE MODIFIED="2017-02-14 18:32:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ward HJ</AU>
<TI>A preliminary comparison of superior to inferior silicone punctal occlusion in hydrogel contact lens wearers with dry eye signs and symptoms</TI>
<SO>American Academy of Optometry; 2001 Dec; Philadelphia (PA)</SO>
<YR>2001</YR>
<PG>Abstract number 300</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2854743"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2854742"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2001" MODIFIED="2017-02-10 12:36:03 +0000" MODIFIED_BY="[Empty name]" NAME="Zhou 2001" YEAR="2001">
<REFERENCE MODIFIED="2017-02-10 12:36:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou S, Wilcox C, Liau C</AU>
<TI>SmartPlugTM - one size fits all punctal plug for dry eyes</TI>
<SO>Investigative Ophthalmology and Visual Science</SO>
<YR>2001</YR>
<VL>42</VL>
<PG>ARVO E-abstract 206</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773849"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773848"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2017-01-12 20:32:15 +0000" MODIFIED_BY="Andrew Law"/>
<ONGOING_STUDIES MODIFIED="2017-02-10 12:39:19 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ChiCTR_x002d_IPR_x002d_16007760" MODIFIED="2017-02-10 12:39:19 +0000" MODIFIED_BY="[Empty name]" NAME="ChiCTR-IPR-16007760" YEAR="2016">
<REFERENCE MODIFIED="2017-02-10 12:39:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ChiCTR-IPR-16007760</AU>
<TI>Treatment of dry eye with absorbable punctual plug (VisiPlug) in a randomized, observer-blind and parallel study</TI>
<SO>www.chictr.org.cn/hvshowproject.aspx?id=5168</SO>
<YR>(accessed 28 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5773851"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-05-24 14:42:24 +0100" MODIFIED_BY="Andrew Law"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5773850"/><IDENTIFIER MODIFIED="2016-05-24 14:42:24 +0100" MODIFIED_BY="Andrew Law" TYPE="OTHER" VALUE="ChiCTR-IPR-16007760 "/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-02-21 15:08:04 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2017-02-21 15:08:04 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-AAO-2003" MODIFIED="2017-02-10 12:40:23 +0000" MODIFIED_BY="[Empty name]" NAME="AAO 2003" TYPE="OTHER">
<AU>American Academy of Ophthalmology (AAO) Cornea/External Disease Panel</AU>
<TI>Preferred Practice Pattern for Dry Eye Syndrome. 2003</TI>
<SO>one.aao.org/CE/PracticeGuidelines/default.aspx</SO>
<YR>(accessed 27 April 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balaram-2001" NAME="Balaram 2001" TYPE="JOURNAL_ARTICLE">
<AU>Balaram M, Schaumberg DA, Dana MR</AU>
<TI>Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2001</YR>
<VL>131</VL>
<NO>1</NO>
<PG>30-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnard-1996" NAME="Barnard 1996" TYPE="JOURNAL_ARTICLE">
<AU>Barnard NA</AU>
<TI>Punctal and intracanalicular occlusion - a guide for the practitioner. The College of Optometrists</TI>
<SO>Ophthalmic and Physiological Optics</SO>
<YR>1996</YR>
<VL>16 Suppl 1</VL>
<PG>S15-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dalzell-2003" NAME="Dalzell 2003" TYPE="JOURNAL_ARTICLE">
<AU>Dalzell MD</AU>
<TI>Dry eye: prevalence, utilization, and economic implications</TI>
<SO>Managed Care</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>12 Suppl</NO>
<PG>9-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Paiva-2006" NAME="De Paiva 2006" TYPE="JOURNAL_ARTICLE">
<AU>De Paiva CS, Chen Z, Koch DD, Hamill MB, Manuel FK, Hassan SS, et al</AU>
<TI>The incidence and risk factors for developing dry eye after myopic LASIK</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2006</YR>
<VL>141</VL>
<NO>3</NO>
<PG>438-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dew-2007" MODIFIED="2017-02-10 12:41:29 +0000" MODIFIED_BY="[Empty name]" NAME="Dew 2007" TYPE="JOURNAL_ARTICLE">
<AU>Dew K</AU>
<TI>A health researcher's guide to qualitative methodologies</TI>
<SO>Australian and New Zealand Journal of Public Health</SO>
<YR>2007</YR>
<VL>31</VL>
<PG>1753-6405</PG>
<PB>Blackwell Publishing Ltd</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DEWS-2007a" MODIFIED="2017-02-10 12:41:50 +0000" MODIFIED_BY="[Empty name]" NAME="DEWS 2007a" TYPE="JOURNAL_ARTICLE">
<AU>Definition and Classification Subcommittee of the International Dry Eye WorkShop</AU>
<TI>The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)</TI>
<SO>The Ocular Surface</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>2</NO>
<PG>75-92</PG>
<IDENTIFIERS MODIFIED="2017-02-08 01:30:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-DEWS-2007b" MODIFIED="2017-02-10 12:42:12 +0000" MODIFIED_BY="[Empty name]" NAME="DEWS 2007b" TYPE="JOURNAL_ARTICLE">
<AU>Management and Therapy Subcommittee of the International Dry Eye WorkShop</AU>
<TI>Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007)</TI>
<SO>The Ocular Surface</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>2</NO>
<PG>163-78</PG>
<IDENTIFIERS MODIFIED="2017-02-08 01:30:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Dohlman-1978" NAME="Dohlman 1978" TYPE="JOURNAL_ARTICLE">
<AU>Dohlman CH</AU>
<TI>Punctal occlusion in keratoconjunctivitis sicca</TI>
<SO>Ophthalmology</SO>
<YR>1978</YR>
<VL>85</VL>
<NO>12</NO>
<PG>1277-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freeman-1975" MODIFIED="2016-12-15 14:48:10 +0000" MODIFIED_BY="[Empty name]" NAME="Freeman 1975" TYPE="JOURNAL_ARTICLE">
<AU>Freeman JM</AU>
<TI>The punctum plug: evaluation of a new treatment for the dry eye.</TI>
<SO>Transactions. Section on Ophthalmology. American Academy of Ophthalmology and Otolaryngology</SO>
<YR>1975</YR>
<VL>79</VL>
<NO>6</NO>
<PG>874-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GetData-Graph-Digitalizer" MODIFIED="2017-02-13 18:54:08 +0000" MODIFIED_BY="[Empty name]" NAME="GetData Graph Digitalizer" TYPE="COMPUTER_PROGRAM">
<AU>www.getdata-graph-digitizer.com</AU>
<TI>GetData Graph Digitalizer</TI>
<YR>2013</YR>
<EN>2.26</EN>
<PB>www.getdata-graph-digitizer.com</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glanville-2006" NAME="Glanville 2006" TYPE="JOURNAL_ARTICLE">
<AU>Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J</AU>
<TI>How to identify randomized controlled trials in MEDLINE: ten years on</TI>
<SO>Journal of the Medical Library Association</SO>
<YR>2006</YR>
<VL>94</VL>
<NO>2</NO>
<PG>130-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2014" MODIFIED="2017-02-10 12:42:40 +0000" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro GDT</TI>
<YR>2014</YR>
<EN>accessed 14 December 2016</EN>
<PB>GRADE Working Group, McMaster University</PB>
<CY>Hamilton (ON)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamano-2005" MODIFIED="2017-02-08 01:30:50 +0000" MODIFIED_BY="[Empty name]" NAME="Hamano 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hamano T</AU>
<TI>Lacrimal duct occlusion for the treatment of dry eye</TI>
<SO>Seminars Ophthalmology</SO>
<YR>2005</YR>
<VL>20</VL>
<PG>71-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2017-02-21 14:36:39 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JP, Altman DG, Sterne JAC editor(s)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2017-02-21 14:37:56 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JP, Deeks JJ, Altman DG editor(s)</AU>
<TI>Chapter 16: Special topics in statistics. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jehangir-2016" MODIFIED="2017-02-08 01:32:57 +0000" MODIFIED_BY="[Empty name]" NAME="Jehangir 2016" TYPE="JOURNAL_ARTICLE">
<AU>Jehangir N, Bever G, Mahmood SM, Moshirfar M</AU>
<TI>Comprehensive review of the literature on existing punctal plugs for the management of dry eye disease</TI>
<SO>Journal of Ophthalmology</SO>
<YR>2016</YR>
<VL>2016</VL>
<PG>9312340</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2002" NAME="Lee 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lee AJ, Lee J, Saw SM, Gazzard G, Koh D, Widjaja D, et al</AU>
<TI>Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2002</YR>
<VL>86</VL>
<NO>12</NO>
<PG>1347-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lemp-1994" NAME="Lemp 1994" TYPE="JOURNAL_ARTICLE">
<AU>Lemp MA</AU>
<TI>Management of the dry-eye patient</TI>
<SO>International Ophthalmology Clinics</SO>
<YR>1994</YR>
<VL>34</VL>
<NO>1</NO>
<PG>101-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lemp-1995" MODIFIED="2017-02-07 20:26:14 +0000" MODIFIED_BY="[Empty name]" NAME="Lemp 1995" TYPE="JOURNAL_ARTICLE">
<AU>Lemp MA</AU>
<TI>Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes</TI>
<SO>The Contact Lens Association of Ophthalmologists Journal</SO>
<YR>1995</YR>
<VL>21</VL>
<NO>4</NO>
<PG>221-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lemp-1998" MODIFIED="2017-02-21 15:05:00 +0000" MODIFIED_BY="[Empty name]" NAME="Lemp 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lemp MA</AU>
<TI>Epidemiology and classification of dry eye</TI>
<SO>Advances in Experimental Medicines and Biology</SO>
<YR>1998</YR>
<VL>438</VL>
<PG>791-803</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marcet-2015" MODIFIED="2017-02-08 01:35:14 +0000" MODIFIED_BY="[Empty name]" NAME="Marcet 2015" TYPE="JOURNAL_ARTICLE">
<AU>Marcet MM, Shtein RM, Bradley EA, Deng SX, Meyer DR, Bilyk JR, et al</AU>
<TI>Safety and efficacy of lacrimal drainage system plugs for dry eye syndrome</TI>
<SO>Ophthalmology</SO>
<YR>2015</YR>
<VL>122</VL>
<NO>8</NO>
<PG>1681-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCarty-1998" NAME="McCarty 1998" TYPE="JOURNAL_ARTICLE">
<AU>McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR</AU>
<TI>The epidemiology of dry eye in Melbourne, Australia</TI>
<SO>Ophthalmology</SO>
<YR>1998</YR>
<VL>105</VL>
<NO>6</NO>
<PG>1114-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moss-2000" NAME="Moss 2000" TYPE="JOURNAL_ARTICLE">
<AU>Moss SE, Klein R, Klein BE</AU>
<TI>Prevalence of and risk factors for dry eye syndrome</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2000</YR>
<VL>118</VL>
<NO>9</NO>
<PG>1264-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nichols-2004" MODIFIED="2017-02-08 01:36:01 +0000" MODIFIED_BY="[Empty name]" NAME="Nichols 2004" TYPE="JOURNAL_ARTICLE">
<AU>Nichols K, Nichols J, Lynn MG</AU>
<TI>The lack of association between signs and symptoms in patients with dry eye disease</TI>
<SO>Journal of Cornea and External Disease</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>8</NO>
<PG>762-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pan-2013" MODIFIED="2017-02-08 01:36:45 +0000" MODIFIED_BY="[Empty name]" NAME="Pan 2013" TYPE="COCHRANE_REVIEW">
<AU>Pan Q, Angelina A, Zambrano A, Marrone M, Stark WJ, Heflin T, et al</AU>
<TI>Autologous serum eye drops for dry eye</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2017-02-07 20:19:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-02-07 20:19:03 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD009327.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pflugfelder-2000" NAME="Pflugfelder 2000" TYPE="JOURNAL_ARTICLE">
<AU>Pflugfelder SC, Solomon A, Stern ME</AU>
<TI>The diagnosis and management of dry eye: a twenty-five-year review</TI>
<SO>Cornea</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>5</NO>
<PG>644-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pucker-2016" MODIFIED="2017-02-08 01:37:10 +0000" MODIFIED_BY="[Empty name]" NAME="Pucker 2016" TYPE="COCHRANE_REVIEW">
<AU>Pucker AD, Ng SM, Nichols JJ</AU>
<TI>Over the counter (OTC) artificial tear drops for dry eye syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2016</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2017-02-07 20:18:17 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-02-07 20:18:17 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD009729.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-5-2014" MODIFIED="2017-02-21 15:08:04 +0000" MODIFIED_BY="[Empty name]" NAME="Review Manager 5 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager 5 (RevMan 5)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sahai-2005" NAME="Sahai 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sahai A, Malik P</AU>
<TI>Dry eye: prevalence and attributable risk factors in a hospital-based population</TI>
<SO>Indian Journal of Ophthalmology</SO>
<YR>2005</YR>
<VL>53</VL>
<NO>2</NO>
<PG>87-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sall-2000" NAME="Sall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sall K, Stevenson OD, Mundorf TK, Reis BL</AU>
<TI>Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group</TI>
<SO>Ophthalmology</SO>
<YR>2000</YR>
<VL>107</VL>
<NO>4</NO>
<PG>631-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schein-1997a" MODIFIED="2017-02-13 08:08:06 +0000" MODIFIED_BY="[Empty name]" NAME="Schein 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Schein OD, Tielsch JM, Munoz B, Bandeen-Roche K, West S</AU>
<TI>Relation between signs and symptoms of dry eye in the elderly. A population-based perspective</TI>
<SO>Ophthalmology</SO>
<YR>1997</YR>
<VL>104</VL>
<NO>9</NO>
<PG>1395-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schein-1997b" MODIFIED="2017-02-13 08:07:58 +0000" MODIFIED_BY="[Empty name]" NAME="Schein 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Schein OD, Munoz B, Tielsch JM, Bandeen-Roche K, West S</AU>
<TI>Prevalence of dry eye among the elderly</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1997</YR>
<VL>124</VL>
<NO>6</NO>
<PG>723-8</PG>
<IDENTIFIERS MODIFIED="2010-07-09 15:37:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Sheppard-2003" NAME="Sheppard 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sheppard JD</AU>
<TI>Dry eye moves beyond palliative therapy</TI>
<SO>Managed Care</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>12 Suppl</NO>
<PG>6-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tai-2002" NAME="Tai 2002" TYPE="JOURNAL_ARTICLE">
<AU>Tai MC, Cosar CB, Cohen EJ, Rapuano CJ, Laibson PR</AU>
<TI>The clinical efficacy of silicone punctal plug therapy</TI>
<SO>Cornea</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>2</NO>
<PG>135-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Willis-1987" NAME="Willis 1987" TYPE="JOURNAL_ARTICLE">
<AU>Willis RM, Folberg R, Krachmer JH, Holland EJ</AU>
<TI>The treatment of aqueous-deficient dry eye with removable punctal plugs. A clinical and impression-cytologic study</TI>
<SO>Ophthalmology</SO>
<YR>1987</YR>
<VL>94</VL>
<NO>5</NO>
<PG>514-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-2003" NAME="Wilson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wilson SE</AU>
<TI>Inflammation: a unifying theory for the origin of dry eye syndrome</TI>
<SO>Managed Care</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>12 Suppl</NO>
<PG>14-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yellepeddi-2015" MODIFIED="2017-02-08 01:38:19 +0000" MODIFIED_BY="[Empty name]" NAME="Yellepeddi 2015" TYPE="JOURNAL_ARTICLE">
<AU>Yellepeddi VK, Sheshala R, McMillan H, Gujral C, Jones D, Raghu Raj Singh T</AU>
<TI>Punctal plug: a medical device to treat dry eye syndrome and for sustained drug delivery to the eye</TI>
<SO>Drug Discovery Today</SO>
<YR>2015</YR>
<VL>20</VL>
<NO>7</NO>
<PG>884-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-02-08 01:38:29 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ervin-2007" MODIFIED="2017-02-08 01:38:29 +0000" MODIFIED_BY="[Empty name]" NAME="Ervin 2007" TYPE="COCHRANE_REVIEW">
<AU>Ervin AM, Wojciechowski R, Schein O</AU>
<TI>Punctal occlusion for dry eye syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2017-02-07 20:19:21 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-02-07 20:19:21 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006775"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ervin-2010" MODIFIED="2017-02-07 20:21:01 +0000" MODIFIED_BY="[Empty name]" NAME="Ervin 2010" TYPE="COCHRANE_REVIEW">
<AU>Ervin AM, Wojciechowski R, Schein O</AU>
<TI>Punctal occlusion for dry eye syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2017-01-19 22:01:02 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-01-19 22:01:02 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006775.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-06-19 08:43:20 +0100" MODIFIED_BY="Anupa Shha">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-06-19 08:43:20 +0100" MODIFIED_BY="Anupa Shha" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-06-19 08:43:20 +0100" MODIFIED_BY="Anupa Shha" STUDY_ID="STD-Altan_x002d_Yaycioglu-2005">
<CHAR_METHODS MODIFIED="2017-04-26 17:16:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: parallel randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: unclear as trial investigators did not report if they had only included one eye in the analysis or took the averaged of both eyes</P>
<P>
<B>Unit of randomization:</B> participant, both eyes received the same intervention</P>
<P>How were missing data handled? No missing data reported</P>
<P>
<B>Reported power calculation</B>: NR</P>
<P>Unusual study design: 22 eyes of age- and gender-matched healthy volunteers were included (tear production and film stability, lacrimal scintigraphy measurements only; no punctal plugs inserted)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-19 08:43:20 +0100" MODIFIED_BY="Anupa Shha">
<P>
<B>Country</B>: Turkey</P>
<P>
<B>Number randomized</B>: 
</P>
<P>24 participants (48 eyes) in total</P>
<P>11 participants (22 eyes) in collagen punctal plugs group</P>
<P>13 participants (26 eyes) in silicone punctal plugs group</P>
<P>
<B>Exclusions after randomization</B>: none reported</P>
<P>
<B>Number analyzed</B>: 
</P>
<P>24 participants (48 eyes) in total</P>
<P>11 participants (22 eyes) in collagen punctal plugs group</P>
<P>13 participants (26 eyes) in silicone punctal plugs group</P>
<P>
<B>Losses to follow-up</B>: none reported</P>
<P>
<B>Overall mean age (SD)</B>: NR</P>
<P>
<B>Age range</B>: NR</P>
<P>
<B>Sex (%)</B>: 21 women (88%) and 3 men (12%) in total; by group not reported</P>
<P>
<B>Inclusion criteria</B>: participants were diagnosed with aqueous tear deficiency; no previous history of punctal plug insertion. All using artificial tears with no subjective or objective improvement in symptoms</P>
<P>
<B>Exclusion criteria</B>: NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-03-28 13:45:06 +0100" MODIFIED_BY="Andrew Law">
<P>No mention of artificial tears use</P>
<P>
<B>Intervention 1</B>: collagen punctal plugs were inserted in the lower punctum</P>
<P>Punctal plug model: NR</P>
<P>Manufacturer of punctal plug: Lacrimedics</P>
<P>Location of manufacturer: Eastsound, WA</P>
<P>
<B>Intervention 2</B>: silicone punctal plugs were inserted in the lower punctum</P>
<P>Punctal plug model: Odyssey-Parasol Punctal Occluder A14 to 203</P>
<P>Manufacturer of punctal plug: Oasis Medical</P>
<P>Location of manufacturer: Memphis, TN</P>
<P>
<B>Length of follow-up</B>:</P>
<P>Planned: protocol not available<BR/>Actual: 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-10 09:40:48 +0000" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcome were not distinguished.</P>
<P>
<B>Outcomes reported</B>: tear production (Schirmer I test at 5 minutes performed before and immediately after occlusion); tear film stability (tear break-up time (TBUT) measured in seconds before and immediately after occlusion); ocular surface staining (Rose Bengal strip before and 3 days after occlusion)<BR/>
<B>Adverse events reported</B>: authors reported "no adverse events," but did not define which adverse events were collected</P>
<P>
<B>Intervals at which outcomes assessed</B>: before treatment, after treatment, and 3 days post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-02-10 08:39:35 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: NR</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: NR</P>
<P>
<B>Disclosures of interest</B>: NR</P>
<P>
<B>Study period</B>: NR</P>
<P>
<B>Reported subgroup analyses</B>: none reported</P>
<P>Investigators did not discuss how they accounted for the correlation between eyes of the same person</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-08 21:15:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brissette-2015">
<CHAR_METHODS MODIFIED="2017-05-08 21:15:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: paired-eye randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: eyes; no mention of analysis accounting for correlation between the left and right eye</P>
<P>
<B>Unit of randomization: </B>each eye of each participant was randomized to a different intervention</P>
<P>How were missing data handled? Excluded from analysis</P>
<P>
<B>Reported power calculation</B>: sample size = 50 participants (25 participants per group); power = 80.7%</P>
<P>Unusual study design: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:47:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: Canada</P>
<P>
<B>Number randomized</B>: 
</P>
<P>26 participants (52 eyes) in total</P>
<P>26 participants (26 eyes) in collagen punctal plugs group</P>
<P>26 participants (26 eyes) in silicone punctal plugs group</P>
<P>
<B>Exclusions after randomization</B>: none reported</P>
<P>
<B>Number analyzed</B>: 
</P>
<P>25 participants (50 eyes) in total</P>
<P>25 participants (25 eyes) in collagen punctal plugs group</P>
<P>25 participants (25 eyes) in silicone punctal plugs group</P>
<P>
<B>Losses to follow up</B>: 
</P>
<P>1 participant (2 eyes) in total</P>
<P>1 participants (1 eyes) in collagen punctal plugs group</P>
<P>1 participants (1 eyes) in silicone punctal plugs group</P>
<P>
<B>Mean age (SD)</B>: 60.05 years (NR) overall</P>
<P>61.7 (17.67) years in the collagen punctal plug group</P>
<P>58.4 (16.18) years in the silicone punctal plug group</P>
<P>
<B>Age range</B>: NR</P>
<P>
<B>Sex (%)</B>: 21 women (81%) and 5 men (19%) in total</P>
<P>10 women (77%) and 3 men (23%) in the collagen punctal plug group</P>
<P>11 women (85%) and 2 men (15%) in the silicone punctal plug group</P>
<P>
<B>Inclusion criteria</B>: "moderate to severe subjective dry eye symptoms as per the Canadian Dry Eye Assessment (CDEA), a validated dry eye symptoms questionnaire based on the Ocular Surface Disease Index (OSDI)" (p 239)</P>
<P>
<B>Exclusion criteria</B>: "dry eye secondary to systemic inflammatory conditions, punctal cautery, punctal stenosis, silicone allergy, and inability to attend multiple follow-up visits for 6 months" (p 239)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-03-28 13:47:44 +0100" MODIFIED_BY="Andrew Law">
<P>Both groups were allowed to use artificial tears throughout the follow up period</P>
<P>
<B>Intervention 1</B>: collagen punctal plugs were inserted in the lower punctum</P>
<P>Punctal plug model: Parasol</P>
<P>Manufacturer of punctal plug: Odyssey Medical</P>
<P>Location of manufacturer: Memphis, TN, USA</P>
<P>
<B>Intervention 2</B>: silicone punctal plugs were inserted in the lower punctum</P>
<P>Punctal plug model: Super Flex</P>
<P>Manufacturer of punctal plug: Eagle Vision</P>
<P>Location of manufacturer: Memphis, TN, USA</P>
<P>
<B>Length of follow-up</B>:</P>
<P>Planned: 6 months</P>
<P>Actual: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-03-27 21:12:44 +0100" MODIFIED_BY="Andrew Law">
<P>
<B>Primary outcomes reported</B>: punctal plug retention at 6 months</P>
<P>"Retention was characterized by last examined date with the punctal plug in place. For example, if a patient returned for his or her 4-month visit, and the plug was gone, the plug was recorded as 3 months of retention." (p 239)</P>
<P>
<B>Secondary outcomes reported</B>: Schirmer I (mm), tear meniscus height as measured at the slit lamp (mm), TBUT (in seconds), inferior fluorescein corneal staining (National Eye Institute (NEI) scale), and average lissamine green conjunctival staining (NEI scale), artificial tear drop frequency</P>
<P>
<B>Adverse events reported</B>: none reported</P>
<P>
<B>Intervals at which outcomes assessed</B>: monthly for primary outcome up to 6 months; months 1, 3, and 6 for secondary outcomes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-02-09 15:21:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: NCT01947517 (clinicaltrials.gov)</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: "The authors indicate no funding support" (p 242)</P>
<P>
<B>Disclosures of interest</B>: "none were reported" (p 242)</P>
<P>
<B>Study period</B>: September 2013 to May 2014 (from clinicaltrials.gov)</P>
<P>*We contacted the authors via email and have received additional information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-05 20:47:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burgess-2008">
<CHAR_METHODS MODIFIED="2017-04-17 13:37:22 +0100" MODIFIED_BY="Andrew Law">
<P>
<B>Study design</B>: parallel randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: unclear as both eyes of 15 participants could have receive the same or different intervention</P>
<P>
<B>Unit of randomization: </B>&#8220;each eye was treated as independent for the purposes of the study&#8221; (p 391)</P>
<P>How were missing data handled? NA, no missing data reported</P>
<P>
<B>Reported power calculation</B>: NR</P>
<P>Unusual study design: authors did not perform the appropriate pair-wise analysis and each eye treated as being independent</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:47:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: UK (assumed from author's origin)</P>
<P>
<B>Number randomized</B>: 
</P>
<P>21 participants (36 eyes) in total</P>
<P>NR participant (18 eyes) in silicone punctal plug group</P>
<P>NR participants (18 eyes) in acrylic punctal plug group</P>
<P>
<B>Exclusions after randomization</B>: none reported</P>
<P>
<B>Number analyzed</B>: 
</P>
<P>21 participants (36 eyes) in total</P>
<P>NR participant (18 eyes) in silicone punctal plug group</P>
<P>NR participants (18 eyes) in acrylic punctal plug group</P>
<P>
<B>Losses to follow-up</B>: none reported</P>
<P>
<B>Overall mean age (SD)</B>: 60.0 (NR) years in total; by group not reported</P>
<P>
<B>Age range</B>: 33-78 years; by group not reported</P>
<P>
<B>Sex (%)</B>: 20 women (95%) and 1 man (5%) in total; by group not reported</P>
<P>
<B>Inclusion criteria</B>: participants with subjective symptoms consistent with dry eye, tear film break-up time of &lt; 5 seconds, and ocular surface abnormalities as demonstrated by fluorescein or Rose Bengal staining. All used artificial tears for more than 6 months with no subjective or objective improvement in symptoms.</P>
<P>
<B>Exclusion criteria</B>: use of punctal plugs within previous 6 months or contact lens use</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-03-28 13:49:05 +0100" MODIFIED_BY="Andrew Law">
<P>Both groups were allowed to use artificial tears throughout the follow up period</P>
<P>
<B>Intervention 1</B>: silicone punctal plugs were inserted in the lower punctum</P>
<P>Punctal plug model: Soft Plug</P>
<P>Manufacturer of punctal plug: Oasis Medical</P>
<P>Location of manufacturer: Glendora, CA</P>
<P>
<B>Intervention 2</B>: acrylic punctal plugs were inserted in the lower punctum</P>
<P>Punctal plug model: SmartPlugs</P>
<P>Manufacturer of punctal plug: Medennium</P>
<P>Location of manufacturer: Irvine, CA</P>
<P>
<B>Length of follow-up</B>:</P>
<P>Planned: NR<BR/>Actual: mean follow-up 11.2 weeks (range, 8-18 weeks) in total</P>
<P>11.27 ± 2.54 weeks in silicone punctal plug group</P>
<P>11.11 ± 2.56 weeks in acrylic punctal plug group</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-04-26 17:16:59 +0100" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcome were not distinguished</P>
<P>
<B>Outcomes reported</B>:</P>
<P>Subjective symptoms: dryness, foreign body sensation, grittiness, stinging, pain, itching and burning; 10 cm visual analog scale; scores added to derive a summary score</P>
<P>Tear film stability: TBUT measured in seconds</P>
<P>Tear meniscus height: measured using calibrated slit-lamp in mm, midway between canthi along the lower lid Average of 3 measurements</P>
<P>Tear production: Schirmer I test without anesthesia</P>
<P>Ocular surface staining: Rose Bengal staining in nasal and temporal cornea and conjunctiva; graded on 0-3 scale; fluorescein staining in 5 areas of cornea; graded on 0-3 scale</P>
<P>Topical artificial tears used</P>
<P>
<B>Adverse events reported</B>: NR</P>
<P>
<B>Intervals at which outcomes assessed</B>: all above outcomes were assessed before and at approximately 11 weeks after occlusion (mean 11.2 weeks; range 8 to 18 weeks)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-02-10 08:39:53 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: NR</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: National Health Service Lothian, Edinburgh, UK</P>
<P>
<B>Disclosures of interest</B>: "the authors state that they have no proprietary interest in the products named in this article"</P>
<P>
<B>Study period</B>: NR</P>
<P>
<B>Reported subgroup analyses</B>: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-05 20:47:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2010">
<CHAR_METHODS MODIFIED="2017-03-27 21:18:43 +0100" MODIFIED_BY="Andrew Law">
<P>
<B>Study design</B>: parallel randomized control trial</P>
<P>
<B>Unit of analysis</B>: unclear as trial investigators did not report if they had only included one eye in the analysis or took the averaged of both eyes</P>
<P>
<B>Unit of randomization</B>: participant, both eyes received the same intervention</P>
<P>How were missing data handled? NA</P>
<P>
<B>Reported power calculation</B>: no</P>
<P>Unusual study design: the study included 40 participants, 20 of whom were healthy controls. For this review, we will only refer to 20 dry eye participants. Healthy controls were also randomly assigned: "The 40 eyes of the normal subjects (group II) were similarly assigned to group IIA (upper punctal occlusion group, n = 20 eyes) or group IIB (lower punctal occlusion group, n = 20 eyes)."</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:47:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: China</P>
<P>
<B>Number randomized</B>: 
</P>
<P>Total: 20 participants (40 eyes)</P>
<P>Per group: 10 participants (20 eyes)</P>
<P>
<B>Exclusions after randomization</B>: none</P>
<P>
<B>Number analyzed</B>: 
</P>
<P>Total: 20 participants (40 eyes)</P>
<P>Per group: 10 participants (20 eyes)</P>
<P>
<B>Losses to follow-up</B>: none</P>
<P>
<B>Mean age ± SD (years)</B>: 22.5 ± 2.4 total; by group not reported</P>
<P>
<B>Sex (%)</B>: 16 women (80%) and 4 men (20%); by group not reported</P>
<P>
<B>Inclusion criteria</B>: subjective symptoms of dry eye, a Schirmer I test result &lt; 5 mm or TBUT &lt; 5 seconds, and evidence of corneal surface damage on fluorescein staining</P>
<P>
<B>Exclusion criteria</B>: history of atopy; allergic diseases; Stevens-Johnson syndrome; chemical, thermal, or radiation injury; or any other ocular or systemic disorder or had undergone any ocular surgery or contact lens use that would create an ocular surface problem or dry eye; lacrimal dysfunction, as determined by slit lamp examination and irrigation</P>
<P>
<B>Equivalence of baseline characteristics</B>: yes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-03-27 21:19:13 +0100" MODIFIED_BY="Andrew Law">
<P>No mention of artificial tear use</P>
<P>
<B>Intervention 1</B>: collagen punctal plugs in the lower puncta (1A)</P>
<P>Punctal plug model: NR</P>
<P>Manufacturer of punctal plug: Lacrimedics</P>
<P>Location of manufacturer: Eastsound, WA</P>
<P>
<B>Intervention 2</B>: collagen punctal plugs in the upper puncta (1B)</P>
<P>Punctal plug model: NR</P>
<P>Manufacturer of punctal plug: Lacrimedics</P>
<P>Location of manufacturer: Eastsound, WA</P>
<P>
<B>Length of follow-up</B>:</P>
<P>Planned: protocol not available</P>
<P>Actual: 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-09 15:04:12 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary and secondary outcome not differentiated, as defined in study reports</B>: symptom scoring, upper and lower tear menisci, tear breakup time, corneal fluorescein staining, and Schirmer I test</P>
<P>
<B>Adverse events reported</B>: "no complication was observed in dry eye patients or control subjects during the period of this study"</P>
<P>
<B>Intervals at which outcomes assessed</B>: day 1, 4, 7, and 10</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-02-10 08:40:02 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: NR</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: Chinese National Science and Technology Development Supporting Program and Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents</P>
<P>
<B>Disclosures of interest</B>: none</P>
<P>
<B>Study period</B>: NR</P>
<P>
<B>Reported subgroup analyses</B>: yes, healthy controls and dry eye groups</P>
<P>
<B>Did trial investigators need to be contacted?</B> yes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-05 20:47:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farrell-2003">
<CHAR_METHODS MODIFIED="2017-03-27 21:20:46 +0100" MODIFIED_BY="Andrew Law">
<P>
<B>Study design</B>: parallel randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: unclear as trial investigators did not report if they had only included one eye in the analysis or took the averaged of both eyes</P>
<P>
<B>Unit of randomization:</B> participant, both eyes received the same intervention</P>
<P>How were missing data handled? NA</P>
<P>
<B>Reported power calculation</B>: NR</P>
<P>Unusual study design: 45 age- and gender- matched healthy volunteers were included (for comparison with dry eye participant baseline measurements only; no punctal plugs inserted)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:47:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: UK</P>
<P>
<B>Number randomized</B>: 
</P>
<P>62 participants (121 eyes) in total</P>
<P>NR participants (71 eyes) in lower punctum group</P>
<P>NR participants (50 eyes) in lower and upper punctum group</P>
<P>
<B>Exclusions after randomization</B>: none reported</P>
<P>
<B>Number analyzed</B>: 
</P>
<P>62 participants (121 eyes) in total</P>
<P>NR participants (71 eyes) in lower punctum group</P>
<P>NR participants (50 eyes) in lower and upper punctum group</P>
<P>
<B>Losses to follow-up</B>: none reported</P>
<P>
<B>Overall mean age (SD)</B>: NR</P>
<P>
<B>Age range</B>: 24-87 years</P>
<P>
<B>Sex (%)</B>: 52 women (84%) and 10 men (16%) in total; by group not reported</P>
<P>
<B>Inclusion criteria</B>: (at least 3 of the 4 had to be met to be eligible): Schirmer score &lt; 10 mm at 5 minutes; TBUT &lt; 10 seconds; Mucin filaments and tear meniscus discontinuity; Rose Bengal score of &#8805; 3.5 (corneal epithelium and bulbar conjunctiva)</P>
<P>
<B>Exclusion criteria</B>: NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-03-27 21:21:26 +0100" MODIFIED_BY="Andrew Law">
<P>No mention of artificial tears use</P>
<P>
<B>Intervention 1</B>: collagen punctal plugs were inserted in the lower punctum of 71 eyes</P>
<P>Punctal plug model: NR</P>
<P>Manufacturer of punctal plug: Lacrimedics, Inc</P>
<P>Location of manufacturer: NR</P>
<P>
<B>Intervention 2</B>: collagen punctal plugs were inserted in the lower and upper puncta of 50 eyes</P>
<P>Punctal plug model: NR</P>
<P>Manufacturer of punctal plug: Lacrimedics, Inc</P>
<P>Location of manufacturer: NR</P>
<P>
<B>Length of follow-up</B>:<BR/>Actual: 12 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-10 09:51:17 +0000" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcome were not distinguished.</P>
<P>
<B>Outcomes reported</B>:</P>
<UL>
<LI>Subjective symptoms: McMonnies symptom questionnaire (modified); 1 point for each reported symptom; scores added to derive a summary score</LI>
<LI>Tear film stability: tear thinning time measured in seconds; average of 3 measurements</LI>
<LI>Tear meniscus height: measured using video slit-lamp in mm, midway between the canthi along the lower lid; Average of 3 measurements</LI>
</UL>
<P>
<B>Adverse events reported</B>:</P>
<P>
<B>Intervals at which outcomes assessed</B>: 5 and 12 days after occlusion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-02-10 08:41:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: NR</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: Lacrimedics, Inc donated collagen plugs</P>
<P>
<B>Disclosures of interest</B>: "none of the authors have any other vested interest in Lacrimedics Inc. or their products"</P>
<P>
<B>Study period</B>: NR</P>
<P>
<B>Reported subgroup analyses</B>: none reported</P>
<P>Each eye treated as independent</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-05 20:47:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feng-2011">
<CHAR_METHODS MODIFIED="2017-03-27 21:29:38 +0100" MODIFIED_BY="Andrew Law">
<P>
<B>Study design</B>: unclear if it was a parallel or paired-eye randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: eyes; no mention of analysis accounting for correlation between the left and right eye</P>
<P>
<B>Unit of randomization: </B>unclear if each eye of each participant were randomized to the same or different interventions</P>
<P>How were missing data handled? NR</P>
<P>
<B>Reported power calculation</B>: none reported</P>
<P>Unusual study design: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:47:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: China</P>
<P>
<B>Number randomized</B>: 
</P>
<P>Total: 54 participants (108 eyes)</P>
<P>Per group: 27 participants (54 eyes)</P>
<P>
<B>Exclusions after randomization</B>: none</P>
<P>
<B>Number analyzed</B>: 
</P>
<P>Total: 54 participants (108 eyes)</P>
<P>Per group: 27 participants (54 eyes)</P>
<P>
<B>Losses to follow-up</B>: NR</P>
<P>
<B>Mean age ± SD</B>: 20 ± 6 years; by group not reported</P>
<P>
<B>Age range</B>: 18-34 years in total; by group not reported</P>
<P>
<B>Sex (%)</B>: 19 men (35%) and 35 women (65%) in total; by group not reported</P>
<P>
<B>Inclusion criteria</B>: "patients treated with LASIK in our hospital" (p 1666)</P>
<P>
<B>Exclusion criteria</B>: NR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-02-10 09:04:37 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention 1</B>: collagen punctual occlusion</P>
<P>Punctal plug model: A12-103</P>
<P>Manufacturer of punctal plug: Odyssey</P>
<P>Location of manufacturer: NR</P>
<P>
<B>Intervention 2</B>: artificial tear (dextran and hypromellose eye drops) by Alcon, 1 drop 3 times/day.</P>
<P>
<B>Length of follow-up</B>: 
</P>
<P>Planned: protocol not available</P>
<P>Actual: 2 weeks after punctual occlusion surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-10 09:41:13 +0000" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcome were not distinguished.</P>
<P>
<B>Outcomes reported</B>:</P>
<UL>
<LI>Schirmer I test</LI>
<LI>TBUT</LI>
<LI>fluorescein staining test</LI>
</UL>
<P>
<B>Adverse events reported</B>: NR</P>
<P>
<B>Intervals at which outcomes assessed</B>: NA</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-04-25 20:47:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Type of study</B>: published</P>
<P>
<B>Funding sources</B>: NR</P>
<P>
<B>Disclosures of interest</B>: NR</P>
<P>
<B>Study period</B>: June 2009 to September 2009</P>
<P>
<B>Reported subgroup analyses</B>: no</P>
<P>
<B>Do trial investigators need to be contacted?</B>
</P>
<P>Yes, the investigators need to be contacted for randomization method</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-05 20:48:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaido-2012">
<CHAR_METHODS MODIFIED="2017-05-05 20:47:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: parallel randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: right eye of each participant</P>
<P>
<B>Unit of randomization</B>: participant; both eyes received the same treatment but only the right eye was analyzed</P>
<P>How were missing data handled? NA</P>
<P>
<B>Reported power calculation</B>: none reported</P>
<P>Unusual study design: unclear whether both of eyes had similar values of TBUT at baseline</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:48:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: Japan</P>
<P>
<B>Number randomized</B>: 
</P>
<P>43 participants (43 eyes) in total</P>
<P>19 participants (19 eyes) in upper occlusion group</P>
<P>24 participants (24 eyes) in lower occlusion group</P>
<P>
<B>Exclusions after randomization</B>: none</P>
<P>
<B>Number analyzed</B>: 
</P>
<P>43 participants (43 eyes) in total</P>
<P>19 participants (19 eyes) in upper occlusion group</P>
<P>24 participants (24 eyes) in lower occlusion group</P>
<P>
<B>Losses to follow-up</B>: none</P>
<P>
<B>Mean age ± SD</B>: 55.8 ± 16.1 years; by group not reported</P>
<P>
<B>Age range</B>: 22-82 years in total; by group not reported</P>
<P>
<B>Sex (%)</B>: 9 men (21%) and 34 women (79%) in total; by group not reported</P>
<P>
<B>Inclusion criteria</B>:</P>
<UL>
<LI>Previously used non-preserved artificial tear drops but still complained of persistent visual dry eye symptoms (fatigue; blurred vision; not being able to perform continued visual tasks such as watching television, reading, video)</LI>
<LI>TBUT values &#8804; 5 seconds</LI>
<LI>No positive fluorescein staining or scores &lt; 3 points (based on the Japanese dry eye diagnostic criteria and van Bijsterveld scoring system (scale of 0 to 9 points)</LI>
</UL>
<P>
<B>Exclusion criteria</B>:</P>
<UL>
<LI>Sjogren syndrome diagnosed by Fox criteria</LI>
<LI>Cicatricial keratoconjunctival diseases</LI>
<LI>Undergone penetrating keratoplasty</LI>
<LI>Use of contact lenses</LI>
<LI>Cconvergence insufficiency, accommodative disorders, phorias, and corneal hypoesthesia</LI>
<LI>Conjunctivochalasis and meibomian gland disease</LI>
<LI>Glaucoma, uveitis, and retinal disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-03-27 21:32:33 +0100" MODIFIED_BY="Andrew Law">
<P>No mention of artificial tears </P>
<P>
<B>Intervention 1</B>: silicone punctal plugs in the lower puncta</P>
<P>Punctal plug model: Super Flex plug</P>
<P>Manufacturer of punctal plug: Eagle Vision</P>
<P>Location of manufacturer: Memphis, TN</P>
<P>
<B>Intervention 2</B>: silicone punctal plugs in the upper puncta</P>
<P>Punctal plug model: Super Flex plug</P>
<P>Manufacturer of punctal plug: Eagle Vision</P>
<P>Location of manufacturer: Memphis, TN</P>
<P>
<B>Length of follow-up</B>:</P>
<P>Planned: protocol not available</P>
<P>Actual: 1 month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-10 09:32:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary and secondary outcomes not differentiated, as defined in study reports</B>:</P>
<UL>
<LI>Schirmer test (mm of wetting for 5 minutes)</LI>
<LI>TBUT</LI>
<LI>Fluorescein staining score</LI>
<LI>Visual acuity and functional visual acuity (including visual maintenance ratio and blink frequency)</LI>
<LI>Participant satisfaction with occlusion treatment</LI>
</UL>
<P>
<B>Adverse events reported</B>: no</P>
<P>
<B>Intervals at which outcomes assessed</B>: 1 month</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-04-25 20:58:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Trial registry</B>: NR</P>
<P>
<B>Funding sources</B>: NR</P>
<P>
<B>Disclosures of interest</B>: "The authors have no financial or conflicts of interest to disclose (p 1009)."</P>
<P>
<B>Study period</B>: NR</P>
<P>
<B>Reported subgroup analyses</B>: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-05 20:48:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lowther-1995">
<CHAR_METHODS MODIFIED="2017-04-25 17:13:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: paired-eye randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: eyes; no mention of analysis accounting for correlation between the left and right eye</P>
<P>
<B>Unit of randomization: </B>eyes; each eye of each participant were randomized to a different intervention </P>
<P>How were missing data handled? NA</P>
<P>
<B>Reported power calculation</B>: yes, sample size = 32 (64 eyes); P value = 0.05; 50% of the patients indicated that the eye with the implants was better, 25% said the opposite eye was better, and 25% said no difference</P>
<P>Unusual study design: authors did not perform the appropriate pair-wise analysis and each eye treated as independent</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:48:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: USA (assumed from author's origin)</P>
<P>
<B>Number randomized</B>: 
</P>
<P>Total: 32 participants (64 eyes)</P>
<P>Per group: 32 eyes</P>
<P>
<B>Exclusions after randomization</B>: none reported</P>
<P>
<B>Number analyzed</B>: 32 participants (64 eyes); 32 eyes in each group</P>
<P>
<B>Losses to follow-up</B>: none reported</P>
<P>
<B>Overall mean age (SD)</B>: participant age was collected but not reported</P>
<P>
<B>Age range</B>: participant age was collected but not reported</P>
<P>
<B>Sex (%)</B>: NR</P>
<P>
<B>Inclusion criteria</B>: participants reporting bilateral dry eye symptoms (based on responses to a modified McMonnies' questionnaire) and wearing hydrogel contact lenses were included</P>
<P>
<B>Exclusion criteria</B>: none reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-03-27 21:36:18 +0100" MODIFIED_BY="Andrew Law">
<P>No mention of artificial tears</P>
<P>
<B>Intervention 1</B>: collagen intracanalicular plugs were inserted in the upper and lower puncta</P>
<P>Punctal plug model: 0.3 mm diameter</P>
<P>Manufacturer of punctal plug: Lacrimedics, Inc.</P>
<P>Location of manufacturer: Rosemead, CA</P>
<P>
<B>Intervention 2</B>: sham plug insertion in participants contralateral eye</P>
<P>
<B>Length of follow-up</B>:</P>
<P>Planned: protocol not available<BR/>Actual: 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-10 09:36:35 +0000" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcome were not distinguished.</P>
<P>
<B>Outcomes reported</B>:</P>
<P>Subjective symptoms: McMonnies symptom questionnaire (modified)</P>
<P>Tear meniscus height: measured using video slit-lamp in mm</P>
<P>Tear film stability: TBUT measured in seconds</P>
<P>Ocular surface staining: Rose Bengal and fluorescein staining scored 0 (no staining) to 4 (heavy, coalesced staining)</P>
<P>Tear lactoferrin immunoassay test: lactoplate tear lactoferrin immunoassay test; left in cul-de-sac for 2-4 minutes; precipitation ring diameter measured in mm 3 days later<BR/>
<B>Adverse events reported</B>:</P>
<P>
<B>Intervals at which outcomes assessed</B>: before and at 5 days after occlusion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-02-10 08:37:24 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: NR</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: funded by Bausch and Lomb inVision Institute; Eagle Vision, Inc. supplied implants and Lactoplate tests</P>
<P>
<B>Disclosures of interest</B>: NR</P>
<P>
<B>Study period</B>: NR</P>
<P>
<B>Reported subgroup analyses</B>: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-16 15:23:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mansour-2007">
<CHAR_METHODS MODIFIED="2017-04-25 17:13:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: paired-eye randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: eyes; no mention of analysis accounting for correlation between the left and right eye</P>
<P>
<B>Unit of randomization: </B>each eye of each participant was randomized to a different intervention</P>
<P>How were missing data handled? Participants lost to follow-up were excluded from analysis</P>
<P>
<B>Reported power calculation</B>: NR</P>
<P>Unusual study design: authors did not perform the appropriate pair-wise analysis and each eye treated as independent</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:48:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: Netherlands (assumed from location of ethics committee)</P>
<P>
<B>Number randomized</B>: 
</P>
<P>Total: 20 participants (40 eyes)</P>
<P>Per group: 20 eyes in each group</P>
<P>
<B>Exclusions after randomization</B>: none reported</P>
<P>
<B>Number analyzed</B>: 13 participants (26 eyes); 13 eyes in each group</P>
<P>
<B>Losses to follow-up</B>: 7 participants (14 eyes); 7 eyes in each group</P>
<P>
<B>Overall mean age (SD)</B>: NR</P>
<P>
<B>Age range</B>: NR</P>
<P>
<B>Sex (%)</B>: 17 women (85%) and 3 men (15%)</P>
<P>
<B>Inclusion criteria</B>: European criteria for the diagnosis of Sjögren's syndrome were used to identify eligible participants: subjective symptom report (ocular and oral symptoms of dryness). Schirmer test, Rose Bengal staining, and TBUT; xerostomia</P>
<P>
<B>Exclusion criteria</B>: none reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-03-27 21:37:48 +0100" MODIFIED_BY="Andrew Law">
<P>No mention of artificial tears</P>
<P>
<B>Intervention 1</B>: silicone punctal plugs inserted in the upper and lower puncta</P>
<P>Punctal plug model: tapered-shaft silicone punctal plugs, 0.7 mm diameter</P>
<P>Manufacturer of punctal plug: Eagle Vision</P>
<P>Location of manufacturer: Memphis, TN</P>
<P>Duration of plug occlusion was 6 to 20 weeks</P>
<P>If plugs extruded during course of study, larger plug inserted and follow-up deferred for period of at least 6 weeks</P>
<P>
<B>Intervention 2</B>: other eye of participant remained unoccluded</P>
<P>
<B>Length of follow-up</B>:</P>
<P>Planned: protocol not available<BR/>Actual: between 6 to 20 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-16 15:23:23 +0100" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcome were not distinguished.</P>
<P>
<B>Outcomes reported</B>:</P>
<P>Subjective discomfort (at least 1 of the following complaints): foreign body sensation, photophobia, stinging, pain, burning, and ocular fatigue</P>
<P>Subjective symptoms: abovementioned symptom discomfort complaints scored and scores added to derive a summary score (0 to 10)</P>
<P>Tear production: Schirmer test without anesthesia</P>
<P>Ocular surface staining: Rose Bengal staining scored according to Van Bijsterveld classification</P>
<P>Mucus debris: measured on scale of 0 (no mucus debris) to 3 (mucus threads and filaments)<BR/>
<B>Adverse events reported</B>: NR</P>
<P>
<B>Intervals at which outcomes assessed</B>: before and at least 6 weeks after occlusion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-02-10 08:37:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: NR</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: NR</P>
<P>
<B>Disclosures of interest</B>: NR</P>
<P>
<B>Study period</B>: NR</P>
<P>
<B>Reported subgroup analyses</B>: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-05 20:48:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nava_x002d_Castaneda-2003">
<CHAR_METHODS MODIFIED="2017-04-25 20:58:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: parallel randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: unclear as trial investigators did not report if they had only included one eye in the analysis or took the averaged of both eyes</P>
<P>
<B>Unit of randomization:</B> participant, both eyes received the same intervention</P>
<P>How were missing data handled? NA, no missing data reported</P>
<P>
<B>Reported power calculation</B>: yes, sample size = 30 participants in each group; "based on the assumption that 80% of the patients subjected to canalicular occlusion would have a successful outcome (reduction in dry eye/conjunctivitis symptoms), in contrast to 30% of those receiving medical treatment alone (artificial tears). It was further assumed that 74 patients would have to be randomized to the 2 treatment groups to allow for dropouts and ensure that 60 patients would complete the study" (p 11)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:48:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: Mexico</P>
<P>
<B>Number randomized</B>: 
</P>
<P>61 participants (122 eyes) in total</P>
<P>31 participants (31 eyes) in Collagen/silicone plug group</P>
<P>30 participants (30 eyes) in sham group</P>
<P>
<B>Exclusions after randomization</B>: 1 participant (2 eyes)</P>
<P>
<B>Number analyzed</B>: 60 participants (120 eyes); 30 participants (60 eyes) in each group</P>
<P>
<B>Losses to follow-up</B>: none reported</P>
<P>
<B>Overall mean age (SD)</B>: 49.8 (NR) years in total; by group not reported</P>
<P>
<B>Age range</B>: 23-80 years</P>
<P>
<B>Sex (%)</B>: 50 women (82%) and 11 men (18%) in total; by group not reported</P>
<P>
<B>Inclusion criteria</B>: 18-80 years old, 2 subjective symptoms of dry eye, ocular surface abnormalities as demonstrated by fluorescein score &gt; 1, conjunctivitis of &#8805; 1 month</P>
<P>
<B>Exclusion criteria</B>: participants were excluded if dry eye attributed to other ocular conditions (see <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>) or if diagnosed with asthma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-03-28 13:52:32 +0100" MODIFIED_BY="Andrew Law">
<P>No mention of artificial tears use</P>
<P>
<B>Intervention 1</B>: collagen/silicone plug group (experimental):</P>
<P>Punctal plug model: NR</P>
<P>Manufacturer of punctal plug: Lacrimedics</P>
<P>Location of manufacturer: Eastsound, WA</P>
<P>Collagen punctal plugs inserted in the upper and lower canaliculi of both eyes. 2 weeks after initial insertion, 1 silicone punctal plug inserted in the upper and 2 collagen plugs inserted in lower canaliculi of both eyes. 4 weeks after initial insertion, permanent plug inserted in lower canaliculi</P>
<P>
<B>Control</B>: sham plug insertion at same intervals as collagen/silicone plug group. Same procedures as collagen/silicone group, but eyes were not occluded</P>
<P>
<B>Length of follow-up</B>:</P>
<P>Planned: protocol not available<BR/>Actual: 8 weeks after initial occlusion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-10 09:47:40 +0000" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcome were not distinguished.</P>
<P>
<B>Outcomes reported</B>:</P>
<P>Subjective symptoms: visual performance and comfort; assessed using a 10 cm visual analogue scale, very poor vision/very uncomfortable and very good vision/very comfortable at the boundaries of the scale</P>
<P>Frequency and severity of dry eye (watery eyes, itching, burning, dryness, fluctuating vision, sandy/foreign body sensation, light sensitivity) and conjunctival (discharge and redness) symptoms; frequency scored 0 (never) to 5 (continually, every hour of the day) and severity 0 (no symptom) to 3 (severe); frequency and severity score for each symptom multiplied and scores summed to derive summary score.</P>
<P>Ocular surface staining: fluorescein staining scored 0 (absent) to 4 (severe)</P>
<P>Topical artificial tears used: frequency scored 0 (never) to 5 (continually, every hour of the day)</P>
<P>Visual acuity<BR/>
<B>Adverse events reported</B>: yes, corneal ulcer (1 participant; not related to treatment) and epiphora (1 participant; related to treatment)</P>
<P>
<B>Intervals at which outcomes assessed</B>: before and at 1 hour and 2, 4, 8 weeks after initial occlusion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-02-10 09:48:22 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: NR</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: Lacrimedics, Inc</P>
<P>
<B>Disclosures of interest</B>: none reported</P>
<P>
<B>Study period</B>: NR</P>
<P>
<B>Reported subgroup analyses</B>: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-05 20:48:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qiu-2012">
<CHAR_METHODS MODIFIED="2017-03-27 21:48:44 +0100" MODIFIED_BY="Andrew Law">
<P>
<B>Study design</B>: parallel randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: unclear as trial investigators did not report if they had only included one eye in the analysis or took the averaged of both eyes</P>
<P>
<B>Unit of randomization:</B> participant, both eyes received the same intervention</P>
<P>How were missing data handled? Excluded from analysis</P>
<P>
<B>Reported power calculation</B>: NR</P>
<P>Unusual study design: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:48:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: China</P>
<P>
<B>Number randomized</B>: 28 participants (56 eyes) in total 
</P>
<P>12 participants (24 eyes) in punctal plug group</P>
<P>16 participants (32 eyes) in artificial tears group</P>
<P>
<B>Exclusions after randomization</B>: none reported</P>
<P>
<B>Number analyzed</B>: 28 participants (56 eyes) in total 
</P>
<P>12 participants (24 eyes) in punctal plug group</P>
<P>16 participants (32 eyes) in artificial tears group</P>
<P>
<B>Losses to follow-up</B>: none reported</P>
<P>
<B>Mean age (SD)</B>: 31.75 (NR) years</P>
<P>31.4 (15.1) years in punctal plug group</P>
<P>32.1 (12.8) years in artificial tears group</P>
<P>
<B>Age range</B>: 22-67</P>
<P>
<B>Sex (%)</B>: 18 women (64%) and 10 men (36%) in total; by group not reported</P>
<P>
<B>Inclusion criteria</B>: "The entry criteria for the patients were that they were diagnosed with dry eyes at our ophthalmology clinic and had no evidence of ocular diseases other than those associated with dry eye changes, such as superficial punctate keratopathy (SPK)" (p 20)</P>
<P>
<B>Exclusion criteria</B>: none listed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-02-10 10:40:02 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention 1</B>: acrylic punctal plug</P>
<P>Punctal plug model: SmartPLUG500</P>
<P>Manufacturer of punctal plug: Medenium</P>
<P>Location of manufacturer: Irvine, CA</P>
<P>
<B>Control</B>: artificial tear solution (Zhuhai Yisheng, Guangdong, China) containing a carbomer gel and basic fibroblast growth factor</P>
<P>
<B>Length of follow-up</B>:</P>
<P>Planned: 2 weeks</P>
<P>Actual: 2 weeks, extended to 4 weeks for corneal fluorescein staining</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-10 09:58:40 +0000" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcomes not differentiated</P>
<P>
<B>Outcomes, as defined by study</B>: 
</P>
<UL>
<LI>Corneal fluorescein staining (punctate epithelial keratopathy)</LI>
<LI>TBUT</LI>
<LI>Schirmer I test without anesthesia</LI>
<LI>Contrast sensitivity</LI>
<LI>Glare disability</LI>
<LI>Dry eye questionnaire</LI>
</UL>
<P>
<B>Adverse events reported</B>: punctate epithelial keratopathy</P>
<P>
<B>Intervals at which outcomes assessed</B>: baseline, 2 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-02-10 08:37:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: NR</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: "seed fund (no. 79495-01) and Linhu fund (no. 79495-02) of Peking University Hospital"</P>
<P>
<B>Disclosures of interest</B>: reported no conflicts of interest</P>
<P>
<B>Enrollement period</B>: May 2009 to October 2009</P>
<P>
<B>Reported subgroup analyses</B>: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-17 13:37:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qiu-2013">
<CHAR_METHODS MODIFIED="2017-04-25 17:20:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: parallel randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: right eye of each participant</P>
<P>
<B>Unit of randomization: </B>participant as only the right eye of each participant was randomized to intervention or control</P>
<P>How were missing data handled? Excluded from analysis</P>
<P>
<B>Reported power calculation</B>: NR</P>
<P>Unusual study design: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:48:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: China</P>
<P>
<B>Number randomized</B>: 42 participants (42 eyes) in total 
</P>
<P>22 participants (22 eyes) in punctal plug group</P>
<P>20 participants (20 eyes) in artificial tears group</P>
<P>
<B>Exclusions after randomization</B>: none reported</P>
<P>
<B>Number analyzed</B>: 40 participants (40 eyes) in total 
</P>
<P>21 participants (21 eyes) in punctal plug group</P>
<P>19 participants (19 eyes) in artificial tears group</P>
<P>
<B>Losses to follow-up</B>: 2 participants (2 eyes) in total 
</P>
<P>1 participant (1 eye) in punctal plug group</P>
<P>1 participant (1 eye) in artificial tears group</P>
<P>
<B>Mean age (SD)</B>: overall NR</P>
<P>35.2 (16.5) years in punctal plug group</P>
<P>34.6 (1.3) years in artificial tears group</P>
<P>
<B>Age range</B>: 22-67 years</P>
<P>
<B>Sex (%)</B>: 36 women (90%) and 4 men (10%) in total</P>
<P>19 women (90.5%) and 2 men (9.5%) in the intervention group</P>
<P>17 women (89.5%) and 2 men (10.5%) in the observation group</P>
<P>
<B>Inclusion criteria</B>: "patients with dry eye who sought for treatment in our ophthalmology clinic from March to October in 2010, diagnosed with primary Sjögren's syndrome &#8230;The entry criteria for the patients were that they were diagnosed with dry eyes at our ophthalmology clinic and had no evidence of ocular diseases other than those associated with dry eye changes, such as superficial punctuate keratopathy (SPK)" (p 2544).</P>
<P>
<B>Exclusion criteria</B>: none specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-02-09 15:04:16 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention 1</B>: acrylic punctal plug</P>
<P>punctal plug model: SmartPLUG500</P>
<P>Manufacturer of punctal plug: Medenium</P>
<P>Location of manufacturer: Irvine, CA</P>
<P>
<B>Control</B>: artificial tears (Zhuhai Yisheng, Guangdong, China) containing a carbomer gel and bFGF</P>
<P>
<B>Length of follow-up</B>:<B> 3 months</B>
</P>
<P>Planned: 3 months</P>
<P>Actual: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-10 10:03:06 +0000" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcomes not differentiated</P>
<P>
<B>Outcomes, defined by the study</B>: 
</P>
<UL>
<LI>Ocular Surface Disease Index</LI>
<LI>Corneal fluorescein staining</LI>
<LI>TBUT</LI>
<LI>Schirmer I test without anesthesia</LI>
<LI>Contrast sensitivity</LI>
<LI>Glare disability</LI>
</UL>
<P>
<B>Adverse events reported</B>: NR</P>
<P>
<B>Intervals at which outcomes assessed</B>: baseline, 3 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-06-17 13:37:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: not reported</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: Seed Fund (No. 79495-01) and Linhu fund (no. 79495) of Peking University Third Hospital 
</P>
<P>
<B>Disclosures of interest</B>: no conflicts of interest to report 
</P>
<P>
<B>Enrollement period</B>: March 2010 to October 2010</P>
<P>
<B>Reported subgroup analyses</B>: NR</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-05 20:48:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabensteiner-2013">
<CHAR_METHODS MODIFIED="2017-04-24 20:26:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: parallel randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: participant; trial investigators reported the average of both eyes of each participant</P>
<P>
<B>Unit of randomization:</B> participant; both eyes received the same intervention</P>
<P>How were missing data handled? Excluded from analysis</P>
<P>
<B>Reported power calculation</B>: NR</P>
<P>Unusual study design: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:48:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: Austria</P>
<P>
<B>Number randomized</B>: 30 participants (60 eyes) in total 
</P>
<P>15 participants (30 eyes) in silicone punctual plugs group</P>
<P>15 participants (30 eyes) in intracanalicular SmartPlugs group</P>
<P>
<B>Exclusions after randomization</B>: none reported</P>
<P>
<B>Number analyzed</B>: 30 participants (57 eyes) in total 
</P>
<P>15 participants (27 eyes) in silicone punctual plugs group</P>
<P>15 participants (30 eyes) in intracanalicular SmartPlugs group</P>
<P>
<B>Losses to follow-up</B>: none reported</P>
<P>
<B>Mean age (SD)</B>: overall NR; by group not reported</P>
<P>
<B>Age range</B>: NR</P>
<P>
<B>Sex (%)</B>: NR</P>
<P>
<B>Inclusion criteria</B>: "moderate to severe dry eye syndrome as described by the DEWS report 2007&#8230; typical dry eye symptoms, reduced tear break&#8211;up time of less than 5 seconds with either a Schirmer test without local anesthesia below 5 mm/ 5 min, or a vital staining score of the cornea (fluorescein) and conjunctiva (Rose Bengal) according to van Bijsterveld (&gt; 3)" (p 522)</P>
<P>
<B>Exclusion criteria</B>: "Sjogren's syndrome, eyelid or blinking problems, contact lens use and previous punctal plug use" (p 522)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-03-27 21:51:21 +0100" MODIFIED_BY="Andrew Law">
<P>Both groups used artificial tears as needed</P>
<P>
<B>Intervention 1</B>: silicone punctual plugs</P>
<P>Punctal plug model: silicone punctual plugs</P>
<P>Manufacturer of punctal plug: FCI Opthalmics</P>
<P>Location of manufacturer: Issy-les-Moulineaux Cedex, France</P>
<P>
<B>Intervention 2</B>: intracanalicular SmartPlugs</P>
<P>Punctal plug model: punctual plugs</P>
<P>Manufacturer of punctal plug: Medenium</P>
<P>Location of manufacturer: Irvine, CA</P>
<P>
<B>Length of follow-up</B>: 
</P>
<P>Planned: 3 months</P>
<P>Actual: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-10 10:07:43 +0000" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcomes not differentiated</P>
<P>
<B>Outcomes, as defined by study</B>: 
</P>
<UL>
<LI>Schirmer I test</LI>
<LI>TBUT</LI>
<LI>Vital staining</LI>
<LI>Subjective symptoms</LI>
<LI>Frequency of artificial tear use</LI>
<LI>
<B>Adverse events reported</B>: no</LI>
</UL>
<P>
<B>Intervals at which outcomes assessed</B>: baseline, 3 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-02-10 10:07:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: NR</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: "no funding source to declare" (p 524)</P>
<P>
<B>Disclosures of interest</B>: no conflicts of interest</P>
<P>
<B>Enrollement period</B>: unclear</P>
<P>
<B>Reported subgroup analyses</B>: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-08 21:15:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roberts-2007">
<CHAR_METHODS MODIFIED="2017-04-24 20:27:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: parallel group randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: participant; trial investigators reported the average of both eyes of each participant</P>
<P>
<B>Unit of randomization:</B> participant, both eyes received the same intervention</P>
<P>How were missing data handled? Excluded from analyses</P>
<P>
<B>Reported power calculation</B>: no</P>
<P>Unusual study design: "for Schirmer testing and rose bengal staining, data were collected from both eyes and averaged before statistical analysis"</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-08 21:15:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: USA</P>
<P>
<B>Number randomized</B>: 
</P>
<P>32 participants (64 eyes) in total</P>
<P>11 participants (22 eyes) in punctal plug group</P>
<P>11 participants (22 eyes) in cyclosporine group</P>
<P>10 participants (20 eyes) in cyclosporine + punctal plugs</P>
<P>
<B>Exclusions after randomization</B>: none</P>
<P>
<B>Number analyzed</B>: 
</P>
<P>30 participants (60 eyes) in total</P>
<P>10 participants (20 eyes) in each group</P>
<P>
<B>Losses to follow-up</B>: 2 participants</P>
<P>
<B>Mean age</B>: 52.1 years in total; by group not reported</P>
<P>
<B>Age range</B>: 38-63 years; by group not reported</P>
<P>
<B>Sex (%)</B>: 25 women (83.3%) and 5 men (16.7%); by group not reported</P>
<P>
<B>Inclusion criteria</B>: "(1) chronic symptoms of burning, sandy, or scratchiness in both eyes; (2) daily need for multiple applications of artificial tears; and (3) rose bengal staining of grade 2 or higher (scale described below)." (p 391)</P>
<P>
<B>Exclusion criteria</B>:</P>
<UL>
<LI>Prior ocular surgery other than cataract surgery</LI>
<LI>Concurrent use of any other topical ocular medications</LI>
<LI>Prior experience with either punctal plugs or topical cyclosporin</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-03-28 13:57:25 +0100" MODIFIED_BY="Andrew Law">
<P>All groups were allowed to use artificial tears throughout the follow up period</P>
<P>
<B>Intervention 1</B>: cyclosporine ophthalmic emulsion 0.05% (RESTASIS; Allergan, Irvine, CA) eye drops to both eyes twice daily</P>
<P>
<B>Intervention 2</B>: bilateral collagen punctal plugs in the lower lids only</P>
<P>Punctal plug model: PARASOL (Punctal Occluder)</P>
<P>Manufacturer of punctal plug: Odyssey Medical</P>
<P>Location of manufacturer: Memphis, TN</P>
<P>
<B>Intervention 3</B>: bilateral collagen punctal plugs in the lower lids + cyclosporine eye drops to both eyes twice daily</P>
<P>
<B>Length of follow-up</B>:</P>
<P>Planned: protocol not available</P>
<P>Actual: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-09 15:04:17 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary and secondary outcome not differentiated, as defined in study reports</B>: "Schirmer scores without anaesthesia, corneal and conjunctival rose bengal staining, and artificial tear use"</P>
<P>
<B>Adverse events reported</B>: 2 participants withdrew: 1 due to discomfort of plugs and 1 due to burning caused by cyclosporine</P>
<P>
<B>Intervals at which outcomes assessed</B>: 1, 3, and 6 months after occlusion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-04-25 20:58:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: NR</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: Allergan</P>
<P>
<B>Disclosures of interest</B>: "Dr. Roberts is a consultant for Allergan. The authors state that they have no proprietary interest in the products named in this article" (p 391)</P>
<P>
<B>Study period</B>: October 2003 to January 2005</P>
<P>
<B>Reported subgroup analyses</B>: none reported</P>
<P>
<B>Do trial investigators need to be contacted?</B> Yes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-08 21:15:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Slusser-1998">
<CHAR_METHODS MODIFIED="2017-03-27 21:57:13 +0100" MODIFIED_BY="Andrew Law">
<P>
<B>Study design</B>: paired-eye randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: eyes; used paired t-tests to account for correlation between left and right eyes of each participant</P>
<P>
<B>Unit of randomization: </B>each eye of each participant was randomized to a different intervention</P>
<P>How were missing data handled? Excluded from analysis</P>
<P>
<B>Reported power calculation</B>: no</P>
<P>Unusual study design: used correct matched analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:49:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: USA</P>
<P>
<B>Number randomized</B>: 
</P>
<P>Total: 35 participants (70 eyes)</P>
<P>Per group: 35 eyes per group</P>
<P>
<B>Exclusions after randomization</B>: 7 participants (14 eyes)</P>
<P>
<B>Number analyzed</B>: 
</P>
<P>Total: 28 participants (56 eyes)</P>
<P>Per group: 28 eyes</P>
<P>
<B>Losses to follow-up</B>: 1 participant (2 eyes)</P>
<P>
<B>Mean age (SD)</B>: NR</P>
<P>
<B>Age range</B>: 21-69 years in total; by group not reported</P>
<P>
<B>Sex (%)</B>: 26 women (74%) and 9 men (26%) in total; by group not reported</P>
<P>
<B>Inclusion criteria</B>:</P>
<P>"1. Dry eye based on the response of at least 'sometimes' on at least 2 of the 3 questions concerning dryness,</P>
<P>lens awareness, and cloudy vision on the recruitment questionnaire (see Table 2).</P>
<P>2. At least one of the following objective signs: grade 1 or greater vital staining; prelens tear film break-up time of less than 15 seconds; tear meniscus height of less than 0.5 mm on slitlamp examination; grade 2 or more tear debris on a 0 to 4 scale.</P>
<P>3. Bilateral involvement of the above criteria.</P>
<P>4. Ability to understand and complete subjective scales daily.</P>
<P>5. Wearing contact lenses that are of equal age, type, and material.</P>
<P>6. Must be able to wear both contact lenses at least 20 hours/week."</P>
<P>
<B>Exclusion criteria</B>:</P>
<P>"1. Dry eye attributed to poor lid apposition or blinking mechanism.</P>
<P>2. Contact lens surface abnormalities (deposits), which cause distortion of a reflected grid pattern.</P>
<P>3. Clinically apparent nasolacrimal occlusion.</P>
<P>4. Patients who take certain hormones (birth control pills, menopausal replacement therapy) who cannot maintain current dosage throughout the study duration.</P>
<P>5. Ocular infection, including active corneal ulcers, keratitis, or conjunctivitis.</P>
<P>6. Use of any topical agents in the eye other than artificial tears, saline, or rewetting drops at the time of study entry.</P>
<P>7. Under 18 yr of age.</P>
<P>8. Known pregnancy."</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-03-27 21:57:58 +0100" MODIFIED_BY="Andrew Law">
<P>
<B>Intervention 1</B>: silicone punctal plugs in the lower and upper puncta</P>
<P>Punctal plug model: Herrick Lacrimal Plugs</P>
<P>Manufacturer of punctal plug: Lacrimedics</P>
<P>Location of manufacturer: Rialto, CA</P>
<P>(upper and lower) &#8211; 1 eye 1<SUP>st</SUP> 4 weeks; plugs + re-wetting drops 5<SUP>th</SUP> week</P>
<P>
<B>Intervention 2</B>: sham treatment</P>
<P>No plugs (sham) - fellow eye &#8211; 1<SUP>st</SUP> 4 weeks; re-wetting drops only 5<SUP>th</SUP> week</P>
<P>
<B>Length of follow-up</B>: 
</P>
<P>Planned: protocol not available</P>
<P>Actual: 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-10 10:17:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary and secondary outcome not differentiated, and were defined in study reports</B>: tear film break-up time, lens water content, vital staining, bulbar conjunctiva with fluorescein, Rose Bengal, patient questionnaires</P>
<P>
<B>Adverse events reported</B>: yes, 3 participants reported epiphora and plugs removed</P>
<P>
<B>Intervals at which outcomes assessed</B>: day 0, 7, 28, 35</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-08 21:15:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: NR</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: Vistaken; Dr. Slusser. "Lacrimedics, Inc. (Rialto, CA) donated the lacrimal plugs and supportive equipment used in this study. Allergan, Inc. (Irvine, CA) provided the non-preserved rewetting drops (p 337)."</P>
<P>
<B>Disclosures of interest</B>: NR</P>
<P>
<B>Study period</B>: March to June; year of study period not reported</P>
<P>
<B>Reported subgroup analyses</B>: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-17 13:38:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsifetaki-2003">
<CHAR_METHODS MODIFIED="2017-03-28 13:58:06 +0100" MODIFIED_BY="Andrew Law">
<P>
<B>Study design</B>: parallel randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: participant; (both eyes of each participant; mean outcome of left and right eyes reported respectively)</P>
<P>
<B>Unit of randomization</B>: participant; both eyes received the same intervention</P>
<P>How were missing data handled? NR</P>
<P>
<B>Reported power calculation</B>: power = 90%; sample size = 25 participants; assuming 90% response rate in the group receiving pilocarpine and a 30% response rate in the group receiving artificial tears</P>
<P>Unusual study design: participants with dry eye due to Sjögren's syndrome</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:49:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: Greece (assumed from author's origin)</P>
<P>
<B>Number randomized</B>: 85 participants (170 eyes) in total</P>
<P>28 participants (NR eyes) in collagen plugs group</P>
<P>29 participants (NR eyes) in oral pilocarpine group</P>
<P>28 participants in artificial tears only group</P>
<P>
<B>Exclusions after randomization</B>: 1 participant (2 eyes) in collagen plugs group</P>
<P>
<B>Number analyzed</B>: NR</P>
<P>
<B>Losses to follow-up</B>: 1 participant (2 eyes) in collagen plugs group</P>
<P>
<B>Mean age (SD)</B>: 
</P>
<P>57.8 (12.9) years in collagen plugs group</P>
<P>59.9 (9.9) years in oral pilocarpine group</P>
<P>57.0 (11.5) years in artificial tears only group</P>
<P>
<B>Age range</B>: NR</P>
<P>
<B>Sex (%)</B>: 85 women (100%) and 0 men in total</P>
<P>
<B>Inclusion criteria</B>: European criteria for the diagnosis of Sjögren's syndrome were used to identify eligible participants</P>
<P>
<B>Exclusion criteria</B>: none reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-04-25 19:56:28 +0100" MODIFIED_BY="[Empty name]">
<P>All groups used artificial tears</P>
<P>
<B>Intervention 1</B>: collagen plugs inserted in the lower puncta of both eyes for 7 days then permanent collagen plugs for the duration of the trial + artificial tears</P>
<P>Punctal plug model: Collagen Plugs</P>
<P>Manufacturer of punctal plug: Lacrimedics Inc.</P>
<P>Location of manufacturer: NR</P>
<P>
<B>Intervention 2</B>: oral pilocarpine (5 mg twice a day) + artificial tears</P>
<P>
<B>Intervention 3</B>: artificial tears only</P>
<P>
<B>Length of follow-up</B>:</P>
<P>Planned: protocol not available<BR/>Actual: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-16 15:23:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome, as defined in study reports</B>: assessed with a dry eye questionnaire<BR/>
<B>Secondary outcomes, as defined in study reports</B>:</P>
<P>Subjective symptoms: 100 mm visual analogue scale; score defined as improvement of &gt; 55 mm in symptoms over course of study</P>
<P>Tear production: Schirmer I test without anesthesia</P>
<P>Ocular surface staining: Rose Bengal staining</P>
<P>Tear film stability: TBUT</P>
<P>Fluorophotometer method</P>
<P>Imprint test (conjunctival impression cytology): improvement defined as increase in cytoplasm/nucleus ratio (epithelial cells) and goblet cells<BR/>
<B>Adverse events reported</B>: yes, "four patients had mild headache, of whom three also presented with nausea, vomiting, and sweating" (p 1205).</P>
<P>
<B>Intervals at which outcomes assessed</B>: every week for the first month, then every month after up to 12 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-06-17 13:38:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: Not reported (NR)</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: NR</P>
<P>
<B>Disclosures of interest</B>: NR</P>
<P>
<B>Study period</B>: NR</P>
<P>
<B>Reported subgroup analyses</B>: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-05 20:49:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yung-2012">
<CHAR_METHODS MODIFIED="2017-05-05 20:49:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: quasi-randomized trial &#8211; divided into 2 groups on the basis of their ID numbers; the plug (even numbers) and non-plug (odd numbers) groups</P>
<P>
<B>Unit of analysis</B>: unclear as both eyes of 10 participants receive the same intervention, but the trial investigators did not report how they analyzed them</P>
<P>
<B>Unit of randomization: </B>participant; assuming ID numbers were assigned to each participant, both eyes of 10 participants receive the same intervention</P>
<P>How were missing data handled? Excluded from analysis</P>
<P>
<B>Reported power calculation</B>: none</P>
<P>Unusual study design: participants' patient ID number as used to assigned them to each group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:49:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: Japan</P>
<P>
<B>Number randomized</B>: 
</P>
<P>18 participants (28 eyes) in total</P>
<P>9 participants (13 eyes) in silicone punctal plugs group</P>
<P>9 participants (15 eyes) in non-plug group</P>
<P>
<B>Exclusions after randomization</B>:</P>
<P>2 participants (NR eyes) in total</P>
<P>2 participants (NR eyes) in silicone punctal plugs group</P>
<P>0 participants (0 eyes) in non-plug group</P>
<P>
<B>Number analyzed</B>: 
</P>
<P>18 participants (28 eyes) in total</P>
<P>9 participants (13 eyes) in silicone punctal plugs group</P>
<P>9 participants (15 eyes) in non-plug group</P>
<P>
<B>Losses to follow-up</B>: none</P>
<P>
<B>Mean age (SD)</B>: 
</P>
<P>32.32 (7.69) years in total*</P>
<P>35.67 (10.74) years in silicone punctal plugs group</P>
<P>30.89 (3.89) years in non-plug group</P>
<P>
<B>Age range</B>: (20-56) years overall</P>
<P>
<B>Sex (%)</B>:</P>
<P>16 women (89%) and 2 men (11%) in total</P>
<P>8 women (89%) and 1 men (11%) in silicone punctal plugs group</P>
<P>8 women (89%) and 1 men (11%) in non-plug group</P>
<P>
<B>Inclusion criteria</B>: "patients who underwent LASIK. All eyes fulfilled the Japanese dry-eye criteria and had not responded to conventional treatment with artificial tears by 1 month postsurgery (p 208)."</P>
<P>
<B>Exclusion criteria</B>: none reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-03-30 20:36:38 +0100" MODIFIED_BY="Andrew Law">
<P>Both groups used artificial tears</P>
<P>
<B>Intervention 1</B>: silicone punctal plugs in upper and lower puncta + artificial tears</P>
<P>Punctal plug model: Eagle plug</P>
<P>Manufacturer of punctal plug: EagleVison</P>
<P>Location of manufacturer: Memphis, TN</P>
<P>
<B>Intervention 2</B>: observation + artificial tears</P>
<P>
<B>Length of follow-up</B>:</P>
<P>Planned: protocol not available</P>
<P>Actual: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-10 10:27:37 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes not identified as primary or secondary. 
</P>
<P>
<B>As defined in study reports</B>: subjective symptoms and satisfaction, corneal sensitivity, tear function and ocular surface (Schimer value, TBUT, and fluorescein score), and visual performance (uncorrected and best-corrected visual acuity (UCVA and BCVA), manifest refraction, and functional visual acuity (FVA))</P>
<P>
<B>Adverse events reported</B>: yes, excessive lacrimation and plugs that were lost were reinserted</P>
<P>
<B>Intervals at which outcomes assessed</B>: 1 and 3 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-02-10 08:38:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: NR</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: NR</P>
<P>
<B>Disclosures of interest</B>: NR</P>
<P>
<B>Study period</B>: January 2008 to March 2009</P>
<P>
<B>Reported subgroup analyses</B>: none reported</P>
<P>*We contacted the authors via email and have received additional information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-16 15:23:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2016">
<CHAR_METHODS MODIFIED="2017-03-28 14:03:27 +0100" MODIFIED_BY="Andrew Law">
<P>
<B>Study design</B>: parallel randomized controlled trial</P>
<P>
<B>Unit of analysis</B>: unclear as both eyes of 10 participants could have receive the same or different intervention</P>
<P>
<B>Unit of randomization: </B>unclear</P>
<P>How were missing data handled? NA, no missing data reported</P>
<P>
<B>Reported power calculation</B>: NR</P>
<P>Unusual study design: for 10 participants, both eyes were included, but for the remaining 70 participants only 1 eye was included</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-05 20:50:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Country</B>: China (assumed from author's affiliations)</P>
<P>
<B>Number randomized</B>: 
</P>
<P>80 participants (90 eyes) in total 
</P>
<P>40 participants (46 eyes) in punctal plug group</P>
<P>40 participants (44 eyes) in artificial tears group</P>
<P>
<B>Exclusions after randomization</B>: none reported</P>
<P>
<B>Number analyzed</B>: 
</P>
<P>80 participants (90 eyes) in total 
</P>
<P>40 participants (46 eyes) in punctal plug group</P>
<P>40 participants (44 eyes) in artificial tears group</P>
<P>
<B>Losses to follow-up</B>: none reported</P>
<P>
<B>Mean age (SD)</B>: 35.21 (NR) overall</P>
<P>35.28 (5.58) years in the punctal plug group</P>
<P>35.13 (6.25) years in the artificial tears group</P>
<P>
<B>Age range</B>: 
</P>
<P>22 to 46 years in the punctal plug group</P>
<P>21 to 48 years in the artificial tears group</P>
<P>
<B>Sex (%)</B>: 31 women (39%) and 49 men (61%)in total</P>
<P>15 women (38%) and 25 men (62%) in the punctal plug group</P>
<P>16 women (40%) and 24 men (60%) in the artificial tears group</P>
<P>
<B>Inclusion criteria</B>: time on viewing a monitor &#8805; 5 hours per day; itching, foreign body sensation, tearing, redness, and photophobia; aqueous tear production &lt; 10 mm/5 min, TBUT&lt; 10 s; artificial tears use &gt; 3 times/d</P>
<P>
<B>Exclusion criteria</B>: not meeting inclusion criteria; corneal, conjunctiva, iris disorder; pregnant; diabetes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-16 15:23:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention 1</B>: Thermal Memory hydrophobic acrylic polymer rigid rod punctal plug</P>
<P>Punctal plug model: NR</P>
<P>Manufacturer of punctal plug: NR</P>
<P>Location of manufacturer: NR</P>
<P>
<B>Control</B>: 1g/L sodium hyaluronate eye drops; 1 drop/time; 4-6 times /day</P>
<P>
<B>Length of follow-up</B>:</P>
<P>Planned: NR</P>
<P>Actual: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-09 15:04:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary and secondary outcomes not differentiated</B>:</P>
<P>
<B>Outcomes reported</B>: tear secretion test, tear film break-up time, scores of dry eye symptoms</P>
<P>
<B>Adverse events reported</B>: inflammation: 12 in control group and 10 in intervention group. Plug prolapses: 1 in control group and 2 in intervention group</P>
<P>
<B>Intervals at which outcomes assessed</B>: baseline and 3 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-02-10 08:39:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registry</B>: none reported</P>
<P>
<B>Type of study</B>: published full-text</P>
<P>
<B>Funding sources</B>: NR</P>
<P>
<B>Disclosures of interest</B>: NR</P>
<P>
<B>Enrollement period</B>: March 2013 to March 2015</P>
<P>
<B>Reported subgroup analyses</B>: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>NA</B>: not applicable; <B>NR</B>: not reported; <B>SD</B>: standard deviation; <B>TBUT</B>: tear break-up time.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-02-10 10:41:13 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-02-10 10:41:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bukhari-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-10 10:41:13 +0000" MODIFIED_BY="[Empty name]">
<P>Wrong intervention; botulinum neurotoxin type A</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-06 14:04:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Capita-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-06 14:04:06 +0000" MODIFIED_BY="[Empty name]">
<P>Wrong intervention; 0.05 mL of hypromellose</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-27 14:09:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Charnetski_x002d_Sites-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-27 14:09:58 +0100" MODIFIED_BY="[Empty name]">
<P>No diagnosis of dry eye syndrome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-31 21:29:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geldis-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-31 21:29:39 +0000" MODIFIED_BY="[Empty name]">
<P>Synthetic punctal plugs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-29 15:25:21 +0100" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Giovagnoli-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-29 15:25:21 +0100" MODIFIED_BY="Anupa Shah">
<P>Not a randomized or quasi-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-29 15:25:28 +0100" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Goto-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-29 15:25:28 +0100" MODIFIED_BY="Anupa Shah">
<P>Not a randomized or quasi-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-29 15:25:14 +0100" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Guzey-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-29 15:25:14 +0100" MODIFIED_BY="Anupa Shah">
<P>Not a randomized or quasi-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-27 14:41:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hamano-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-27 14:41:58 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant comparisons</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-01-19 21:06:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kojima-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-01-19 21:06:01 +0000" MODIFIED_BY="[Empty name]">
<P>Wrong comparison. Trial registration number: JPRN-UMIN000011574</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-04 23:48:01 +0100" MODIFIED_BY="Andrew Law" STUDY_ID="STD-Li-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-04 23:48:01 +0100" MODIFIED_BY="Andrew Law">
<P>No relevant comparisons</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-04 23:48:35 +0100" MODIFIED_BY="Andrew Law" STUDY_ID="STD-Malet-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-04 23:48:35 +0100" MODIFIED_BY="Andrew Law">
<P>Not a randomized or quasi-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-29 15:25:09 +0100" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Murube-del-Castillo-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-29 15:25:09 +0100" MODIFIED_BY="Anupa Shah">
<P>Not a randomized or quasi-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-27 16:49:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nishii-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-27 16:49:03 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant outcome data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-29 15:25:34 +0100" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Ozkan-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-29 15:25:34 +0100" MODIFIED_BY="Anupa Shah">
<P>Not a randomized or quasi-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-27 16:49:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patten-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-27 16:49:43 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant comparisons</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-04 23:49:24 +0100" MODIFIED_BY="Andrew Law" STUDY_ID="STD-Sainz-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-04 23:49:24 +0100" MODIFIED_BY="Andrew Law">
<P>Not a randomized or quasi-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-04 23:49:28 +0100" MODIFIED_BY="Andrew Law" STUDY_ID="STD-Schultze-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-04 23:49:28 +0100" MODIFIED_BY="Andrew Law">
<P>Not a randomized or quasi-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-26 18:08:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharpe-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-26 18:08:05 +0100" MODIFIED_BY="[Empty name]">
<P>Conference proceeding abstract; study met inclusion criteria, but data were not presented by relevant treatment groups; investigators were unable to provide further details</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-29 15:25:00 +0100" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Virtanen-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-29 15:25:00 +0100" MODIFIED_BY="Anupa Shah">
<P>Not a randomized or quasi-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-02 20:52:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ward-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-02 20:52:42 +0100" MODIFIED_BY="[Empty name]">
<P>Conference proceeding abstract; study met inclusion criteria, but no data presented in abstract; unable to locate contact information for sole investigator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-04 23:50:16 +0100" MODIFIED_BY="Andrew Law" STUDY_ID="STD-Zhou-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-04 23:50:16 +0100" MODIFIED_BY="Andrew Law">
<P>Not a randomized or quasi-randomized controlled trial. Authors could not be contacted</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2017-01-12 20:32:15 +0000" MODIFIED_BY="Andrew Law" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-02-10 10:44:46 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2017-02-10 10:44:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ChiCTR_x002d_IPR_x002d_16007760">
<CHAR_STUDY_NAME MODIFIED="2016-05-24 14:44:54 +0100" MODIFIED_BY="Andrew Law">
<P>Treatment of dry eye with absorbable punctual plug (VisiPlug) in a randomized, observer-blind and parallel study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-05-24 14:56:44 +0100" MODIFIED_BY="Andrew Law">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-02-10 10:44:16 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria:</P>
<P>"1. Voluntarily participated in this clinical study and signed an informed consent</P>
<P>2. Male or female, aged 18 to 70 years old</P>
<P>3. Patients with dry eye signs and symptoms, consistent with either criterion as follows:</P>
<UL>
<LI>Criterion 1: Patients with at least 1 positive symptom, such as dry eye, foreign body sensation, burning sensation, eye fatigue, eye distension, vision fluctuation; and tear film break-up time equal to or less than 5 seconds, or Schirmer test (without anaesthetic) equal to or less than 5 mm/5 minutes;</LI>
<LI>Criterion 2: Patients with at least 1 positive symptom, such as dry eye, foreign body sensation, burning sensation, eye fatigue, eye distension, vision fluctuation; And tear film break-up time equal to or less than 10 seconds and longer than 5 seconds, or Schirmer test (without anaesthesia) equal to or less than 10 mm/5 minutes and longer than 5 mm/5 minutes; and patients should show positive corneal fluorescein staining;</LI>
</UL>
<P>4. Willing to follow the requirements of this study;</P>
<P>5. Subjects did not participate in other clinical trials during the last 4 weeks;</P>
<P>6. Subjects did not use any topical medications other than artifical tears, or have used these medications, but withdrew them more than 2 weeks before;</P>
<P>7. The daily life vision of included subjects eye should be equal to or more than 0.1."</P>
<P>Exclusion criteria:</P>
<P>"1. Subjects with inflammation and infection in lacrimal system;</P>
<P>2. Subjects with nasolacrimal duct blocking or stenosis;</P>
<P>3. Subjects with severe conjunctivochalasis;</P>
<P>4. Allergy to any ingredient of the test materials;</P>
<P>5. Clinically diagnosed as fungal, bacterial or viral keratitis/conjunctivitis in active stage;</P>
<P>6. Co-existence with other conjunctiva, cornea and iris lesions;</P>
<P>7. Patients with severe primary disease such as severe heart, brain and blood vessels, liver, kidney and hematopoietic systems disease;</P>
<P>8. Patients who received intraocular surgery or with intraocular trauma in the last 6 months;</P>
<P>9. Postmenopausal women with hormone replacement therapy;</P>
<P>10. Patients received permanent punctal occlusion or absorbable punctal occlusion in the last 6 months;</P>
<P>11. Patients who cannot stop wearing contact lenses during the trial;</P>
<P>12. Patients who cannot obey the required treatments and follow-ups during the trial."</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-02-09 15:04:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention 1</B>: both upper and lower punctal occlusion</P>
<P>
<B>Intervention 2</B>: lower punctal occlusion</P>
<P>
<B>Intervention 3</B>: upper punctal occlusion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-02-10 09:40:28 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes*:</P>
<UL>
<LI>Total score of ocular surface disease index</LI>
<LI>Schirmer I test</LI>
</UL>
<P>Secondary outcomes**:</P>
<UL>
<LI>TBUT</LI>
<LI>Corneal fluorescein staining</LI>
<LI>Lissamine green staining</LI>
<LI>Tear meniscus height</LI>
<LI>Tear meniscus depth</LI>
<LI>Tear meniscus area</LI>
<LI>Frequency of artificial tears usage</LI>
</UL>
<P>* Primary outcomes will be measured at week 4 after treatment</P>
<P>** Secondary outcomes will be measured at week 1, week 4 or week 12 after treatment</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2017-02-10 08:39:12 +0000" MODIFIED_BY="[Empty name]">
<P>NR</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-05-24 14:45:36 +0100" MODIFIED_BY="Andrew Law">
<P>Lan Gong (13501798683@139.com)</P>
<P>Eye &amp; ENT Hospital of Fudan University, 83 Fenyang Road, Shanghai 200031</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-02-10 10:44:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Trial registration number</B>: ChiCTR-IPR-16007760 (registered at Chinese Clinical Trial Registry)</P>
<P>
<B>Source of funding</B>: Eye &amp; ENT Hospital of Fudan University</P>
<P>Accessed on 9 January 2017</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-05-08 21:15:29 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-05-08 21:15:24 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:08:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altan_x002d_Yaycioglu-2005">
<DESCRIPTION>
<P>Sequence generation not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:22:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brissette-2015">
<DESCRIPTION>
<P>"Randomization was achieved using a mathematical computer-generated allocation schema based on permuted blocks with blocks of random sizes" (p 239).</P>
<P>"Each eye was assigned randomly with equal probability to receive either Super Flex or Parasol brand punctal plugs" (p 239).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:28:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgess-2008">
<DESCRIPTION>
<P>Blocked randomization; computer generated numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 08:33:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2010">
<DESCRIPTION>
<P>Sequence generation not discussed in manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 08:41:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farrell-2003">
<DESCRIPTION>
<P>Sequence generation not discussed in manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-26 17:17:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feng-2011">
<DESCRIPTION>
<P>The investigator stated "we randomly picked 54 patients (108 eyes) receiving LASIK surgery in our hospital from June to September in 2009 . . . The patients were randomly assigned to 2 groups, 27 individuals (54 eyes) in each group (p 1666)"</P>
<P>The trial investigator did not describe how the random sequence were generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:32:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaido-2012">
<DESCRIPTION>
<P>Sequence generation not discussed in manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:37:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lowther-1995">
<DESCRIPTION>
<P>Sequence generation not discussed in manuscript. "The patients were randomly assigned to have the implants put into either the right or the left eye but were lead to believe that implants were put in both eyes" (p 238).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:43:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mansour-2007">
<DESCRIPTION>
<P>Computer generated randomization scheme. "The eye to be occluded was chosen at random using a computer-generated randomization scheme" (p 148).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:48:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nava_x002d_Castaneda-2003">
<DESCRIPTION>
<P>Computer-generated randomization scheme.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:59:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qiu-2012">
<DESCRIPTION>
<P>Authors did not report how the random sequence was generated.</P>
<P>"They were randomly assigned into artificial tears group and punctual plugs group" (p 20)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:03:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Qiu-2013">
<DESCRIPTION>
<P>"The patients were randomly assigned into artificial tears group and punctual plugs group using a computer-generated random number table" (p 2544).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-08 21:15:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rabensteiner-2013">
<DESCRIPTION>
<P>"The 30 patients were randomized into two groups &#8230; using the next available number from a set of block randomized computer numbers" (p 522).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-25 20:58:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-2007">
<DESCRIPTION>
<P>"[A] computer-generated randomization schedule" (p 391).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:18:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Slusser-1998">
<DESCRIPTION>
<P>Sequence generation not discussed in manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:22:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsifetaki-2003">
<DESCRIPTION>
<P>Computer-generated randomization scheme. "Patients were randomized according to a computer generated schedule" (p 1204)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:28:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yung-2012">
<DESCRIPTION>
<P>Quasi randomized study &#8211; assigned based on patient ID number (odd/even)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-25 19:57:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhou-2016">
<DESCRIPTION>
<P>Random sequence generated using SAS 9.2 program</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-02-10 10:39:01 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:08:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altan_x002d_Yaycioglu-2005">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-06 14:26:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brissette-2015">
<DESCRIPTION>
<P>From email correspondence with authors: "we had opaque envelopes with assignment once deemed eligible for inclusion."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:28:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burgess-2008">
<DESCRIPTION>
<P>Allocation concealment not discussed in manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 08:33:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2010">
<DESCRIPTION>
<P>Allocation concealment not discussed in manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 08:41:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farrell-2003">
<DESCRIPTION>
<P>Allocation concealment not discussed in manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:05:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feng-2011">
<DESCRIPTION>
<P>Not described, but given the treatment groups it is not possible to mask participants or people administering interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:32:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaido-2012">
<DESCRIPTION>
<P>Allocation concealment not discussed in manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:37:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lowther-1995">
<DESCRIPTION>
<P>Allocation concealment not discussed in manuscript. "The eye to receive the implants was determined just before insertion by randomization" (p 239).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:43:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mansour-2007">
<DESCRIPTION>
<P>Allocation concealment not discussed in manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:48:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nava_x002d_Castaneda-2003">
<DESCRIPTION>
<P>Random assignments prepared by Statistical Committee and placed in sealed envelopes numbered 1-74; randomization list maintained by Statistical Committee</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:59:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qiu-2012">
<DESCRIPTION>
<P>Authors did not report how allocation was concealed.</P>
<P>"They were randomly assigned into artificial tears group and punctual plugs group" (p 20)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:03:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Qiu-2013">
<DESCRIPTION>
<P>"Written allocation assignments were sealed in individual opaque envelopes marked only with study identification numbers" (p 2544).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:08:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rabensteiner-2013">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:13:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roberts-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:18:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Slusser-1998">
<DESCRIPTION>
<P>Allocation concealment not discussed in manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-09 21:36:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsifetaki-2003">
<DESCRIPTION>
<P>Allocation concealment not discussed in manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:28:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yung-2012">
<DESCRIPTION>
<P>"These candidates were divided into two groups on the basis of their ID numbers; the plug (even numbers) and non-plug (odd numbers) groups" (p 209)</P>
<P>"They were randomly divided into a plug and a non-plug group" (p 208)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:39:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2016">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-02-25 14:40:13 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2017-05-08 21:15:25 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Masking of participants and personnel (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:08:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altan_x002d_Yaycioglu-2005">
<DESCRIPTION>
<P>Not described, but given the treatment groups it is not possible to mask participants and people administering interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:22:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brissette-2015">
<DESCRIPTION>
<P>"Participants and all study staff, except an unmasked investigator (A.B.) who inserted punctal plugs, were masked to treatment arms" (p 239).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:28:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgess-2008">
<DESCRIPTION>
<P>Participants were also masked to treatment assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 08:33:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2010">
<DESCRIPTION>
<P>Not described, but given the treatment groups it is not possible to mask participants or people administering interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 08:41:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Farrell-2003">
<DESCRIPTION>
<P>Participants were also masked to treatment assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-05 01:13:08 +0100" MODIFIED_BY="Andrew Law" RESULT="UNKNOWN" STUDY_ID="STD-Feng-2011">
<DESCRIPTION>
<P>Due to the nature of the treatments, participants and personnel cannot be masked for this study, and the results are likely to be influenced by the lack of masking.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:33:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaido-2012">
<DESCRIPTION>
<P>Not described, but given the treatment groups it is not possible to mask participants or people administering interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:37:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lowther-1995">
<DESCRIPTION>
<P>Participants were also masked to treatment assignment. "All of the steps of inserting the implants were performed on both eyes, but an implant was inserted in the upper and lower punctum of one eye only. Therefore, the patients did not know that only one eye received the implants. Because the patients did not know that the puncta of only one eye received the implants and the investigator making the measurements did not know which eye of the patient received the implant, the study was double masked" (p 239).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:43:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mansour-2007">
<DESCRIPTION>
<P>Not described, but given the treatment groups it is not possible to mask participants or people administering interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:49:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nava_x002d_Castaneda-2003">
<DESCRIPTION>
<P>Participants masked to treatment assignment. "Patients subjected to the sham procedure were treated identically to the collagen/silicone plug implantation group (i.e., the punctum was dilated and the canaliculus probed), except that a plug was not actually inserted" (p 11).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:59:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qiu-2012">
<DESCRIPTION>
<P>Due to the nature of the treatments, participants and personnel cannot be masked for this study, and the results are likely to be influenced by the lack of masking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-25 19:44:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qiu-2013">
<DESCRIPTION>
<P>"All para-clinical examinations and analyses were performed by the same experienced technician and the same clinical staff who both were masked to the type of treatment" (p 2544).</P>
<P>However given the nature of the interventions, participants and personnel could not be masked.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-08 21:15:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rabensteiner-2013">
<DESCRIPTION>
<P>Participants were masked to treatment group. "Patients were not informed into which arm of the trial they had been allocated" (p 522).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-25 20:58:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Roberts-2007">
<DESCRIPTION>
<P>"Medication was dispensed open-label" (p 391).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 14:32:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Slusser-1998">
<DESCRIPTION>
<P>"To provide a placebo control, the fellow eye was carefully manipulated in a similar fashion without actual insertion of any plugs. The patient was masked as much as possible to avoid visualizing the plugs during the insertion procedure."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-07 17:31:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsifetaki-2003">
<DESCRIPTION>
<P>It is difficult to mask participants and personnel as the interventions may be visible during examination. Eye examination, ocular surface staining, aqueous tear production, and imprint test performed by masked investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:33:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yung-2012">
<DESCRIPTION>
<P>Given the treatment groups it is not possible to mask participants or people administering interventions. From email correspondence with authors: "The participant and those assessing the outcome were not blinded."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:39:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2016">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-02-25 14:35:58 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2017-05-08 21:15:29 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Masking of outcome assessment (detection bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:09:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altan_x002d_Yaycioglu-2005">
<DESCRIPTION>
<P>Nuclear medicine specialist (outcome assessor) evaluating lacrimal scintigraphy images was masked to treatment assignment (but not an outcome of this review)</P>
<P>Unclear whether other outcome assessors masked</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:22:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brissette-2015">
<DESCRIPTION>
<P>"Plug retention and all other secondary outcomes were evaluated by 1 examiner masked to the treatment arms (Z.M.)" (p 239).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:28:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgess-2008">
<DESCRIPTION>
<P>Outcome assessments performed by investigators not involved in the treatment administration and not informed of treatment status</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 08:40:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 08:41:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Farrell-2003">
<DESCRIPTION>
<P>Outcome assessors measuring tear parameters were masked</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 14:32:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feng-2011">
<DESCRIPTION>
<P>The investigator stated that "all the tests and surgeries were conducted by the same physician", thus the outcome assessor (i.e., the physician) were aware of the interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:33:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaido-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:38:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lowther-1995">
<DESCRIPTION>
<P>Outcome assessors were masked. "Because the patients did not know that the puncta of only one eye received the implants and the investigator making the measurements did not know which eye of the patient received the implant, the study was double masked" (p 239).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:43:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mansour-2007">
<DESCRIPTION>
<P>The same investigator performed all measurements and was presumably unmasked to treatment assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:49:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nava_x002d_Castaneda-2003">
<DESCRIPTION>
<P>Outcome assessors masked to treatment assignment. "Subsequent patient evaluations were performed by one of the initial evaluators who were kept uninformed of the patient's treatment status" (p 11).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:59:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qiu-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:04:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Qiu-2013">
<DESCRIPTION>
<P>"All para-clinical examinations and analyses were performed by the same experienced technician and the same clinical staff who both were masked to the type of treatment" (p 2544).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:08:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rabensteiner-2013">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-08 21:15:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Roberts-2007">
<DESCRIPTION>
<P>"Medication was dispensed open-label" (p 391).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 14:32:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Slusser-1998">
<DESCRIPTION>
<P>"Outcome assessors masked as independent investigator inserted the plugs and performed sham insertion for those receiving no plugs"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:23:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsifetaki-2003">
<DESCRIPTION>
<P>Eye examination, ocular surface staining, aqueous tear production, and imprint test performed by masked investigators. "Eye examination, Schirmer-I test, and rose bengal staining were all performed by another investigator (GK), who was unaware of the treatment allocation. Furthermore, the imprint test was completed by another investigator (CAP) who was also unaware of the treatment arms and the results of Schirmer-I and rose bengal tests" (p 1204)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-06 14:00:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yung-2012">
<DESCRIPTION>
<P>From email correspondence with authors: "The participant and the those assessing the outcome were not blinded."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:39:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2016">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-05-08 21:15:26 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-09 15:09:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altan_x002d_Yaycioglu-2005">
<DESCRIPTION>
<P>No sample size information included in Results section, so it is unclear whether all participants completed follow-up examinations. Most outcomes assessed immediately after insertion of the punctal plugs (ocular surface staining assessed 3 days after occlusion)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-10 10:00:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brissette-2015">
<DESCRIPTION>
<P>2/50 eyes (4%) were excluded from analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-09 15:29:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burgess-2008">
<DESCRIPTION>
<P>Sample size information is not included for all outcomes, so it is unclear whether all randomized participants completed follow-up examinations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-10 08:33:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2010">
<DESCRIPTION>
<P>No missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-10 08:42:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Farrell-2003">
<DESCRIPTION>
<P>Sample sizes reported in the results were consistent with the number randomized, so no loss to follow-up or missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-10 09:06:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feng-2011">
<DESCRIPTION>
<P>Dropouts were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-10 09:33:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaido-2012">
<DESCRIPTION>
<P>No missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-10 09:38:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lowther-1995">
<DESCRIPTION>
<P>Sample sizes reported in the results were consistent with the number randomized, so no loss to follow-up or missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-10 10:00:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mansour-2007">
<DESCRIPTION>
<P>6/20 participants (30%) excluded from the analysis because of spontaneous plug loss and 1 excluded after an inflammatory reaction to plug material</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-10 09:51:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nava_x002d_Castaneda-2003">
<DESCRIPTION>
<P>1 randomized participant was found to be ineligible, but was not excluded from the analysis. 1/61 participants (2%) discontinued treatment and was excluded from the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-10 09:59:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qiu-2012">
<DESCRIPTION>
<P>Only 2/42 lost to follow-up, even across groups. However, reason for lost to follow-up was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-10 10:04:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Qiu-2013">
<DESCRIPTION>
<P>"Two patients did not complete the follow-up period and were excluded from the analysis" (p 2545).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-08 21:15:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rabensteiner-2013">
<DESCRIPTION>
<P>Loss to follow-up was differential across groups.</P>
<P>"All 30 patients completed the study, but in three eyes of group I (collared silicone plugs) spontaneous loss of the plug was noticed at the follow-up visit" (p 522)</P>
<P>"Eyes with a spontaneous lost punctual plug at follow up visit were excluded" (p 522).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-11 20:56:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Roberts-2007">
<DESCRIPTION>
<P>Participants who with drew were replaced and data from withdrawals not included in analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-10 10:19:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Slusser-1998">
<DESCRIPTION>
<P>7/35 participants (20%) were excluded after randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-10 10:00:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsifetaki-2003">
<DESCRIPTION>
<P>1/85 participants (1%) lost to follow-up and 1/85 participants (1%) discontinued due to local infection; not clear if these participants were excluded from the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-10 10:29:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yung-2012">
<DESCRIPTION>
<P>"2 patients lost plug(s) from either eye during the follow-up and had new plug(s) re-inserted but were excluded from the study" (p 208)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-10 10:39:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2016">
<DESCRIPTION>
<P>No participants were reported to have been lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-02-10 10:39:16 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:09:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altan_x002d_Yaycioglu-2005">
<DESCRIPTION>
<P>Insufficient information to determine. Trial registry information and protocol were not available for comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-08 18:10:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brissette-2015">
<DESCRIPTION>
<P>Trial was registered at clinicaltrials.gov and all pre-specified outcomes in the registry were reported in the full-text publications.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:29:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burgess-2008">
<DESCRIPTION>
<P>Study protocol was not available to make comparison. All outcomes reported in the methods section were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 08:34:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2010">
<DESCRIPTION>
<P>Study protocol was not available to make comparison. All outcomes reported in the Methods section were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 08:42:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farrell-2003">
<DESCRIPTION>
<P>Insufficient information to determine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:06:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feng-2011">
<DESCRIPTION>
<P>Study protocol is not available and all of the outcomes were reported as prespecified in the Methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:33:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaido-2012">
<DESCRIPTION>
<P>Insufficient information to determine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:38:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lowther-1995">
<DESCRIPTION>
<P>Insufficient information to determine. Trial registry information and protocol not available for comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:43:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mansour-2007">
<DESCRIPTION>
<P>Insufficient information to determine. Trial registry information and protocol were not available for comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:51:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nava_x002d_Castaneda-2003">
<DESCRIPTION>
<P>Insufficient information to determine although the investigators list the following protocol deviations in the publication: 61 patients instead of 60 enrolled, 1 patient was ineligible, and covariate analyses were not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:59:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qiu-2012">
<DESCRIPTION>
<P>Protocol not available and trial registry number not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:04:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qiu-2013">
<DESCRIPTION>
<P>Protocol not available and trial registry number not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:09:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rabensteiner-2013">
<DESCRIPTION>
<P>Protocol not available and trial registry number not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:13:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roberts-2007">
<DESCRIPTION>
<P>Trial registry record not reported; we were not able to compare the reported outcomes with the trial registry record</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:20:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Slusser-1998">
<DESCRIPTION>
<P>Trial registry or protocol was not reported, hence we were not able to check if all outcomes in the protocol were reported in the full-text publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:23:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsifetaki-2003">
<DESCRIPTION>
<P>Trial registry information and protocol were not available for comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-11 21:04:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yung-2012">
<DESCRIPTION>
<P>Protocol not available for comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:39:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2016">
<DESCRIPTION>
<P>Published protocol or trial registry number were not available for comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-02-10 10:39:18 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:09:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altan_x002d_Yaycioglu-2005">
<DESCRIPTION>
<P>Insufficient information to determine. Source of funding and conflict of interest not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-09 15:23:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brissette-2015">
<DESCRIPTION>
<P>"All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest and none were reported. The authors indicate no funding support" (p 242).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-15 15:35:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burgess-2008">
<DESCRIPTION>
<P>Received government funding (National Health Service Lothian, Edinburgh, UK)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-16 18:16:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2010">
<DESCRIPTION>
<P>Received government funding (Chinese National Science and Technology Development Supporting Program and Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 08:42:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farrell-2003">
<DESCRIPTION>
<P>Insufficient information to determine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-05 01:14:27 +0100" MODIFIED_BY="Andrew Law" RESULT="UNKNOWN" STUDY_ID="STD-Feng-2011">
<DESCRIPTION>
<P>Funding sources and disclosures of interest were not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:33:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaido-2012">
<DESCRIPTION>
<P>Source of funding was not reported and authors explicitly stated no conflicts of interest</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-16 20:18:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lowther-1995">
<DESCRIPTION>
<P>Insufficient information to determine. The source of funding of the study (Bausch and Lomb inVision Institute) was different from the manufacturer (Lacrimedics, Inc.)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:43:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mansour-2007">
<DESCRIPTION>
<P>Insufficient information to determine. Funding source and disclosure of interest not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:50:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nava_x002d_Castaneda-2003">
<DESCRIPTION>
<P>Device manufacturer is the funding source</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 09:59:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Qiu-2012">
<DESCRIPTION>
<P>Non-industry funding and reported no conflict of interest</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:04:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Qiu-2013">
<DESCRIPTION>
<P>Non-industry funding and reported no conflict of interest</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:09:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rabensteiner-2013">
<DESCRIPTION>
<P>Non-industry funding and reported no conflict of interest</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:13:33 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Roberts-2007">
<DESCRIPTION>
<P>Industry funded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:20:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Slusser-1998">
<DESCRIPTION>
<P>Received industry funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:23:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsifetaki-2003">
<DESCRIPTION>
<P>Source of funding and conflict of interest not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:29:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yung-2012">
<DESCRIPTION>
<P>From email correspondence with authors: "Source of funding and conflict of interest not reported. There was no financial support for the trial. We did not use a clinical trial registry for this study.The protocol is only in the patients and methods in the manuscript. I will attach the paragraphs bellow (quoted from full-text)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-10 10:39:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2016">
<DESCRIPTION>
<P>Source of funding and conflict of interest were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-06-19 08:38:40 +0100" MODIFIED_BY="Anupa Shha">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-06-19 08:38:07 +0100" MODIFIED_BY="Anupa Shha" NO="1">
<TITLE MODIFIED="2017-05-08 18:10:25 +0100" MODIFIED_BY="[Empty name]">Summary of findings: punctal plugs versus no punctal plugs</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Punctal plugs compared with no punctal plugs for dry eye syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: adults with dry eye syndrome</P>
<P>
<B>Settings</B>: eye clinics</P>
<P>
<B>Intervention</B>: silicone or collagen punctal plugs</P>
<P>
<B>Comparison</B>: no punctal plugs (observation or sham treatment)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Certainty of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>No punctal plugs</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Punctal plugs</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Symptomatic improvement</B>
</P>
<P>Follow-up: long-term*</P>
<P/>
<P>A lower score favors punctal plugs</P>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>89</P>
<P>(2 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK> reported little or no difference in Ocular and Oral Symptoms score, which ranged from 0 to 10 points (MD -0.46 points, 95% CI -1.24 to 0.32; eyes = 26).</P>
<P>
<LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> reported a slight decrease in symptom score, assumed to range from 0 to 105 points, but it does not seem to be clinically important (MD -2.62 points, 95% CI -3.32 to -1.93; eyes = 61).</P>
<P>
<LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> reported little or no difference in dry eye symptom score, ranging from 0 to 3 points (MD -0.75 points, 95% CI -1.53 to 0.02; eyes = 28)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Ocular surface staining </B>
</P>
<P>Follow-up: long-term*</P>
<P/>
<P>A higher value is less advantageous</P>
<P/>
<P>Both Rose Bengal and fluorescein staining scores ranged from 0 to 4, where 0 represented no staining and 4 represented heavy staining</P>
</TD>
<TD VALIGN="TOP">
<P>The mean fluorescein staining score was 1.70</P>
</TD>
<TD VALIGN="TOP">
<P>MD 1.50 lower than observation group</P>
<P>(1.88 to 1.12 lower (better) than observation group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>61</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>c,d</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Aqueous tear production</B>
</P>
<P/>
<P>Follow-up: long-term*</P>
<P/>
<P>A higher value is more advantageous</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>c,d</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK> did not provide quantitative data, but reported that "Schirmer values tended to increase in the plug group after plug insertion; however, the changes did not reach significance"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Tear film stability </B>
</P>
<P/>
<P>Follow-up: 6 months</P>
<P/>
<P>A higher value is more advantageous</P>
</TD>
<TD VALIGN="TOP">
<P>The mean tear film stability was 2.34 seconds</P>
</TD>
<TD VALIGN="TOP">
<P>MD 1.93 seconds longer than observation group</P>
<P>(0.67 to 3.20 seconds longer (better) than observation group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Artificial tear use</B>
</P>
<P>Follow-up: long-term*</P>
<P/>
<P>Fewer applications favors punctal plugs</P>
</TD>
<TD VALIGN="TOP">
<P>The mean number of applications was 3.6 applications</P>
</TD>
<TD VALIGN="TOP">
<P>MD 2.70 fewer applications than observation group</P>
<P>(3.11 to 2.29 fewer applications than observation group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>61</P>
<P>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>e</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
<P>Follow-up: end of study</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>146<BR/>(4 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very</B> <B>low</B>
<SUP>f,g</SUP>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>: all adverse events occurred in the punctal plug group, reported 23/28 participants had epiphora, 3/28 participants reported itching in area of plug placement, 1/28 participants had tenderness and swelling of lids with mucous discharge.</P>
<P/>
<P>Spontaneous plug loss occurred in 6/20 eyes with silicone punctal plugs in the <LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>.</P>
<P/>
<P>One or 31 participants receiving collagen and silicone punctal plugs experienced epiphora in the <LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK> study.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio; <B>SMD</B>: standardized mean difference; <B>RCT</B>: randomized controlled trial.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High-certainty</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate-certainty</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low-certainty</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low-certainty</B>: we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded two levels for methodological heterogeneity.<BR/>
<SUP>b</SUP>Downgraded one level for high risk of detection and attrition bias.</P>
<P>
<SUP>c</SUP>Downgraded one level for imprecision as indirectness of evidence because the confidence interval was either wide or clinically not important.</P>
<P>
<SUP>d</SUP>Downgraded one level for high risk of attrition bias.</P>
<P>
<SUP>e</SUP>Downgraded two levels for high risk of performance, detection, and attrition bias.</P>
<P>
<SUP>f</SUP>Downgraded two levels for attrition bias.</P>
<P>
<SUP>g</SUP>Downgraded one level for sparse and inconsistent data, particularly with respect to epiphora.</P>
<P>*We defined long-term follow-up as between two months and one year.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2017-06-19 08:38:12 +0100" MODIFIED_BY="Anupa Shha" NO="2">
<TITLE MODIFIED="2017-02-10 11:03:50 +0000" MODIFIED_BY="[Empty name]">Summary of findings: punctal plugs versus cyclosporine</TITLE>
<TABLE COLS="6" ROWS="13">
<TR>
<TD COLSPAN="6">
<P>
<B>Punctal plugs compared with cyclosporine for dry eye syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population</B>: adults with dry eye syndrome</P>
<P>
<B>Settings</B>: eye clinics</P>
<P>
<B>Intervention</B>: punctal plugs</P>
<P>
<B>Comparison</B>: cyclosporine</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Certainty of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Cyclosporine</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Punctal plugs</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Symptomatic improvement</B>
</P>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P>Study investigators did not report this outcome at 2 weeks, 1 month, or long-term.<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Ocular surface staining</B>
</P>
<P>Follow-up: 6 months</P>
<P/>
<P>Any value greater than zero is abnormal</P>
<P/>
<P>Range: 0 to 4 points; 0 = no staining, 1 = staining of the nasal conjunctiva only, 2 = staining of both the nasal and temporal conjunctiva, 3 = peripheral corneal staining, 4 = central corneal staining</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
<P>(1 RCT)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The study investigators of <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> stated: "there was greater improvement in conjunctival staining with cyclosporine or the combination than with plugs alone." It was unclear whether Rose Bengal or fluorescein staining was used. Also,</P>
<P>the study investigators did not specify the time point and so we assumed that their statement applies for 1, 3, and 6 months follow-up.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Aqueous tear production</B>
</P>
<P>Follow-up: 6 months</P>
<P/>
<P>A higher value is more advantageous</P>
</TD>
<TD VALIGN="TOP">
<P>The mean change in aqueous tear production was 1.5 mm/3 min lower than baseline</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.80 mm/3 min higher than cyclosporine group</P>
<P>(0.74 lower (better) to 2.34 higher (worse) than cyclosporine group)</P>
</TD>
<TD VALIGN="TOP">
<P>20<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The study investigators of <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> stated: "There was a greater increase in Schirmer score with plugs, either alone or in combination with cyclosporine." The study investigators did not specify the for which time point and so we assumed that their statement applies for 1, 3, and 6 months follow-up.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Tear film stability</B>
</P>
<P>Follow-up: 6 months</P>
<P/>
<P/>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P>Study investigators did not report this outcome at 2 weeks, 1 month, or long-term.<BR/>
</P>
<P>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Artificial tear use</B>
</P>
<P>Follow-up: 6 months</P>
<P/>
<P>range: 1-5 applications</P>
<P/>
<P>Fewer applications favors punctal plugs</P>
</TD>
<TD VALIGN="TOP">
<P>The mean change in number of applications from baseline was 3.2 more applications than baseline</P>
</TD>
<TD VALIGN="TOP">
<P>MD 1.10 applications more than baseline</P>
<P>(0.04 fewer to 2.24 more applications than cyclosporine group)</P>
</TD>
<TD VALIGN="TOP">
<P>20<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The study investigators of <LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> stated: "decreased frequency of artificial tears was greatest for combination therapy and least for punctal plugs." The study investigators did not specify the for which time point and so we assumed that their statement applies for 1, 3, and 6 months follow-up.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
<P>Follow-up: end of study</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>22<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK> reported 1/11 participants experienced plug displacement in the plug group, while 1/11 participants experienced a burning sensation in the cyclosporine group.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> is the control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio; <B>RCT</B>: randomized controlled trial.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High-certainty</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate-certainty</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low-certainty</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low-certainty</B>: we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded one level for imprecision of results (wide confidence intervals).</P>
<P>
<SUP>b</SUP>Downgraded two levels for high risk of detection, performance, attrition, and other bias.</P>
<P>*We defined long-term follow-up as between two months and one year.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2017-06-19 08:37:54 +0100" MODIFIED_BY="Anupa Shha" NO="3">
<TITLE MODIFIED="2017-02-10 11:04:30 +0000" MODIFIED_BY="[Empty name]">Summary of findings: punctal plugs versus oral pilocarpine</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Punctal plugs compared with oral pilocarpine for dry eye syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: adults with dry eye syndrome</P>
<P>
<B>Settings</B>: eye clinics</P>
<P>
<B>Intervention</B>: punctal plugs</P>
<P>
<B>Comparison</B>: oral pilocarpine</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>No of eyes<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Certainty of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Oral pilocarpine</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Punctal plugs </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Symptomatic improvement</B>
</P>
<P>Follow-up: 3 months</P>
<P/>
<P>The study investigators defined improvements in subjective ocular symptoms as an improvement of &gt;55 mm for responses to the eye questionnaire on a 100 mm visual analog scale.</P>
<P/>
<P>A RR less than one favors punctal plugs.</P>
</TD>
<TD VALIGN="TOP">
<P>897 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>619 per 1000</P>
<P>(439 to 852)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.69</P>
<P>(0.49 to 0.95)</P>
</TD>
<TD VALIGN="TOP">
<P>55<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Ocular surface staining</B>
</P>
<P>Follow-up: 3 months</P>
<P/>
<P>A higher value is less advantageous</P>
<P/>
<P>Range: van Bijsterveld schema, which is on a scale of 0 to 9 points</P>
</TD>
<TD VALIGN="TOP">
<P>The mean change in Rose Bengal staining score was 1.00 lower (better) than baseline in the right eye</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.10 higher (worse) than oral pilocarpine group</P>
<P>(0.56 lower (better) to 0.76 higher (worse) than oral pilocarpine group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>55<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>The mean change in Rose Bengal staining score was 1.10 lower (better) than baseline in the left eye</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.60 higher (worse) than oral pilocarpine group</P>
<P>(0.10 to 1.10 higher (worse) than oral pilocarpine group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>55<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Aqueous tear production</B>
</P>
<P>Follow-up: 3 months</P>
<P/>
<P>A higher value more advantageous</P>
</TD>
<TD VALIGN="TOP">
<P>The mean change in aqueous tear production was 0.30 mm/5 min higher (better) than baseline in the right eye</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.10 mm/5 min lower (worse) than oral pilocarpine group</P>
<P>(0.53 mm/5 min lower (worse) to 0.33 mm/5 min higher (better) than oral pilocarpine group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>55<BR/>(1 RCT)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>The mean change in aqueous tear production was 1.2 mm/5 min higher (better) than baseline in the left eye</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.50 mm/5 min lower (worse) than oral pilocarpine group</P>
<P>(1.06 mm/5 min lower (worse) to 0.06 mm/5 min higher (better) than oral pilocarpine group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>55<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Tear film stability</B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Study investigators did not report this outcome.<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Artificial tear use </B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Study investigators did not report this outcome.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
<P>Follow-up: 3 months</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>55<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK> reported: "commonly reported adverse events were headache, increased sweating,nausea, and vomiting in the pilocarpine group, while 1 patient in the inferior puncta occlusion group had blepharitis and was withdrawn from the study." pg 1204</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> is the control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio; <B>RCT</B>: randomized controlled trial</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High-certainty</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate-certainty</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low-certainty</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low-certainty</B>: we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded two levels for high risk of performance and detection bias as the participant and outcome assessors were not masked to the treatment groups and the self-reported symptomatic improvement might be biased.<BR/>
<SUP>b</SUP>Downgraded one level for imprecision as the confidence interval is either wide or clinically not important.</P>
<P>*We defined long-term follow-up as between two months and one year.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2017-06-19 08:38:21 +0100" MODIFIED_BY="Anupa Shha" NO="4">
<TITLE MODIFIED="2017-02-10 11:05:13 +0000" MODIFIED_BY="[Empty name]">Summary of findings: punctal plugs versus artificial tears</TITLE>
<TABLE COLS="7" ROWS="17">
<TR>
<TD COLSPAN="7">
<P>
<B>Punctal plugs compared with artificial tears for dry eye syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: adults with dry eye syndrome</P>
<P>
<B>Settings</B>: eye clinics</P>
<P>
<B>Intervention</B>: punctal plugs</P>
<P>
<B>Comparison</B>: artificial tears</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>No of eyes<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Certainty of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Artificial tears</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Punctal plugs</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Symptomatic improvement</B>
</P>
<P>Follow-up: 3 months</P>
<P/>
<P>The study investigators defined improvements in subjective ocular symptoms as an improvement of &gt;55 mm for responses to the eye questionnaire on a 100 mm visual analog scale.</P>
<P/>
<P>A RR greater than one favors punctal plugs.</P>
<P/>
<P>Both studies used different symptomatic improvement score; one study used the Ocular Surface Disease Index that ranged from 0 points = never to 4 points = all the time. The second study use the sum of scores for dryness, foreign body sensation, and visual fatigue; each score had a different range, but a higher score corresponded to more symptoms.</P>
</TD>
<TD VALIGN="TOP">
<P>286 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>654 per 1000</B>
</P>
<P>(343 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 2.29</B>
</P>
<P>(1.2 to 4.38)</P>
</TD>
<TD VALIGN="TOP">
<P>54</P>
<P>(1 RCT)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very</B> <B>low</B>
<SUP>a,b,c</SUP>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>The mean symptomatic improvement score ranged from 15.9 to 26.92</P>
</TD>
<TD VALIGN="TOP">
<P>SMD 0.88 lower (better) than artificial tears group</P>
<P>(1.24 to 0.51 lower (better) than artificial tears group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>130</P>
<P>(2 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Ocular surface staining</B>
</P>
<P>Follow-up: 3 months</P>
<P/>
<P>Range: 0 = absent; 1 = trace; 2 = mild; 3 = moderate; 4 =</P>
<P>severe</P>
<P/>
<P>A higher value is worse</P>
</TD>
<TD VALIGN="TOP">
<P>The mean change in Rose Bengal staining score was 1.0 point lower (better) than baseline in the right eye</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.10 points higher (worse) than artificial tears group</P>
<P>(0.56 lower (better) to 0.76 higher (worse) than artificial tears group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>55<BR/>(1 RCT)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>d</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>The mean change in Rose Bengal staining score was 1.1 lower (better) than baseline in the left eye</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.60 points higher (worse) than artificial tears group</P>
<P>(0.10 to 1.10 higher (worse) than artificial tears group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>55<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Aqueous tear production</B>
</P>
<P>Follow-up: long-term*</P>
<P/>
<P>A higher value is more advantageous</P>
</TD>
<TD VALIGN="TOP">
<P>The mean change in aqueous tear production was 0.2 mm/5 min higher (better) than baseline in the right eye</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.00 mm/5 min higher (better) than artificial tears group</P>
<P>(0.33 mm/5 min lower (worst) to 0.33 mm/5 min higher (better) than artificial tears group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>54<BR/>(1 RCT)</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>c,e</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>The mean change in aqueous tear production was 0.6 mm/5 min higher (better) than baseline in the left eye</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.10 mm/5 min higher (better) than artificial tears group</P>
<P>(0.35 mm/5 min lower (worst) to 0.55 mm/5 min higher (better) than artificial tears group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>54<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>The mean aqueous tear production ranged from 4.89 to 8.95 mm/ 5 min</P>
</TD>
<TD VALIGN="TOP">
<P>MD 2.16 mm/ 5 min higher (better)</P>
<P>(1.41 to 2.90 mm/ 5 min higher (better) than artificial tears group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>130</P>
<P>(2 RCTs)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Tear film stability</B>
</P>
<P>Follow-up: long-term*</P>
<P/>
<P>A higher value is more advantageous</P>
</TD>
<TD VALIGN="TOP">
<P>The mean tear film stability ranged from 3.24 to 6 seconds</P>
</TD>
<TD VALIGN="TOP">
<P>MD 1.02 seconds longer (better) than artificial tears group</P>
<P>(0.60 to 1.44 seconds longer (better) than artificial tears group)<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>130<BR/>(2 RCT)<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate</B>
<SUP>c</SUP>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Artificial tear use</B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Outcome not relevant to this comparison</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events </B>(punctate epithelial keratopathy)</P>
<P/>
<P>Follow-up: end of study</P>
</TD>
<TD VALIGN="TOP">
<P>375 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>499 per 1000</P>
<P>(214 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.33 (0.57 to 3.12)</P>
</TD>
<TD VALIGN="TOP">
<P>54<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>a,c</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK> reported: "four patients had mild headache, of whom three also presented with nausea, vomiting, and sweating" (p 1205) and "one patient in the inferior puncta occlusion group had blepharitis and was withdrawn from the study" (p 1204)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> is the control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio; <B>RCT</B>: randomized controlled trial</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High-certainty</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate-certainty</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low-certainty</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low-certainty</B>: we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded two levels for high risk of performance and detection bias as participants and outcome assessors were unmasked to the assigned treatment group and might influence the self-reported symptomatic improvement.<BR/>
<SUP>b</SUP>Downgraded one level for high unexplained statistical heterogeneity or inconsistent results.<BR/>
<SUP>c</SUP>Downgraded one level for imprecision of results as the confidence interval was either wide or clinically not important.<BR/>
<SUP>d</SUP>Downgraded two levels for imprecision of results as the confidence interval was wide and clinically not important.<BR/>
<SUP>e</SUP>Downgraded for inconsistent results.</P>
<P>*We defined long-term follow-up as between two months and one year.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2017-06-19 08:38:25 +0100" MODIFIED_BY="Anupa Shha" NO="5">
<TITLE MODIFIED="2017-02-10 11:05:55 +0000" MODIFIED_BY="[Empty name]">Summary of findings: punctal plugs in the upper versus lower puncta</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Punctal plugs occluded in the upper puncta compared with the lower puncta for dry eye syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: adults with dry eye syndrome</P>
<P>
<B>Settings</B>: eye clinics</P>
<P>
<B>Intervention</B>: punctal plugs occluded in the upper puncta</P>
<P>
<B>Comparison</B>: punctal plugs occluded in the lower puncta</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>No of eyes<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Certainty of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Lower puncta</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Upper puncta</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Symptomatic improvement</B>
</P>
<P>Follow-up: long-term*</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Study investigators did not report this outcome.</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Ocular surface staining </B>
</P>
<P>Follow-up: long-term*</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Study investigators did not report this outcome.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Aqueous tear production</B>
</P>
<P>Follow-up: long-term*</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Study investigators did not report this outcome.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Tear film stability</B>
</P>
<P>Follow-up: long-term*</P>
<P/>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Study investigators did not report this outcome.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Artificial tear use</B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Study investigators did not report this outcome.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>40<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK> reported "no complication was observed in dry eye patients or control subjects during the period of this study." It is unclear which complications were collected.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> is the control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio; <B>RCT</B>: randomized controlled trial</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High-certainty</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate-certainty</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low-certainty</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low-certainty</B>: we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded one level for potential bias as there was unclear risk of selection, performance, detection, attrition, and reporting bias.<BR/>
<SUP>b</SUP>Downgraded one level for imprecision of results as the confidence interval was wide.<BR/>
</P>
<P>*We defined long-term follow-up as between two months and one year.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2017-06-19 08:38:29 +0100" MODIFIED_BY="Anupa Shha" NO="6">
<TITLE MODIFIED="2017-02-10 11:02:25 +0000" MODIFIED_BY="[Empty name]">Summary of findings: acrylic versus silicone punctal plugs</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Acrylic punctal plugs compared with silicone punctal plugs for dry eye syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: mostly women with dry eye syndrome</P>
<P>
<B>Settings</B>: eye clinics</P>
<P>
<B>Intervention</B>: acrylic punctal plugs</P>
<P>
<B>Comparison</B>: silicone punctal plugs</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>No of eyes<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Certainty of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Silicone punctal plugs</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Acrylic punctal plugs</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Symptomatic improvement</B>
</P>
<P>Follow-up: 11 weeks</P>
<P/>
<P>Range: 0 to 70 points</P>
<P/>
<P>A visual analog scales 10 cm in length for seven symptoms: dryness, grittiness, foreign body sensation, pain, stinging, burning, and itching was used.</P>
<P/>
<P>A lower score favors acrylic punctal plugs</P>
</TD>
<TD VALIGN="TOP">
<P>The mean symptomatic improvement score was 21.9 points</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.90 points higher than silicone punctal plug group</P>
<P>(6.94 points lower than silicone punctal plug group to 8.74 points higher than silicone punctal plug group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>36<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Ocular surface staining </B>
</P>
<P>Follow-up: 11 weeks</P>
<P/>
<P>A higher value is less advantageous</P>
<P/>
<P>Range: 0 to 3 points</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>The mean fluorescein staining score was 1.63 points</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.43 points higher (worst) than silicone punctal plug group</P>
<P>(1.61 lower (better) than silicone punctal plug group to 2.47 higher (worse) than silicone punctal plug group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>36<BR/>(1 RCT)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>The mean Rose Bengal staining score was 0.55 points</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.45 points higher (worst) than silicone punctal plug group</P>
<P>(0.09 lower (better) than silicone punctal plug group to 0.99 higher (worst) than silicone punctal plug group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Aqueous tear production</B>
</P>
<P>Follow-up: 11 weeks</P>
<P/>
<P>A higher value is more advantageous</P>
</TD>
<TD VALIGN="TOP">
<P>The mean aqueous tear production was 3.8 mm/5 min</P>
</TD>
<TD VALIGN="TOP">
<P>MD 1.07 mm/5 min higher than silicone punctal plug group</P>
<P>(1.62 lower than silicone punctal plug group to 3.76 higher than silicone punctal plug group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>36<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Authors did not report the time interval in which the Schirmer's test 1 without anesthesia was performed. We assumed it was done over 5 minutes.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Tear film stability </B>
</P>
<P>Follow-up: 11 weeks</P>
<P/>
<P>A higher value is more advantageous</P>
</TD>
<TD VALIGN="TOP">
<P>The mean tear film stability was 3.5 seconds</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.36 seconds longer than silicone punctal plug group</P>
<P>(1.22 seconds shorter than silicone punctal plug group to 1.94 longer than silicone punctal plug group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>36<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Artificial tear use</B>
</P>
<P>Follow-up: 11 weeks</P>
<P/>
<P>Range: 1-5 applications</P>
<P/>
<P>Fewer applications favors punctal plugs</P>
</TD>
<TD VALIGN="TOP">
<P>The mean number of applications was 4.67 applications</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.11 more applications than silicone punctal plug group</P>
<P>(2.32 fewer applications than silicone punctal plug group to 2.54 more applications than silicone punctal plug group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>36<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
<P>Follow-up: 11 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>36<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 acrylic punctal plug participant experienced epiphora, 1 silicone punctal plug participant experienced intermittent ocular irritation, and 2 silicone and 1 acrylic punctal plug participants experienced temporary foreign body sensation.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> is the control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio; <B>RCT</B>: randomized controlled trial.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High-certainty</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate-certainty</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low-certainty</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low-certainty</B>: we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded two levels for imprecision of results (wide confidence intervals).</P>
<P>
<SUP>b</SUP>Downgraded one level for risk of bias as selection, attrition and reporting bias were judged to be unclear.</P>
<P>*We defined long-term follow-up as between two months and one year.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-07" MODIFIED="2017-06-19 08:38:34 +0100" MODIFIED_BY="Anupa Shha" NO="7">
<TITLE MODIFIED="2017-02-10 11:03:05 +0000" MODIFIED_BY="[Empty name]">Summary of findings: intracanalicular versus silicone punctal plugs</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Intracanalicular punctal plugs compared with silicone punctal plugs for dry eye syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: adults with dry eye syndrome</P>
<P>
<B>Settings</B>: eye clinics</P>
<P>
<B>Intervention</B>: intracanalicular punctal plugs</P>
<P>
<B>Comparison</B>: silicone punctal plugs</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>No of eyes<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Certainty of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Silicone punctal plugs</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Intracanalicular punctal plugs</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Symptomatic improvement</B>
</P>
<P>Follow-up: 3 months</P>
<P/>
<P>Subjective dry eye symptoms for each eye was reported; investigators measured soreness, scratching, grittiness, dryness and/or burning using a 100 mm visual analog scale (VAS; 0 mm = no symptoms, 100 mm = maximum intensity)</P>
</TD>
<TD VALIGN="TOP">
<P>The mean symptomatic improvement was 38.5 points</P>
</TD>
<TD VALIGN="TOP">
<P>The mean difference in symptomatic improvement was 3.10 points lower (14.97 lower to 8.77 higher)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>57<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Ocular surface staining </B>
</P>
<P>Follow-up: 3 months</P>
<P/>
<P>A higher value is less advantageous</P>
<P/>
<P>Range: 0 to 3 points; 0 = no staining and 3 = most intense staining</P>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>The mean Rose Bengal staining score was 3.0</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.20 higher than observation group</P>
<P>(0.71 lower to 1.11 higher than silicone punctal plugs group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>57<BR/>(1 RCT)<BR/>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>The mean fluorescein staining score was 0.7 points</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.40 points higher than observation group</P>
<P>(0.04 lower to 0.84 higher than silicone punctal plugs group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>57<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Aqueous tear production</B>
</P>
<P>Follow-up: 3 months</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Study investigators did not report this outcome.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Tear film stability</B>
</P>
<P>Follow-up: 3 months</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Study investigators did not report this outcome.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Artificial tear use</B>
</P>
<P>Follow-up: 3 months</P>
<P/>
<P>Fewer applications favors intracanalicular plugs</P>
</TD>
<TD VALIGN="TOP">
<P>The mean artificial tear use was 6.4</P>
</TD>
<TD VALIGN="TOP">
<P>MD 1.30 fewer applications</P>
<P>(4.04 fewer to 1.44 more applications)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>57<BR/>(1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
<P/>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>Study investigators did not report on adverse events.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> is the control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio; <B>RCT</B>: randomized controlled trial</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High-certainty</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate-certainty</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low-certainty</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low-certainty</B>: we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded two levels for imprecision of results (wide confidence intervals).<BR/>
<SUP>b</SUP>Downgraded one level for high risk of attrition bias.</P>
<P>*We defined long-term follow-up as between two months and one year.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-08" MODIFIED="2017-06-19 08:38:40 +0100" MODIFIED_BY="Anupa Shha" NO="8">
<TITLE MODIFIED="2017-02-10 11:01:54 +0000" MODIFIED_BY="[Empty name]">Summary of findings: collagen versus silicone punctal plugs</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Collagen punctal plugs compared with silicone punctal plugs for dry eye syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: adults with dry eye syndrome</P>
<P>
<B>Settings</B>: eye clinics</P>
<P>
<B>Intervention</B>: collagen punctal plugs</P>
<P>
<B>Comparison</B>: silicone punctal plugs</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>No of eyes<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Certainty of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Silicone punctal plugs</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Collagen punctal plugs</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Symptomatic improvement</B>
</P>
<P>Follow-up: 3 months</P>
<P/>
<P>The Canadian Dry Eye Assessment range from 0 to 48 points; where less than 5 points was normal, 5 to 15 points was mild, 20 to 25 points was moderate, 30 to 48 points was severe.</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>The mean symptomatic improvement score was 0.25 points</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.81 higher than silicone punctal group</P>
<P>(2.94 lower to 4.56 higher than silicone punctal group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
<P>(1 RCT)<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Ocular surface staining</B>
</P>
<P>Follow-up: 3 months</P>
<P/>
<P>Range: 0 to 15 points</P>
<P/>
<P>A higher value is less advantageous</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>The mean fluorescein stain score was 2.00</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.76 lower than silicone punctal group</P>
<P>(18.5 lower to 17.0 higher than silicone punctal group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
<P>(1 RCT)</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Aqueous tear production</B>
</P>
<P>Follow-up: 3 months</P>
<P/>
<P>A higher value is more advantageous</P>
</TD>
<TD VALIGN="TOP">
<P>The mean aqueous tear production was 16.89 mm/5 min</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.67 mm/5 min higher than silicone punctal group</P>
<P>(17.28 lower to 18.62 higher than silicone punctal group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
<P>(1 RCT)</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Authors did not report the time interval in which the Schirmer's test 1 without anesthesia was performed. We assumed it was done over 5 minutes.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Tear film stability</B>
</P>
<P>Follow-up: 3 months</P>
<P/>
<P>A higher value is more advantageous</P>
</TD>
<TD VALIGN="TOP">
<P>The mean tear film stability was 4.67 seconds</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.21 seconds higher than silicone punctal group<BR/>(1.81 lower to 2.23 higher than silicone punctal group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
<P>(1 RCT)</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Artificial tear use </B>
</P>
<P>Follow-up: 3 months</P>
<P/>
<P>Fewer applications favors collagen punctal plugs</P>
</TD>
<TD VALIGN="TOP">
<P>The mean number of artificial tear applications was 1.34 applications</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.06 fewer applications</P>
<P>(0.23 fewer to 0.12 more applications than silicone punctal group)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
<P>(1 RCT)</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>a</SUP>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
<P>Follow-up: end of study</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>98</P>
<P>(2 RCT)</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>a,b</SUP>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Both studies reported that none of the participants developed adverse events or complications related to punctal plugs.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio; <B>RCT</B>: randomized controlled trial.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High-certainty</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate-certainty</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low-certainty</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low-certainty</B>: we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded two levels for imprecision of results as the confidence interval was wide and clinically not important.</P>
<P>
<SUP>b</SUP>Downgraded one level for risk of bias as risk of bias as we judged selection, performance, detection, attrition, and reporting bias to be unclear.</P>
<P>*We defined long-term follow-up as between two months and one year.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2017-02-14 17:48:35 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2017-02-14 17:48:35 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2017-01-19 22:13:33 +0000" MODIFIED_BY="[Empty name]">Comparisons</TITLE>
<TABLE COLS="3" ROWS="30">
<TR>
<TH COLSPAN="3">
<P>1. Punctal plugs versus observation.</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lowther-1995" TYPE="STUDY">Lowther 1995</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Collagen intracanalicular plugs were inserted in the upper and lower puncta</P>
</TD>
<TD VALIGN="TOP">
<P>Sham treatment</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Mansour-2007" TYPE="STUDY">Mansour 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Silicone punctal plugs</P>
</TD>
<TD VALIGN="TOP">
<P>No occlusion</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Nava_x002d_Castaneda-2003" TYPE="STUDY">Nava-Castaneda 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Collagen plus silicone punctal plugs</P>
</TD>
<TD VALIGN="TOP">
<P>Sham treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK>
</P>
</TD>
<TD>
<P>Bilateral collagen punctal plugs in the lower lids + cyclosporine eye drops to both eyes twice daily</P>
</TD>
<TD>
<P>Cyclosporine ophthalmic emulsion 0.05%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Slusser-1998" TYPE="STUDY">Slusser 1998</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Silicone punctal plugs in the upper and lower puncta</P>
</TD>
<TD VALIGN="TOP">
<P>Sham treatment</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yung-2012" TYPE="STUDY">Yung 2012</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Silicone punctal plugs</P>
</TD>
<TD VALIGN="TOP">
<P>Observation</P>
</TD>
</TR>
<TR>
<TH COLSPAN="3" VALIGN="TOP">
<P>2. Punctal plugs versus cyclosporine.</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Roberts-2007" TYPE="STUDY">Roberts 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Bilateral collagen punctal plugs in the lower lids only</P>
</TD>
<TD VALIGN="TOP">
<P>Cyclosporine ophthalmic emulsion 0.05%</P>
</TD>
</TR>
<TR>
<TH COLSPAN="3" VALIGN="TOP">
<P>3. Punctal plugs versus oral pilocarpine.</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Collagen punctal plugs</P>
</TD>
<TD VALIGN="TOP">
<P>Oral pilocarpine</P>
</TD>
</TR>
<TR>
<TH COLSPAN="3" VALIGN="TOP">
<P>4. Punctal plugs versus artificial tears.</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Feng-2011" TYPE="STUDY">Feng 2011</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Collagen punctal plugs</P>
</TD>
<TD VALIGN="TOP">
<P>Artificial tears</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Qiu-2012" TYPE="STUDY">Qiu 2012</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Acrylic punctal plugs</P>
</TD>
<TD VALIGN="TOP">
<P>Artificial tears</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Qiu-2013" TYPE="STUDY">Qiu 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Acrylic punctal plugs</P>
</TD>
<TD VALIGN="TOP">
<P>Artificial tears</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK>
</P>
</TD>
<TD>
<P>Collagen punctal plugs</P>
</TD>
<TD>
<P>Artificial tears</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Zhou-2016" TYPE="STUDY">Zhou 2016</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Thermal Memory hydrophobic acrylic polymer rigid rod punctal plug</P>
</TD>
<TD VALIGN="TOP">
<P>Artificial tears</P>
</TD>
</TR>
<TR>
<TH COLSPAN="3" VALIGN="TOP">
<P>5. Punctal plugs in the lower puncta versus the upper puncta.</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chen-2010" TYPE="STUDY">Chen 2010</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Collagen punctal plugs in the lower puncta</P>
</TD>
<TD VALIGN="TOP">
<P>Collagen punctal plugs in the upper puncta</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Farrell-2003" TYPE="STUDY">Farrell 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Collagen punctal plugs in the lower puncta</P>
</TD>
<TD VALIGN="TOP">
<P>Collagen punctal plugs in the lower and upper puncta</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kaido-2012" TYPE="STUDY">Kaido 2012</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Silcone punctal plugs in the lower puncta</P>
</TD>
<TD VALIGN="TOP">
<P>Silcone punctal plugs in the upper puncta</P>
</TD>
</TR>
<TR>
<TH COLSPAN="3">
<P>
<B>6. Acrylic punctal plugs versus silicone punctal plugs.</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Burgess-2008" TYPE="STUDY">Burgess 2008</LINK>
</P>
</TD>
<TD>
<P>Acrylic punctal plugs</P>
</TD>
<TD>
<P>Silicone punctal plugs</P>
</TD>
</TR>
<TR>
<TH COLSPAN="3">
<P>
<B>7. Intracanalicular plugs versus Silicone punctal plugs.</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rabensteiner-2013" TYPE="STUDY">Rabensteiner 2013</LINK>
</P>
</TD>
<TD>
<P>Intracanicular</P>
</TD>
<TD>
<P>Silicone punctal plugs</P>
</TD>
</TR>
<TR>
<TH COLSPAN="3">
<P>
<B>8. Collagen punctal plugs versus silicone punctal plugs.</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Altan_x002d_Yaycioglu-2005" TYPE="STUDY">Altan-Yaycioglu 2005</LINK>
</P>
</TD>
<TD>
<P>Collagen punctal plugs</P>
</TD>
<TD>
<P>Silicone punctal plugs</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brissette-2015" TYPE="STUDY">Brissette 2015</LINK>
</P>
</TD>
<TD>
<P>Collagen punctal plugs were inserted in the lower punctum</P>
</TD>
<TD>
<P>Silicone punctal plugs were inserted in the lower punctum</P>
</TD>
</TR>
<TR>
<TH COLSPAN="3" VALIGN="TOP">
<P>
<B>Excluded comparisons</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tsifetaki-2003" TYPE="STUDY">Tsifetaki 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Artificial tears</P>
</TD>
<TD VALIGN="TOP">
<P>Oral pilocarpine</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-05-08 18:14:59 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2017-05-08 18:14:59 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Punctal plug versus observation</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2017-05-08 18:14:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="53.24234902175744" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="57" TOTAL_2="58" UNITS="points" WEIGHT="0.0" Z="0.0">
<NAME>Symptomatic improvement at 1 month</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>No punctal plug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors observation</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6323823802955408" CI_START="-2.6323823802955406" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="6.0" MODIFIED="2017-01-19 16:57:48 +0000" MODIFIED_BY="[Empty name]" ORDER="71" SD_1="2.24" SD_2="2.0" SE="0.8328634572734829" STUDY_ID="STD-Mansour-2007" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
<CONT_DATA CI_END="-17.746310889085585" CI_START="-29.05368911091442" EFFECT_SIZE="-23.400000000000002" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="33.1" MODIFIED="2016-12-02 13:25:00 +0000" MODIFIED_BY="[Empty name]" ORDER="73" SD_1="8.0" SD_2="13.7" SE="2.8845882656569186" STUDY_ID="STD-Nava_x002d_Castaneda-2003" TOTAL_1="31" TOTAL_2="30" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.99249143146213" CI_START="-0.8442514314621297" EFFECT_SIZE="0.07412000000000019" ESTIMABLE="YES" MEAN_1="2.56734" MEAN_2="2.49322" MODIFIED="2017-02-13 20:09:47 +0000" MODIFIED_BY="[Empty name]" ORDER="70" SD_1="1.12287" SD_2="1.35591" SE="0.4685654627871361" STUDY_ID="STD-Yung-2012" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2017-05-08 18:14:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="102.3676016343849" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="44" TOTAL_2="45" UNITS="points" WEIGHT="0.0" Z="0.0">
<NAME>Symptomatic improvement (long-term)</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>No punctal plug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors observation</GRAPH_LABEL_2>
<CONT_DATA CI_END="-22.792724940362607" CI_START="-33.60727505963739" EFFECT_SIZE="-28.2" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="30.7" MODIFIED="2016-12-02 13:28:41 +0000" MODIFIED_BY="[Empty name]" ORDER="73" SD_1="3.1" SD_2="14.8" SE="2.758864500720058" STUDY_ID="STD-Nava_x002d_Castaneda-2003" TOTAL_1="31" TOTAL_2="30" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.0550745338892048" CI_START="-1.8303054661107958" EFFECT_SIZE="-0.9426900000000002" ESTIMABLE="YES" MEAN_1="1.27805" MEAN_2="2.22074" MODIFIED="2017-02-13 20:09:50 +0000" MODIFIED_BY="[Empty name]" ORDER="71" SD_1="1.0593" SD_2="1.33479" SE="0.45287335538417695" STUDY_ID="STD-Yung-2012" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2017-05-08 18:14:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="61" TOTAL_2="61" UNITS="points" WEIGHT="0.0" Z="0.0">
<NAME>Ocular surface staining at 2 weeks</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>No punctal plug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors observation</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4978189856891364" CI_START="-1.1021810143108637" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="2.1" MODIFIED="2016-12-05 17:45:51 +0000" MODIFIED_BY="[Empty name]" ORDER="28" SD_1="0.8" SD_2="0.9" SE="0.15417681992854404" STUDY_ID="STD-Nava_x002d_Castaneda-2003" TOTAL_1="61" TOTAL_2="61" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2017-05-08 18:14:59 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.27" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="13" TOTAL_2="15" UNITS="points" WEIGHT="0.0" Z="0.0">
<NAME>Ocular surface staining at 1 month</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>No punctal plug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors observation</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3681299353296796" CI_START="-0.18668993532968015" EFFECT_SIZE="0.5907199999999997" ESTIMABLE="YES" MEAN_1="2.99578" MEAN_2="2.40506" MODIFIED="2017-03-28 20:05:23 +0100" MODIFIED_BY="[Empty name]" ORDER="65" SD_1="1.35021" SD_2="0.50633" SE="0.3966450105521276" STUDY_ID="STD-Yung-2012" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2017-05-08 18:14:59 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.32" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="31" TOTAL_2="30" UNITS="points" WEIGHT="0.0" Z="0.0">
<NAME>Ocular surface staining (long-term)</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>No punctal plug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors observation</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.1154541489076868" CI_START="-1.8845458510923132" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="1.7" MODIFIED="2017-05-04 18:44:37 +0100" MODIFIED_BY="[Empty name]" ORDER="67" SD_1="0.4" SD_2="1.0" SE="0.19620046803184232" STUDY_ID="STD-Nava_x002d_Castaneda-2003" TOTAL_1="31" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2017-05-08 18:14:59 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.204716903144654" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="13" TOTAL_2="15" UNITS="seconds" WEIGHT="0.0" Z="0.0">
<NAME>Tear film stability at 1 month</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>No punctal plug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors observation</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4257359055012233" CI_START="-1.2458159055012237" EFFECT_SIZE="-0.4100400000000002" ESTIMABLE="YES" MEAN_1="1.99163" MEAN_2="2.40167" MODIFIED="2016-12-02 13:25:00 +0000" MODIFIED_BY="[Empty name]" ORDER="6" SD_1="1.08368" SD_2="1.17155" SE="0.4264241139601121" STUDY_ID="STD-Yung-2012" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2017-05-08 18:14:59 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="13" TOTAL_2="15" UNITS="seconds" WEIGHT="0.0" Z="0.0">
<NAME>Tear film stability (long-term)</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>No punctal plug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors observation</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.1990480828383356" CI_START="0.6670519171616647" EFFECT_SIZE="1.9330500000000002" ESTIMABLE="YES" MEAN_1="4.27615" MEAN_2="2.3431" MODIFIED="2016-12-02 13:25:00 +0000" MODIFIED_BY="[Empty name]" ORDER="7" SD_1="1.96234" SD_2="1.34728" SE="0.6459292583049315" STUDY_ID="STD-Yung-2012" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2017-05-08 18:14:59 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.14" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="31" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Artificial tear use at 2 weeks</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>No punctal plug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors observation</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.9388225510302832" CI_START="-1.8611774489697166" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="3.5" MODIFIED="2017-05-04 18:45:50 +0100" MODIFIED_BY="[Empty name]" ORDER="31" SD_1="1.1" SD_2="0.7" SE="0.23529894049453234" STUDY_ID="STD-Nava_x002d_Castaneda-2003" TOTAL_1="31" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2017-05-08 18:14:59 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="31" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Artificial tear use at 1 month</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>No punctal plug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors observation</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.396122012423784" CI_START="-2.203877987576216" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="3.6" MODIFIED="2017-05-04 18:45:59 +0100" MODIFIED_BY="[Empty name]" ORDER="32" SD_1="0.9" SD_2="0.7" SE="0.20606398421703354" STUDY_ID="STD-Nava_x002d_Castaneda-2003" TOTAL_1="31" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2017-05-08 18:14:59 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="31" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Artificial tear use (long-term)</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>No punctal plug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours observation</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.2944889383370617" CI_START="-3.1055110616629387" EFFECT_SIZE="-2.7" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="3.6" MODIFIED="2017-05-04 18:46:04 +0100" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="0.7" SD_2="0.9" SE="0.20689720059223426" STUDY_ID="STD-Nava_x002d_Castaneda-2003" TOTAL_1="31" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2017-05-05 19:44:16 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Punctal plugs versus cyclosporine</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2017-02-14 13:57:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.12" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="points" WEIGHT="0.0" Z="0.0">
<NAME>Ocular surface staining at 1 month</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Cyclosporine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors cyclosporine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5154716842332997" CI_START="-0.31547168423329974" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.3" MODIFIED="2016-12-02 13:25:28 +0000" MODIFIED_BY="[Empty name]" ORDER="10" SD_1="0.474" SD_2="0.474" SE="0.21197924426698006" STUDY_ID="STD-Roberts-2007" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2017-05-05 19:43:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="points" WEIGHT="0.0" Z="0.0">
<NAME>Ocular surface staining at 6 months</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Cyclosporine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors cyclosporine</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1532475296667155" CI_START="0.04675247033328467" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="-0.9" MODIFIED="2016-12-02 13:25:28 +0000" MODIFIED_BY="[Empty name]" ORDER="12" SD_1="0.822" SD_2="0.348" SE="0.2822743346462799" STUDY_ID="STD-Roberts-2007" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2017-02-14 13:58:56 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="mm/3 min" WEIGHT="0.0" Z="0.0">
<NAME>Aqueous tear production at 1 month</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Cyclosporine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors cyclosporine</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.038965797615615" CI_START="4.961034202384385" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="-1.5" MODIFIED="2016-12-02 13:25:28 +0000" MODIFIED_BY="[Empty name]" ORDER="13" SD_1="1.36" SD_2="0.98" SE="0.5300943312279429" STUDY_ID="STD-Roberts-2007" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2017-05-05 19:44:08 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.3" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="mm/3 min" WEIGHT="0.0" Z="0.0">
<NAME>Aqueous tear production at 6 months</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Cyclosporine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors cyclosporine</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.340810948937404" CI_START="-0.7408109489374044" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="3.0" MODIFIED="2016-12-02 13:25:28 +0000" MODIFIED_BY="[Empty name]" ORDER="15" SD_1="1.49" SD_2="1.99" SE="0.7861424807247094" STUDY_ID="STD-Roberts-2007" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2017-02-13 08:14:06 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.552432908182226" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Artificial tear use at 1 month</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Cyclosporine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors cyclosporine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.35880593970215036" CI_START="-3.0411940602978493" EFFECT_SIZE="-1.6999999999999997" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-0.6" MODIFIED="2016-12-02 13:25:28 +0000" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="1.99" SD_2="0.85" SE="0.6842952579113785" STUDY_ID="STD-Roberts-2007" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2017-05-05 19:44:16 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.38" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Artificial tear use at 6 months</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Cyclosporine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors cyclosporine</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.241500254918696" CI_START="-0.0415002549186958" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-3.2" MODIFIED="2016-12-02 13:25:28 +0000" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="1.52" SD_2="1.04" SE="0.5824087911424415" STUDY_ID="STD-Roberts-2007" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2017-05-05 19:42:30 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Punctal plugs versus oral pilocarpine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-05-05 19:42:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.14" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Symptomatic improvement at 3 months</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral pilocarpine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors oral pilocarpine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9529023360265867" CI_START="0.49441789085236415" EFFECT_SIZE="0.6863905325443787" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="26" LOG_CI_END="-0.020951608383956124" LOG_CI_START="-0.305905822389554" LOG_EFFECT_SIZE="-0.1634287153867551" MODIFIED="2016-12-02 13:25:35 +0000" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.16738351585299655" STUDY_ID="STD-Tsifetaki-2003" TOTAL_1="26" TOTAL_2="29" VAR="0.028017241379310345" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2017-02-14 13:59:36 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="52" TOTAL_2="58" UNITS="points" WEIGHT="0.0" Z="0.0">
<NAME>Ocular surface staining</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral pilocarpine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors oral pilocarpine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.01" MODIFIED="2016-12-02 13:25:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Right eye</NAME>
<CONT_DATA CI_END="0.760773821877323" CI_START="-0.560773821877323" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-1.0" MODIFIED="2016-12-02 13:25:35 +0000" MODIFIED_BY="[Empty name]" ORDER="63" SD_1="1.2" SD_2="1.3" SE="0.3371356959053445" STUDY_ID="STD-Tsifetaki-2003" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.02" MODIFIED="2016-12-02 13:25:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Left eye</NAME>
<CONT_DATA CI_END="1.1021357529309728" CI_START="0.09786424706902741" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-1.1" MODIFIED="2016-12-02 13:25:35 +0000" MODIFIED_BY="[Empty name]" ORDER="65" SD_1="0.9" SD_2="1.0" SE="0.2561964183483755" STUDY_ID="STD-Tsifetaki-2003" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2017-02-14 14:00:06 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.25" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="52" TOTAL_2="58" UNITS="mm/5 min" WEIGHT="0.0" Z="0.0">
<NAME>Aqueous tear production</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral pilocarpine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors oral pilocarpine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.01" MODIFIED="2016-12-02 13:25:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Right eye</NAME>
<CONT_DATA CI_END="0.32886047180862654" CI_START="-0.5288604718086265" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.3" MODIFIED="2016-12-02 13:25:35 +0000" MODIFIED_BY="[Empty name]" ORDER="63" SD_1="0.4" SD_2="1.1" SE="0.2188103838598174" STUDY_ID="STD-Tsifetaki-2003" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.02" MODIFIED="2016-12-02 13:25:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Left eye</NAME>
<CONT_DATA CI_END="0.06429009448503487" CI_START="-1.0642900944850349" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.2" MODIFIED="2016-12-02 13:25:35 +0000" MODIFIED_BY="[Empty name]" ORDER="65" SD_1="0.8" SD_2="1.3" SE="0.2879083998155492" STUDY_ID="STD-Tsifetaki-2003" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2017-05-05 19:44:32 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Punctal plugs versus artificial tears</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2017-02-14 14:00:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="16" UNITS="points" WEIGHT="0.0" Z="0.0">
<NAME>Symptomatic improvement at 2 weeks</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Artificial tears</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors artificial tears</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors punctal plug</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.274360333611019" CI_START="-3.8743603336110204" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="15.8" MEAN_2="16.1" MODIFIED="2017-01-18 14:30:32 +0000" MODIFIED_BY="[Empty name]" ORDER="51" SD_1="4.6" SD_2="5.0" SE="1.8236867421060374" STUDY_ID="STD-Qiu-2012" TOTAL_1="12" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-14 14:00:32 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="12.12" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Symptomatic improvement at 3 months</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Artificial tears</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors artificial tears</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.3792807925594595" CI_START="1.195871299669955" EFFECT_SIZE="2.2884615384615383" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" LOG_CI_END="0.6414027923603227" LOG_CI_START="0.07768444315514042" LOG_EFFECT_SIZE="0.3595436177577316" MODIFIED="2016-12-05 21:42:25 +0000" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.33113094877395644" STUDY_ID="STD-Tsifetaki-2003" TOTAL_1="26" TOTAL_2="28" VAR="0.10964770523594054" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="11.097027290668576" CI_END="-2.531031324876162" CI_START="-5.871123504394371" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.201077414635266" ESTIMABLE="YES" I2="90.98857762708312" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2017-05-05 18:49:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="8.646743476774521E-4" P_Q="1.0" P_Z="8.207017242694472E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="63" UNITS="" WEIGHT="100.0" Z="4.930379155067195">
<NAME>Symptomatic improvement at 3 months</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Artificial tears</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors artificial tears</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors punctal plug</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.806399173444614" CI_START="-3.4063991734446155" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="15.1" MEAN_2="15.9" MODIFIED="2017-05-05 18:46:16 +0100" MODIFIED_BY="[Empty name]" ORDER="55" SD_1="4.2" SD_2="4.2" SE="1.3298199324087374" STUDY_ID="STD-Qiu-2013" TOTAL_1="21" TOTAL_2="19" WEIGHT="41.055850699562114">
<FOOTNOTE>Ocular Surface Disease Index (OSDI); each item on the questionnaire is graded from 0 to 4 points, where 0 = never, 1 = some of the time, 2 = half of the time, 3 = most of the time, and 4 = all the time</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-4.394755371857654" CI_START="-8.745244628142347" EFFECT_SIZE="-6.57" ESTIMABLE="YES" MEAN_1="20.35" MEAN_2="26.92" MODIFIED="2017-05-05 18:49:23 +0100" MODIFIED_BY="[Empty name]" ORDER="49" SD_1="4.85" SD_2="5.63" SE="1.1098390813812895" STUDY_ID="STD-Zhou-2016" TOTAL_1="46" TOTAL_2="44" WEIGHT="58.94414930043788">
<FOOTNOTE>Symptoms score, defined as the sum of scores for dryness, foreign body sensation, and visual fatigue; each score had a different range.</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2017-02-14 14:00:52 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="27" TOTAL_2="27" UNITS="points" WEIGHT="0.0" Z="0.0">
<NAME>Ocular surface staining at 2 weeks</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Artificial tears</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors artificial tears</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.7077246823670968" CI_START="-0.08772468236709574" EFFECT_SIZE="0.8100000000000005" ESTIMABLE="YES" MEAN_1="6.23" MEAN_2="5.42" MODIFIED="2016-12-02 13:25:51 +0000" MODIFIED_BY="[Empty name]" ORDER="68" SD_1="1.12" SD_2="2.1" SE="0.4580312135571031" STUDY_ID="STD-Feng-2011" TOTAL_1="27" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2017-02-14 14:01:06 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.38" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="52" TOTAL_2="58" UNITS="points" WEIGHT="0.0" Z="0.0">
<NAME>Ocular surface staining at 3 months (Rose Bengal)</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Artificial tears</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors artificial tears</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.05.01" MODIFIED="2016-12-02 13:25:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Right eye</NAME>
<CONT_DATA CI_END="0.760773821877323" CI_START="-0.560773821877323" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-1.0" MODIFIED="2016-12-02 13:25:51 +0000" MODIFIED_BY="[Empty name]" ORDER="63" SD_1="1.2" SD_2="1.3" SE="0.3371356959053445" STUDY_ID="STD-Tsifetaki-2003" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.05.02" MODIFIED="2016-12-02 13:25:51 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Left eye</NAME>
<CONT_DATA CI_END="1.1021357529309728" CI_START="0.09786424706902741" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-1.1" MODIFIED="2016-12-02 13:25:51 +0000" MODIFIED_BY="[Empty name]" ORDER="65" SD_1="0.9" SD_2="1.0" SE="0.2561964183483755" STUDY_ID="STD-Tsifetaki-2003" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.06" MODIFIED="2017-02-14 14:01:17 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="19" UNITS="points" WEIGHT="0.0" Z="0.0">
<NAME>Ocular surface staining at 3 months (fluorescein)</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Artificial tears</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors artificial tears</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.07473333801593549" CI_START="-0.49473333801593544" EFFECT_SIZE="-0.21" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.3" MODIFIED="2017-01-19 15:27:25 +0000" MODIFIED_BY="[Empty name]" ORDER="56" SD_1="0.29" SD_2="0.57" SE="0.1452747806908064" STUDY_ID="STD-Qiu-2013" TOTAL_1="21" TOTAL_2="19" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2953793848487239" CI_END="2.709286050138377" CI_START="-1.0519612882316625" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8286623809533572" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" MODIFIED="2017-02-13 22:06:34 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.5867938204908372" P_Q="1.0" P_Z="0.3877954528014721" Q="0.0" RANDOM="NO" SCALE="11.35" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="43" UNITS="mm/5 min" WEIGHT="100.0" Z="0.8636222379970498">
<NAME>Aqueous tear production at 2 weeks</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Artificial tears</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors artificial tears</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.0930058877329567" CI_START="-0.9930058877329553" EFFECT_SIZE="1.0500000000000007" ESTIMABLE="YES" MEAN_1="11.9" MEAN_2="10.85" MODIFIED="2016-12-02 13:25:51 +0000" MODIFIED_BY="[Empty name]" ORDER="71" SD_1="4.2" SD_2="3.42" SE="1.0423690964976529" STUDY_ID="STD-Feng-2011" TOTAL_1="27" TOTAL_2="27" WEIGHT="84.73533661747287"/>
<CONT_DATA CI_END="4.413470138758804" CI_START="-5.2134701387588045" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="14.4" MODIFIED="2017-01-19 15:24:56 +0000" MODIFIED_BY="[Empty name]" ORDER="52" SD_1="3.39" SD_2="9.01" SE="2.455897239299723" STUDY_ID="STD-Qiu-2012" TOTAL_1="12" TOTAL_2="16" WEIGHT="15.264663382527132"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.08" MODIFIED="2017-05-05 19:44:32 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="52" TOTAL_2="56" UNITS="mm/5 min" WEIGHT="0.0" Z="0.0">
<NAME>Aqueous tear production at 3 months</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Artificial tears</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors artificial tears</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.08.01" MODIFIED="2016-12-02 13:25:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Right</NAME>
<CONT_DATA CI_END="0.3338330715092861" CI_START="-0.3338330715092861" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.2" MODIFIED="2016-12-02 13:25:51 +0000" MODIFIED_BY="[Empty name]" ORDER="72" SD_1="0.4" SD_2="0.8" SE="0.17032612545052805" STUDY_ID="STD-Tsifetaki-2003" TOTAL_1="26" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.08.02" MODIFIED="2016-12-02 13:25:51 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Left</NAME>
<CONT_DATA CI_END="0.5535271791634031" CI_START="-0.35352717916340315" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.6" MODIFIED="2016-12-02 13:25:51 +0000" MODIFIED_BY="[Empty name]" ORDER="68" SD_1="0.8" SD_2="0.9" SE="0.23139566989024676" STUDY_ID="STD-Tsifetaki-2003" TOTAL_1="26" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.15956711152590758" CI_END="2.902118987993802" CI_START="1.4100191408902296" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.1560690644420157" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.09" MODIFIED="2017-02-13 22:08:15 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6895555844905361" P_Q="1.0" P_Z="1.4766386298958917E-8" Q="0.0" RANDOM="NO" SCALE="10.75" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="63" UNITS="mm/5 min" WEIGHT="100.0" Z="5.664255944654608">
<NAME>Aqueous tear production at 3 months</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Artificial tears</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors artificial tears</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors punctal plug</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.12746086930723" CI_START="0.7925391306927716" EFFECT_SIZE="2.460000000000001" ESTIMABLE="YES" MEAN_1="11.41" MEAN_2="8.95" MODIFIED="2017-01-19 15:46:35 +0000" MODIFIED_BY="[Empty name]" ORDER="57" SD_1="2.65" SD_2="2.72" SE="0.85076097441583" STUDY_ID="STD-Qiu-2013" TOTAL_1="21" TOTAL_2="19" WEIGHT="20.01817485316196"/>
<CONT_DATA CI_END="2.91420393680564" CI_START="1.24579606319436" EFFECT_SIZE="2.08" ESTIMABLE="YES" MEAN_1="6.97" MEAN_2="4.89" MODIFIED="2017-01-06 18:46:51 +0000" MODIFIED_BY="[Empty name]" ORDER="50" SD_1="2.32" SD_2="1.68" SE="0.4256220743777611" STUDY_ID="STD-Zhou-2016" TOTAL_1="46" TOTAL_2="44" WEIGHT="79.98182514683805"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6926368165567716" CI_END="1.0905129011058587" CI_START="-0.5748770886486291" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2578179062286148" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.10" MODIFIED="2017-02-13 08:16:27 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.40526934939901393" P_Q="1.0" P_Z="0.543956162328578" Q="0.0" RANDOM="NO" SCALE="4.38021555952462" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="43" UNITS="seconds" WEIGHT="100.0" Z="0.6068414171891395">
<NAME>Tear film stability at 2 weeks</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Artificial tears</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors punctal plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors artificial tears</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.0930058877329567" CI_START="-0.9930058877329553" EFFECT_SIZE="1.0500000000000007" ESTIMABLE="YES" MEAN_1="11.9" MEAN_2="10.85" MODIFIED="2016-12-02 13:25:51 +0000" MODIFIED_BY="[Empty name]" ORDER="69" SD_1="4.2" SD_2="3.42" SE="1.0423690964976529" STUDY_ID="STD-Feng-2011" TOTAL_1="27" TOTAL_2="27" WEIGHT="16.612411181959466"/>
<CONT_DATA CI_END="1.0118748674550047" CI_START="-0.8118748674550054" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="6.5" MODIFIED="2017-01-18 18:45:38 +0000" MODIFIED_BY="[Empty name]" ORDER="53" SD_1="1.3" SD_2="1.1" SE="0.46525082840692866" STUDY_ID="STD-Qiu-2012" TOTAL_1="12" TOTAL_2="16" WEIGHT="83.38758881804053"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.2295160197091315" CI_END="1.4436471028912212" CI_START="0.596637450612064" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0201422767516426" ESTIMABLE="YES" I2="55.14721620477692" I2_Q="0.0" ID="CMP-004.11" MODIFIED="2017-02-13 08:16:14 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.13539634869715866" P_Q="1.0" P_Z="2.344813828603989E-6" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="63" UNITS="seconds" WEIGHT="99.99999999999999" Z="4.721179070769163">
<NAME>Tear film stability at 3 months</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Artificial tears</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors artificial tears</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors punctal plug</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.95211524336057" CI_START="0.6878847566394308" EFFECT_SIZE="1.8200000000000003" ESTIMABLE="YES" MEAN_1="7.82" MEAN_2="6.0" MODIFIED="2017-01-18 18:56:05 +0000" MODIFIED_BY="[Empty name]" ORDER="58" SD_1="1.84" SD_2="1.81" SE="0.577620431952092" STUDY_ID="STD-Qiu-2013" TOTAL_1="21" TOTAL_2="19" WEIGHT="13.993793199101377"/>
<CONT_DATA CI_END="1.3466605198988826" CI_START="0.4333394801011169" EFFECT_SIZE="0.8899999999999997" ESTIMABLE="YES" MEAN_1="4.13" MEAN_2="3.24" MODIFIED="2017-01-06 18:48:24 +0000" MODIFIED_BY="[Empty name]" ORDER="51" SD_1="1.15" SD_2="1.06" SE="0.2329943424986187" STUDY_ID="STD-Zhou-2016" TOTAL_1="46" TOTAL_2="44" WEIGHT="86.00620680089861"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-004.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-07 22:21:19 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Punctate epithelial keratopathy</NAME>
<GROUP_LABEL_1>Punctal plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Artificial tears</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors artificial tears</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors punctal plug</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.115443049201624" CI_START="0.5706340156766333" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4935198166905914" LOG_CI_START="-0.2436423434739915" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2017-01-18 18:47:09 +0000" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.4330127018922193" STUDY_ID="STD-Qiu-2012" TOTAL_1="12" TOTAL_2="16" VAR="0.1875" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2017-02-14 14:02:00 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Punctal plugs in the upper versus lower puncta</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-02-14 14:01:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.07" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Symptomatic improvement at 1 month</NAME>
<GROUP_LABEL_1>Upper puncta</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower puncta</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors upper puncta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors lower puncta</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3597658506574875" CI_START="0.8477913924490057" EFFECT_SIZE="1.0736842105263158" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.13346413004500166" LOG_CI_START="-0.07171099709886207" LOG_EFFECT_SIZE="0.030876566473069796" MODIFIED="2016-12-02 13:25:59 +0000" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="0.12052088531756487" STUDY_ID="STD-Kaido-2012" TOTAL_1="19" TOTAL_2="24" VAR="0.014525283797729625" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2017-02-14 14:02:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="11.15" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="24" UNITS="mm/5 min" WEIGHT="0.0" Z="0.0">
<NAME>Aqueous tear production at 1 month</NAME>
<GROUP_LABEL_1>Upper puncta</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower puncta</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors upper puncta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors lower puncta</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3704260021999852" CI_START="-8.629573997800016" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="11.1" MODIFIED="2016-12-07 20:54:53 +0000" MODIFIED_BY="[Empty name]" ORDER="74" SD_1="4.8" SD_2="8.8" SE="2.1069642250437086" STUDY_ID="STD-Kaido-2012" TOTAL_1="19" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2017-02-13 08:17:13 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.204716903144654" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="24" UNITS="seconds" WEIGHT="0.0" Z="0.0">
<NAME>Tear film stability at 1 month</NAME>
<GROUP_LABEL_1>Upper punctal occlusion</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower punctal occlusion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors lower puncta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors upper puncta</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.5331313847350097" CI_START="-1.7331313847350107" EFFECT_SIZE="-0.10000000000000053" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="6.2" MODIFIED="2016-12-07 20:59:07 +0000" MODIFIED_BY="[Empty name]" ORDER="50" SD_1="2.8" SD_2="2.6" SE="0.8332456094177965" STUDY_ID="STD-Kaido-2012" TOTAL_1="19" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2017-02-14 14:02:58 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Acrylic punctal plugs versus silicone punctal plugs</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2017-02-14 14:02:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="11.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" UNITS="points" WEIGHT="0.0" Z="0.0">
<NAME>Symptomatic improvement at 11 weeks</NAME>
<GROUP_LABEL_1>Acrylic plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Silicone plug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors acrylic plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors silicone plug</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.735635435217649" CI_START="-6.935635435217653" EFFECT_SIZE="0.8999999999999986" ESTIMABLE="YES" MEAN_1="21.9" MEAN_2="21.0" MODIFIED="2016-12-02 13:25:13 +0000" MODIFIED_BY="[Empty name]" ORDER="56" SD_1="8.8" SD_2="14.5" SE="3.997846642603713" STUDY_ID="STD-Burgess-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.02" MODIFIED="2017-02-14 14:02:19 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="36" TOTAL_2="36" UNITS="points" WEIGHT="0.0" Z="0.0">
<NAME>Ocular surface staining at 11 weeks</NAME>
<GROUP_LABEL_1>Acrylic plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Silicone plug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors acrylic plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors silicone plug</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.02.01" MODIFIED="2016-12-02 13:25:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Rose Bengal</NAME>
<CONT_DATA CI_END="0.9905222333555587" CI_START="-0.09052223335555876" EFFECT_SIZE="0.44999999999999996" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.55" MODIFIED="2016-12-02 13:25:13 +0000" MODIFIED_BY="[Empty name]" ORDER="52" SD_1="0.71" SD_2="0.93" SE="0.2757817172249741" STUDY_ID="STD-Burgess-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.02.02" MODIFIED="2016-12-02 13:25:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Fluorescein</NAME>
<CONT_DATA CI_END="2.468577165430921" CI_START="-1.6085771654309209" EFFECT_SIZE="0.43000000000000016" ESTIMABLE="YES" MEAN_1="2.06" MEAN_2="1.63" MODIFIED="2016-12-02 13:25:13 +0000" MODIFIED_BY="[Empty name]" ORDER="57" SD_1="2.48" SD_2="3.65" SE="1.0401095027821723" STUDY_ID="STD-Burgess-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.03" MODIFIED="2017-02-14 14:02:58 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" UNITS="mm" WEIGHT="0.0" Z="0.0">
<NAME>Aqueous tear production at 11 weeks</NAME>
<GROUP_LABEL_1>Acrylic plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Silicone plug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors acrylic plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors silicone plug</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.764857428340942" CI_START="-1.6248574283409414" EFFECT_SIZE="1.0700000000000003" ESTIMABLE="YES" MEAN_1="4.87" MEAN_2="3.8" MODIFIED="2016-12-02 13:25:13 +0000" MODIFIED_BY="[Empty name]" ORDER="53" SD_1="5.45" SD_2="2.08" SE="1.3749525244329146" STUDY_ID="STD-Burgess-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.04" MODIFIED="2017-02-07 21:33:28 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.38021555952462" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" UNITS="seconds" WEIGHT="0.0" Z="0.0">
<NAME>Tear film stability at 11 weeks</NAME>
<GROUP_LABEL_1>Acrylic plug</GROUP_LABEL_1>
<GROUP_LABEL_2>Silicone plug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors acrylic plug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors silicone plug</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.9419012742746382" CI_START="-1.2219012742746385" EFFECT_SIZE="0.3599999999999999" ESTIMABLE="YES" MEAN_1="3.86" MEAN_2="3.5" MODIFIED="2016-12-05 19:03:50 +0000" MODIFIED_BY="[Empty name]" ORDER="54" SD_1="2.34" SD_2="2.5" SE="0.8071073176611783" STUDY_ID="STD-Burgess-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.05" MODIFIED="2017-02-07 21:50:00 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.465559853060928" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Artificial tear use at 11 weeks</NAME>
<GROUP_LABEL_1>Acrylic plugs</GROUP_LABEL_1>
<GROUP_LABEL_2>Silicone plugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors silicone plugs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors acrylic plugs</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.543799521621511" CI_START="-2.32379952162151" EFFECT_SIZE="0.11000000000000032" ESTIMABLE="YES" MEAN_1="4.78" MEAN_2="4.67" MODIFIED="2016-12-05 19:05:50 +0000" MODIFIED_BY="[Empty name]" ORDER="54" SD_1="3.68" SD_2="3.77" SE="1.24175726738808" STUDY_ID="STD-Burgess-2008" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2017-02-13 19:25:50 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Intracanalicular plugs versus silicone punctal plugs</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2017-02-13 08:12:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="27" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Symptomatic improvement (long-term)</NAME>
<GROUP_LABEL_1>Intracanalicular</GROUP_LABEL_1>
<GROUP_LABEL_2>Silicone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors intracanalicular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors silicone</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.768231243729797" CI_START="-14.9682312437298" EFFECT_SIZE="-3.1000000000000014" ESTIMABLE="YES" MEAN_1="35.4" MEAN_2="38.5" MODIFIED="2017-01-18 19:05:56 +0000" MODIFIED_BY="[Empty name]" ORDER="67" SD_1="20.0" SD_2="25.1" SE="6.055331290444565" STUDY_ID="STD-Rabensteiner-2013" TOTAL_1="30" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.02" MODIFIED="2017-02-13 08:12:24 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.1156595036266372" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="60" TOTAL_2="54" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Ocular surface staining (long-term)</NAME>
<GROUP_LABEL_1>Intracanalicular</GROUP_LABEL_1>
<GROUP_LABEL_2>Silicone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors intracanalicular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors silicone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.02.01" MODIFIED="2017-01-18 19:18:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Rose Bengal</NAME>
<CONT_DATA CI_END="1.109110967627006" CI_START="-0.7091109676270054" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="3.0" MODIFIED="2017-01-18 19:18:32 +0000" MODIFIED_BY="[Empty name]" ORDER="72" SD_1="1.9" SD_2="1.6" SE="0.46384064952109166" STUDY_ID="STD-Rabensteiner-2013" TOTAL_1="30" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.02.02" MODIFIED="2017-01-18 19:06:47 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Fluorescein</NAME>
<CONT_DATA CI_END="0.8413345554502323" CI_START="-0.04133455545023201" EFFECT_SIZE="0.40000000000000013" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="0.7" MODIFIED="2017-01-18 19:06:47 +0000" MODIFIED_BY="[Empty name]" ORDER="68" SD_1="0.9" SD_2="0.8" SE="0.2251748291965683" STUDY_ID="STD-Rabensteiner-2013" TOTAL_1="30" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.03" MODIFIED="2017-02-13 08:12:31 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.38021555952462" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="27" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Aqueous tear production (long-term)</NAME>
<GROUP_LABEL_1>Intracanalicular</GROUP_LABEL_1>
<GROUP_LABEL_2>Silicone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors silicone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors intracanalicular</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.03.01" MODIFIED="2017-01-18 19:07:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Schirmer test I without anesthesia</NAME>
<CONT_DATA CI_END="2.0630420625183064" CI_START="-3.463042062518305" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="6.4" MEAN_2="7.1" MODIFIED="2017-01-18 19:07:40 +0000" MODIFIED_BY="[Empty name]" ORDER="69" SD_1="5.1" SD_2="5.5" SE="1.4097412423456903" STUDY_ID="STD-Rabensteiner-2013" TOTAL_1="30" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.04" MODIFIED="2017-02-13 08:13:06 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.29637443085379" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="27" UNITS="seconds" WEIGHT="0.0" Z="0.0">
<NAME>Tear film stability (long-term)</NAME>
<GROUP_LABEL_1>Intracanalicular</GROUP_LABEL_1>
<GROUP_LABEL_2>Silicone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors intracanalicular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors silicone</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6049385407742274" CI_START="-0.004938540774227618" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="3.3" MODIFIED="2017-01-18 19:08:26 +0000" MODIFIED_BY="[Empty name]" ORDER="70" SD_1="1.6" SD_2="1.5" SE="0.4106904755003051" STUDY_ID="STD-Rabensteiner-2013" TOTAL_1="30" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.05" MODIFIED="2017-02-13 08:12:37 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.552432908182226" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="27" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Artificial tear use (long-term)</NAME>
<GROUP_LABEL_1>Intracanalicular</GROUP_LABEL_1>
<GROUP_LABEL_2>Silicone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors intracanalicular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors silicone</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.440213770526571" CI_START="-4.040213770526572" EFFECT_SIZE="-1.3000000000000007" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="6.4" MODIFIED="2017-01-18 19:09:15 +0000" MODIFIED_BY="[Empty name]" ORDER="71" SD_1="3.2" SD_2="6.6" SE="1.3980939405729025" STUDY_ID="STD-Rabensteiner-2013" TOTAL_1="30" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-05-08 21:15:30 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-02-08 01:20:17 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArwAAAJdCAYAAADQoqRkAABc4ElEQVR42u2dD2Qd2Rv3f1StqqpS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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-05-08 21:15:30 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWcAAAPaCAIAAADEEQ5YAAAvdElEQVR42u3dvY4cx9nF8QUMGA4Y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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2017-02-21 14:32:50 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2017-01-17 18:27:49 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-07-09 13:29:35 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-01-17 18:27:49 +0000" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor: [Dry Eye Syndromes] explode all trees<BR/>#2 (dry near/2 eye*)<BR/>#3 (ocular near/2 dry*)<BR/>#4 MeSH descriptor: [Tears] explode all trees<BR/>#5 tear*<BR/>#6 MeSH descriptor: [Xerophthalmia] explode all trees<BR/>#7 xerophthalmi*<BR/>#8 MeSH descriptor: [Vitamin A Deficiency] explode all trees<BR/>#9 ("vitamin A" near/3 deficien*)<BR/>#10 ("avitaminosis a" or retinol deficien* or "hypovitaminosis A")<BR/>#11 MeSH descriptor: [Keratoconjunctivitis Sicca] explode all trees<BR/>#12 (Keratoconjunctiv* or kerato conjunctivitis)<BR/>#13 MeSH descriptor: [Sjogren's Syndrome] explode all trees<BR/>#14 ((Sjogren* or Sjoegren*) near/2 (syndrom* or disease*))<BR/>#15 sicca syndrom*<BR/>#16 MeSH descriptor: [Stevens-Johnson Syndrome] explode all trees<BR/>#17 (Steven* and Johnson and (syndrom* or disease*))<BR/>#18 MeSH descriptor: [Pemphigoid, Benign Mucous Membrane] explode all trees<BR/>#19 Benign Muco* Pemphigoid*<BR/>#20 (Cicatricial near/2 Pemphigoid*)<BR/>#21 blepharoconjunctiviti*<BR/>#22 MeSH descriptor: [Meibomian Glands] explode all trees<BR/>#23 (meibomian or tarsal)<BR/>#24 MeSH descriptor: [Lacrimal Apparatus Diseases] explode all trees<BR/>#25 (lacrima* or epiphora)<BR/>#26 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25<BR/>#27 (occlu* or plug* or cauter*) near/4 (puncta* or punctum* or canalicula* or Intracanalicula* or lacrima*)<BR/>#28 (Silicone near/2 plug*) or (Collagen near/2 plug*)<BR/>#29 #27 or #28<BR/>#30 #26 and #29</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2017-02-21 14:32:50 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2017-02-13 08:22:14 +0000" MODIFIED_BY="[Empty name]">MEDLINE (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-02-21 14:32:50 +0000" MODIFIED_BY="[Empty name]">
<P>1. Randomized Controlled Trial.pt.<BR/>2. Controlled Clinical Trial.pt.<BR/>3. (randomized or randomised).ab,ti.<BR/>4. placebo.ab,ti.<BR/>5. drug therapy.fs.<BR/>6. randomly.ab,ti.<BR/>7. trial.ab,ti.<BR/>8. groups.ab,ti.<BR/>9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8<BR/>10. exp animals/ not humans.sh.<BR/>11. 9 not 10<BR/>12. exp dry eye syndromes/<BR/>13. (dry adj2 eye*).tw.<BR/>14. (ocular adj2 dry*).tw.<BR/>15. exp tears/<BR/>16. tear*.tw.<BR/>17. exp xerophthalmia/<BR/>18. xerophthalmi*.tw.<BR/>19. exp vitamin A deficiency/<BR/>20. (vitamin A adj3 deficien*).tw.<BR/>21. (avitaminosis a or retinol deficien* or hypovitaminosis A).tw.<BR/>22. exp keratoconjunctivitis sicca/<BR/>23. (Keratoconjunctiv* or kerato conjunctivitis).tw.<BR/>24. exp Keratoconjunctivitis/<BR/>25. limit 24 to yr="1966 - 1985"<BR/>26. exp Sjogren's syndrome/<BR/>27. ((Sjogren* or Sjoegren*) adj2 (syndrom* or disease*)).tw.<BR/>28. sicca syndrom*.tw.<BR/>29. exp Stevens Johnson syndrome/<BR/>30. (Steven* and Johnson and (syndrom* or disease*)).tw.<BR/>31. exp Pemphigoid, Benign Mucous Membrane/<BR/>32. Benign Muco* Pemphigoid*.tw.<BR/>33. (Cicatricial adj2 Pemphigoid*).tw.<BR/>34. blepharoconjunctiviti*.tw.<BR/>35. exp meibomian glands/<BR/>36. (meibomian or tarsal).tw.<BR/>37. exp lacrimal apparatus diseases/<BR/>38. (lacrima* or epiphora).tw.<BR/>39. or/12-23,25-38<BR/>40. ((occlu* or plug* or cauter*) adj4 (puncta* or punctum* or canalicula* or Intracanalicula* or lacrima*)).tw.<BR/>41. ((Silicone adj2 plug*) or (Collagen adj2 plug*)).tw.<BR/>42. 40 or 41<BR/>43. 11 and 39 and 42<BR/>
</P>
<P>The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by <LINK REF="REF-Glanville-2006" TYPE="REFERENCE">Glanville 2006</LINK>.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2017-02-13 08:22:27 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2017-02-13 08:22:27 +0000" MODIFIED_BY="[Empty name]">Embase.com search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-01-17 18:29:34 +0000" MODIFIED_BY="[Empty name]">
<P>#1 'randomized controlled trial'/exp<BR/>#2 'randomization'/exp<BR/>#3 'double blind procedure'/exp<BR/>#4 'single blind procedure'/exp<BR/>#5 random*:ab,ti<BR/>#6 #1 OR #2 OR #3 OR #4 OR #5<BR/>#7 'animal'/exp OR 'animal experiment'/exp<BR/>#8 'human'/exp<BR/>#9 #7 AND #8<BR/>#10 #7 NOT #9<BR/>#11 #6 NOT #10<BR/>#12 'clinical trial'/exp<BR/>#13 (clin* NEAR/3 trial*):ab,ti<BR/>#14 ((singl* OR doubl* OR trebl* OR tripl*) NEAR/3 (blind* OR mask*)):ab,ti<BR/>#15 'placebo'/exp<BR/>#16 placebo*:ab,ti<BR/>#17 random*:ab,ti<BR/>#18 'experimental design'/exp<BR/>#19 'crossover procedure'/exp<BR/>#20 'control group'/exp<BR/>#21 'latin square design'/exp<BR/>#22 #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21<BR/>#23 #22 NOT #10<BR/>#24 #23 NOT #11<BR/>#25 'comparative study'/exp<BR/>#26 'evaluation'/exp<BR/>#27 'prospective study'/exp<BR/>#28 control*:ab,ti OR prospectiv*:ab,ti OR volunteer*:ab,ti<BR/>#29 #25 OR #26 OR #27 OR #28<BR/>#30 #29 NOT #10<BR/>#31 #30 NOT (#11 OR #23)<BR/>#32 #11 OR #24 OR #31<BR/>#33 'dry eye'/exp<BR/>#34 (dry NEAR/2 eye*):ab,ti<BR/>#35 (ocular NEAR/2 dry*):ab,ti<BR/>#36 'lacrimal fluid'/exp<BR/>#37 tear*:ab,ti<BR/>#38 'xerophthalmia'/exp<BR/>#39 xerophthalmi*:ab,ti<BR/>#40 'retinol deficiency'/exp<BR/>#41 ('vitamin a' NEAR/3 deficien*):ab,ti<BR/>#42 'avitaminosis a':ab,ti OR (retinol NEAR/1 deficien*):ab,ti OR 'hypovitaminosis a':ab,ti<BR/>#43 'keratoconjunctivitis sicca'/exp<BR/>#44 keratoconjunctiv*:ab,ti OR 'kerato conjunctivitis':ab,ti<BR/>#45 'sjoegren syndrome'/exp<BR/>#46 ((sjogren* OR sjoegren*) NEAR/2 (syndrom* OR disease*)):ab,ti<BR/>#47 (sicca NEXT/1 syndrom*):ab,ti<BR/>#48 'stevens johnson syndrome'/exp<BR/>#49 steven*:ab,ti AND johnson:ab,ti AND (syndrom*:ab,ti OR disease*:ab,ti)<BR/>#50 'mucous membrane pemphigoid'/exp<BR/>#51 benign AND muco* AND pemphigoid*:ab,ti<BR/>#52 (cicatricial NEAR/2 pemphigoid*):ab,ti<BR/>#53 blepharoconjunctiviti*:ab,ti<BR/>#54 'meibomian gland'/exp<BR/>#55 meibomian:ab,ti OR tarsal:ab,ti<BR/>#56 'lacrimal gland disease'/exp<BR/>#57 lacrima*:ab,ti OR epiphora:ab,ti<BR/>#58 #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57<BR/>#59 ((occlu* OR plug* OR cauter*) NEAR/4 (puncta* OR punctum* OR canalicula* OR intracanalicula* OR lacrima*)):ab,ti<BR/>#60 (silicone NEAR/2 plug*):ab,ti OR (collagen NEAR/2 plug*):ab,ti<BR/>#61 #59 OR #60<BR/>#62 #32 AND #58 AND #61<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2017-01-17 18:37:59 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2017-01-17 18:31:00 +0000" MODIFIED_BY="[Empty name]">PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-01-17 18:31:22 +0000" MODIFIED_BY="[Empty name]">
<P>1. ((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomised[tiab] OR randomized[tiab]) OR (placebo[tiab]) OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) NOT (animals[mh] NOT humans[mh])<BR/>2. (dry[tw] AND eye*[tw]) NOT Medline[sb]<BR/>3. (ocular[tw] AND dry*[tw]) NOT Medline[sb]<BR/>4. tear*[tw] NOT Medline[sb]<BR/>5. xerophthalmi*[tw] NOT Medline[sb]<BR/>6. ("vitamin A"[tw] AND deficien*[tw]) NOT Medline[sb]<BR/>7. ("avitaminosis a"[tw] OR retinol deficien*[tw] OR "hypovitaminosis A"[tw]) NOT Medline[sb]<BR/>8. (Keratoconjunctiv*[tw] OR "kerato conjunctivitis"[tw]) NOT Medline[sb]<BR/>9. ((Sjogren*[tw] OR Sjoegren*[tw]) AND (syndrom*[tw] OR disease*[tw])) NOT Medline[sb]<BR/>10. sicca syndrom*[tw] NOT Medline[sb]<BR/>11. (Steven*[tw] AND Johnson[tw] AND (syndrom*[tw] OR disease*[tw])) NOT Medline[sb]<BR/>12. Benign Muco* Pemphigoid*[tw] NOT Medline[sb]<BR/>13. (Cicatricial[tw] AND Pemphigoid*[tw]) NOT Medline[sb]<BR/>14. blepharoconjunctiviti*[tw] NOT Medline[sb]<BR/>15. (Meibomian[tw] OR tarsal[tw]) NOT Medline[sb]<BR/>16. (lacrima*[tw] OR epiphora[tw]) NOT Medline[sb]<BR/>17. #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16<BR/>18. ((occlu*[tw] OR plug*[tw] OR cauter*[tw]) AND (puncta*[tw] OR punctum*[tw] OR canalicula*[tw] OR Intracanalicula*[tw] OR lacrima*[tw])) NOT Medline[sb]<BR/>19. ((Silicone[tw] AND plug*[tw]) OR (Collagen[tw] AND plug*[tw])) NOT Medline[sb]<BR/>20. #18 OR #19<BR/>21. #1 AND #17 AND #20</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2017-01-17 18:37:59 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2010-07-09 13:31:02 +0100" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-01-17 18:29:58 +0000" MODIFIED_BY="[Empty name]">
<P>((occlu$ OR plug$ OR cauter$) AND (puncta$ OR punctum$ OR canalicula$ OR Intracanalicula$ OR lacrima$)) OR (silicone plug$) OR (collagen plug$)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2017-01-17 18:32:09 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2010-07-09 13:31:26 +0100" MODIFIED_BY="[Empty name]">
<I>meta</I>Register of Controlled Trials search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-03-31 15:04:32 +0100" MODIFIED_BY="[Empty name]">
<P>punctal or punctum</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2017-01-17 18:32:05 +0000" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2010-07-09 13:31:44 +0100" MODIFIED_BY="[Empty name]">ClinicalTrials. gov search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-04-19 17:34:02 +0100" MODIFIED_BY="[Empty name]">
<P>(punctal OR punctum OR canalicular OR Intracanalicular OR lacrimal) AND (occlusion OR plug OR cautery)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2017-01-17 18:32:02 +0000" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2016-03-31 15:05:09 +0100" MODIFIED_BY="[Empty name]">ICTRP search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-03-31 15:05:20 +0100" MODIFIED_BY="[Empty name]">
<P>Punctal OR punctum OR canalicular OR intracanalicular OR lacrimal</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 studies included quantitative synthesis (meta-analysis)&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;18 &lt;/span&gt;studies included in qualitative synthesis and one ongoing study identified&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 included studies and no ongoing studies in the previous version of the review (from search as of 23 June 2010)&lt;/p&gt;" WIDTH="213"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;11 included studies and 1 ongoing study added to the review&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;20 full-text reports assessed for eligibility&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;211 records screened &lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;211 recrods identified through searching electronic databases (23 June 2010 to 19 December 2016)&lt;/p&gt;"/>
<OUT TEXT="&lt;p&gt;&lt;span&gt;192&lt;/span&gt; records excluded&lt;/p&gt;" WIDTH="166"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;8 studies excluded, with reasons&lt;/p&gt;" WIDTH="163"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>